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Abstract 
 
 
Tamoxifen is an effective and well-tolerated treatment for early disease and/or pre-
menopausal patients with breast cancer (BC); although many women go on to develop 
resistance.  Currently the five-year survival rate following Tamoxifen resistance (TR) is < 
20%; hence the mechanisms need to be better understood. Recent research has focussed on 
specific pathways, however additional mechanisms are involved and we investigated these 
using cell line models of BC (MCF7) and TR using a variety of proteomic approaches.  
 
Differential expression and phosphorylation of proteins between the MCF7 and TR cell lines 
were detected by antibody arrays; which detected changes in Mitogen Activated Protein 
Kinases and Receptor Tyrosine Kinases family members, and in apoptosis related proteins. 
There were 21 novel proteins found to be altered in TR. 
 
262 quantifiable proteins were found using SILAC; 29% over expressed in resistance and 
25% down regulated. 5 were subsequently picked for validation by Western blot and 2 of 
these (IQGAP1 and cortactin) were chosen for further investigation with siRNA and 
functional assays.  
 
IQGAP1 was found to play a role in TR; as decreasing expression of IQGAP1 using SiRNA 
decreased the proliferation of TR cells and significantly modulated the TR cells ability to 
invade matrigel.  
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Stable isotope labeling with amino acids in culture 
siRNA 
 
Silencing RNA 
SMAC 
 
Second Mitochondria-derived Activator of Caspases 
SPA  
 
Sinapinic Acid 
Src 
 
Tyrosine-protein kinase Src 
SRM/MRM Selected reaction monitoring/ multiple reaction monitoring 
STAT3 
 
Signal transducer and activator of transcription 3 
TBS-T 
 
Tris buffered Saline – Tween20 
TEAM trial Tamoxifen Exemestane Adjuvant Multinational trial 
TFA 
 
Tri-fluoroacetic acid 
TGFb 
 
Transforming growth factor beta 
TMA 
 
Tissue micro array 
TNF 
 
Tumor necrosis factor 
VEGFR2 
 
Vascular endothelial growth factor receptor 2 
WB 
 
Western blot 
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1 Introduction 
1.1 Proteomics 
“Proteomics includes not only the identification and quantification of proteins, but also 
the determination of their localization, modifications, interactions, activities, and, 
ultimately, their function.” (Fields, 2001) 
 
Proteomics can be defined as the study of proteins within a system. A system can 
encompass a whole cell, a particular sub-cellular fraction or components of the cell for 
example the nucleus, protein secretions from cell lines (secretomes), human body fluids 
such as nipple aspirate, serum, plasma, urine and cerebral spinal fluid. A whole cell lysate 
sample contains thousands of proteins whereas a more defined experiment (for example, 
immunoprecipitation) would contain fewer. 
Proteomics is still in its infancy compared to genomics. The human genome was 
sequenced in 2001 (Lander et al., 2001 and Venter et al., 2001) whereas an understanding 
of the entire proteome is expected to be years away, this is in part due to the dynamic 
nature of proteins. Analysis of proteins is also hampered by the fact that there is no way 
in which a protein can be amplified as there is in molecular biology (polymerase chain 
reaction, PCR for example). In proteomics, the instrumentation has to become more 
sensitive to analyse the less abundant proteins. In recent literature the idea of global 
assessment of proteins in a sample, with a view to elucidating fundamental mechanisms 
of disease has become tangible; even reasonable. An organism’s genome is reasonably 
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stable unlike an organism’s proteome in which the proteins are in a constant state of flux. 
The flux of a proteome can include processes such as post translational modifications 
(PTMs), localisation, proteolysis, increased and decreased expression, interactions (which 
can vary with differing conditions within the cell), and signalling cascades can be 
triggered, all of which can be captured in a “snap-shot” look at the cell proteome using 
proteomics.  Messenger RNA expression does not always correlate with protein 
expression (Celis et al., 2000) and investigation of the genome only tells part of the story. 
There are approximately 21,000 human protein encoding genes in the human genome, but 
the total human proteome may well reach approximately 1,000,000 proteins (Jensen, 
2004) and approximately 3000 of these represent druggable targets. 
One aspect of proteomics is the identification of biomarkers. Biomarkers are 
biological markers often used in diagnostics for the detection and diagnosis of early stage 
disease (such as cancer), the prognosis or stage and the potential of therapy response. 
Biomarkers have been found using various proteomic technologies including Matrix 
Assisted Laser Desorption Ionisation (MALDI) and Surface Enhanced Laser Desorption 
Ionisation (SELDI) (detailed below - 1.1.4 ) 
Untargeted platforms for proteomics, for instance global shotgun approaches, can 
be used to compare superficial or complex proteomes at the first stages of 
experimentation. This provides a way in which to identify novel proteins that exhibit 
differences in abundance and are generally considered to be the mainstay of proteomic 
based experiments. However, a more targeted proteomic approach is becoming more 
popular; tissue microarrays, multiplexed Western blots, peptide microarray and antibody 
arrays. The latter two being considered for a larger scale analysis of samples, and are 
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among the more versatile tools as long as there is an antibody available that can be 
immobilised. Antibody arrays were used in this study and are detailed below in section 
1.1.1. 
1.1.1 Antibody based proteomics 
Tissue microarrays (TMA) and multiplexed Western blots are considered more targeted 
approaches to antibody based proteomics whilst antibody and protein micro-arrays are 
suitable for high throughput analysis. Antibody arrays enable the detection of multiple 
proteins in parallel and have proven useful in many instances, including basic biological 
and applied research. Over the past few years the range of commercially available 
antibodies that have a highly selective binding capacity to the native protein or the post 
translational modifications of proteins, has become extensive. There are now many 
commercially available (and bespoke platform) antibody array technologies based upon 
the high affinity antibodies which are being used extensively in studies to quantify 
antigens (Kolch et al., 2010). In many ways the antibody array has become 
complementary to mass spectrometry based technology, potentially acting as a control if 
the same protein is identified. Antibody arrays have been used to identify possible 
biomarkers in cancer for instance gastric (Mohri et al., 2009) and oesophageal squamous 
cell carcinoma (Shao et al., 2009). They have been used to profile cytokines in samples 
(Ghoniem et al., 2011) and glycopeptide profiling in colorectal cancer serum (Pedersen et 
al., 2011). Profiling of receptor tyrosine kinase (RTK) signalling and protein-protein 
interactions have also been investigated using this technology (Engels et al., 2011 and 
Patel et al., 2011). The arrays can be used to look at a multitude of different samples; 
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tissue, cell culture lysates, serum, plasma and conditioned media. When used on samples 
such as conditioned media and secreted proteins, there is minimal preparation work 
involved as the proteins are already soluble. This application could be utilised in the 
profiling of cytokines, signalling growth factors, and potential biomarkers. 
 When used in a clinical setting the antibody arrays can provide a potentially 
valuable tool for the prognosis, diagnosis, and determination of therapy/drug response. 
Combinations of markers (multi-markers) (Mion et al., 2007) have been proven to 
produce less false positives in a clinical setting. If a number of markers in combination 
were used on an array, it could provide a test that could be carried out using relatively 
low volumes of sample and allowing the parallel detection of proteins in one sample. 
Away from the clinical setting, antibody arrays have great potential in basic and applied 
biological research. They allow the co-ordinated changes in pathways known to be 
important in several diseases including cancer, such as mitogen activating protein kinase 
(MAPK), to be investigated fully in several experimental models simultaneously. As the 
whole proteome is very complex it is unlikely that the development of an array that 
targets a significant portion of the total proteome will come to fruition for many years. 
The largest array commercially available is from Sigma –Aldrich which assays 725 
proteins. Antibody arrays are evolving rapidly into being extremely useful tools in both 
basic and applied research. 
1.1.2 Mass spectrometry based proteomics 
Mass spectrometers are essentially analytical tools that can determine the 
elemental composition, or chemical structure, of a compound or a sample. They are, in 
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the most basic sense comprised of 3 parts; an ion source, a mass analyser, and a form of 
mass detection unit (see Figure 1-1 below).  
 
Figure 1-1 A basic figure of a mass spectrometer work flow. The sample is introduced at 
the inlet, followed by the ion source where the ions are made into gas phase ions, this is 
followed by the mass analyser where the ions are sorted by size and then the ions are 
detected using a mass detection unit. The data gathered from this is then analysed in the 
mass spectrometer software and results produced in the form of a mass spectrum. 
Adapted from www.ionsource.com (February 2010)  
 
The ion source is used to create a charged analyte, the analyser is used to record the ratio 
of mass to charge (m/z) of the ion and the detector measures the relative abundance of the 
ion. Normally, protein samples are enzymatically digested (often using porcine trypsin) 
producing much smaller, structurally less complicated peptides.  When proteins are 
digested with trypsin to form peptides they are cut at the C terminal side of lysine (K) or 
arginine (R) amino acid residues, allowing prediction of the cleavage sites. When 
proteins are trypsinised to form peptides it increases the number of separate entities in the 
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sample, therefore it is often necessary to separate the peptides so that relatively few are 
introduced into the mass spectrometer simultaneously. Reverse phase – high performance 
liquid chromatography (RP HPLC). It is often used to separate the peptides and this less 
complicated mixture of peptides is then introduced into the mass spectrometer for 
analysis.  
Electro spray Ionisation (ESI) (see Figure 1-2) is one of the most common mass 
spectrometry methods for biological sample analysis. The analytes leave the HPLC and 
are sprayed into the mass spectrometer via a needle. The analyte passes out of the needle 
and is ejected in a particular shape, known as a Taylor cone (Taylor, 1964) (see Figure 1-
2). This shape occurs because of the large potential difference (1-5Kv) and high 
temperature (approximately 200°C) between the needle and the mass spectrometer inlet. 
The desolvation of the analyte is aided by these conditions. 
There are several ways in which the instrumentation can be optimised to deal with 
peptides including using a low flow rate (0.1-1μl/min) which allows the samples to be 
concentrated more effectively and also aids with the desolvation process. The high 
potential difference between the needle and the inlet helps to draw the positively charged 
peptide ions (after desolvation) into the ion trap. 
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Figure 1-2 Electro Spray Ionisation (ESI) The analytes are dissolved in a volatile solvent, 
usually a mixture of acetonitrile, water and a source of protons (diluted in the mobile 
phase). The analytes are sprayed in to the mass spectrometer via a needle producing a 
cone shape (known as Taylor cone). Desolvation of the analyte takes place over a high 
potential difference and temperature and the positively charged analyte then enters the 
mass spectrometer. 
 
In this study an ion trap mass spectrometer was used; inside an ion trap there is a 
high vacuum (created using vacuum pumps), the purpose of this is to eliminate the 
prospect of the peptide ions colliding with molecules from the atmosphere. The path that 
the ions take into the ion trap decreases in pressure, ultimately finishing at 10 e-3 Torr. 
When in the trap the ions are manipulated; firstly they are trapped, then isolated followed 
by excitation and finally ejected from the trap. Trapping is where all the ions are allowed 
to enter the ion trap, there is a direct relationship between the mass and the charge of an 
ion and the position it is in relative to the radio-frequency (RF) voltage (RF voltage is 
used to control the ions within the trap). This relationship allows all the ions within a 
+
+
+
+
+
+
+
+
-
-
-
-
High potential difference 
High Temperature 
Taylor cone 
Desolvation 
~ 18 ~ 
 
defined range of mass to be trapped. The isolation step can be used to isolate ions of a 
particular size (within a mass tolerance) which then can be used in the excitation step.  
Collision induced disassociation (CID) is a process used to fragment the ions (of a 
particular mass) for MS/MS and was used in this study. In CID helium is used as a 
neutral gas to collide with the peptides with sufficient energy to allow the intra-peptide 
bonds to break – frequently the middle amide bond between the adjacent amino acids. 
The charge can either be retained on the N-terminal of the fragment the ion which is then 
classified as a B ion, or the charge is retained on the C-terminus of the fragment then the 
ion will be classified a Y ion (see Figure 1-3). The detected mass of the fragments is what 
is used to determine the mass “fingerprint” of the ion and eventually lead to the sequence 
being resolved. The peptides do not fragment sequentially it is a random process.  The 
final step in the ion trap is ejection; ions are scanned out of the trap in increasing m/z 
order where the mass of the ion is recorded.   
 
Figure 1-3 Fragmentation showing B and Y ions of a peptide. 
 
 
The analysis of peptides by mass spectrometry is done in two stages; in the first 
stage, MS analysis, the m/z ratio of the peptide ion is recorded collectively with the ions 
relative abundance (the intensity of the ions signal). The second stage of peptide analysis 
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is determination of the mass fingerprint (MS/MS analysis) of a peptide can be then used 
to determine the sequence of the tryptic peptides using computer programs such as 
Sequest. The m/z ratio and the fragmentation pattern enable the peptide sequence to be 
predicted using suitable search algorithms. This sequence identification is achieved when 
the mass of the first ion is compared with the next 500 peptides that are closest in mass to 
the trypic fragment; these 500 predicted peptides are sourced from searchable database 
such as Human_FASTA ipi. From the list of predicted matches the software makes a 
comparison with the predicted and the actual peptide fragment and the closest match is 
likely to be the sequence of the actual peptide. Multiple peptides from the same protein 
increase the confidence in the identification. 
Predicted peptides are given a score, the more accurate the match the higher the 
score. This is done using Bioworks browser software and Sequest, and the score given to 
the peptide is called Xcorr. Xcorr is an indicator of accuracy and is a raw cross-
correlation score, derived from several relevant parameters.  
1.1.3 Labelling strategies – Quantitation in Mass spectrometry 
Use of a labelled approach helps to lessen the effect of ion suppression, the origin 
and mechanisms of which are not fully understood. It describes a change in the intensity 
which is often observed as a loss in response. The term ion suppression was introduced 
originally by Buhrman et al., 1996 and it is usually apparent in the early stages of the 
ionization process in LC–MS, usually when a component is eluted from the HPLC 
column which influences the ionisation of a co eluted analyte. Ion suppression can occur 
when elution of more than one analyte occurs in the same retention window as the 
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analyte of interest. As the peptides in SILAC (heavy and light) are chemically indistinct 
they elute in the same elution window and are subject to the same level of ion 
suppression. 
There are now many labelling strategies for mass spectrometry (MS) based 
quantitation. MS is an ideal technology for the identifying peptides and /or proteins. It 
can be used in conjunction with a labelling technology so that the relative protein 
abundance in the sample can also be assessed. This is frequently carried out through 
stable isotope labelling (which can be broadly classified into a tag based technology or a 
biological incorporation technology); stable (non-radioactive) heavier isotopes of carbon 
(
13 
C), hydrogen (
2
H), oxygen (
18
O) or nitrogen (
14 
N) are incorporated into one 
experimental sample and the corresponding light isotopes in another.  Early strategies 
included isotope-coded affinity tags (ICAT) labelling cystine residues (Gygi et al., 1999) 
and H2
18 
O labelling (Heller et al., 2003) (trypsin catalysed) and the now preferred 
techniques of stable isotope labelling in amino acids in cell culture (SILAC) (Ong et al., 
2002) which was used in this study, isobaric tags for relative and absolute quantitation 
(iTRAQ) (Cong et al., 2006) and isotope coded protein label (ICPL) labelling 
(Kellerman, 2008) are generally used. There is also label free quantitation which is 
increasingly being used (Wright et al., 2011), unfortunately the performance of the mass 
spectrometers and software used during this project could not be used in conjunction with 
iTRAQ or label free quantitation  such as spectral counts (Friso et al., 2011) and Selected 
Reaction Monitoring (SRM) (Lange et al., 2008). ICPL is a more recent advance in 
labelling strategy and was not available for this study.  
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The addition of a heavy stable isotope to one sample and a light stable isotope to 
the other allows for the simultaneous measurement of the same molecule and both the 
heavy and light isotopes, all subjected to the same environment and subsequently the 
relative intensities are deemed quantative (Pieniaszek et al., 1999).  
SILAC was first described in 2002 (Ong et al., 2002) who showed the 
incorporation of specific amino acids into all cellular proteins in vivo. In this they used 
deuterated leucine residues as the label, but more recently papers cite labelled arginine 
and lysine as the preferred residues for the label. The ability to measure the same 
molecule but distinguish between two samples; heavy and light labelled which co-elute 
so the MS analysis takes place simultaneously, this makes the ratio of peptides reliable. 
This is important as it forms the basis of the MS based quantitative analysis of peptides 
and proteins as the ratio of intensities of the peptide peaks in a mass spectrum provides us 
with a relative ratio of abundance between the two species. 
As the cells are grown in the heavy and light media they begin the incorporation 
of the particular isotopic variants into newly synthesised proteins and after a minimum of 
six population doublings achieve 95% incorporation (Ong et al., 2002). The distinct mass 
difference (6Da in 
13
C lysine) and the common retention time of the co-eluting peptides is 
the key to identifying from which sample the peptide originates. The difference between 
heavy and light isotopes does not affect the cells (morphological, biochemical, or 
proliferative differences are not observed) as the isotopes are chemically indistinct.  
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Figure 1-4 SILAC overview work flow: two populations of cells (MCF7 and TAMRBU 
shown here) MCF7 here are grown in Heavy isotope labelled media (designated with a 
red star) and TAMRBU are grown in the C12 light isotope labelled media. These are 
grown for a minimum of 6 population doublings to ensure high level incorporation of the 
isotope. The cells are then counted and mixed, then lysed. A protein assay is carried out 
and the protein run on a gel, in-gel digested and the tryptic peptides analysed on the mass 
spectrometer. 
 
A distinct advantage of SILAC is that the incorporation of the isotope can 
approach 100% and the samples from two populations can be mixed at a very early stage 
then processed by further fractionation as one sample eliminating the potential for 
experimental variance between samples which may otherwise be seen if processing was 
done separately. In the literature, SILAC has been used to investigate a great number of 
processes; including MAPK pathway analysis (Blagoev et al., 2006), protein interactions 
(Thomas et al., 2011), cisplatin resistance in HeLa cells (Chavez et al., 2011), secretome 
MCF7 TAMRBU
GROW CELL POPULATIONS IN MEDIA
GROW FOR 6 POPULATION DOUBLINGS 
CHECK % INCORPORATION
MIX CELL POPULATIONS 1:1
PREPARE CELL LYSATES 
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EXCISE GEL BANDS AND PERFORM 
IN-GEL DIGETION 
ANALYSE TRYPTIC PEPTIDES ON MS
Adapted from Invitrogen user manual (May, 2006)
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analysis of gliobastomas (Formolo et al., 2011), and profiling Myc associated proteins 
(Agrawal et al., 2010). 
1.1.4 Matrix Assisted Laser Desorption Ionisation (MALDI) and Surface 
Enhanced Laser Desorbtion/Ionisation (SELDI) 
MALDI is a laser based soft ionisation technique that has been proven to be one 
of the most popular methods of MS for protein analysis and can be used for the 
identification of xenobiotics and also in MS imaging. MALDI  and SELDI based 
technology allows for rapid production of protein profiles from complex mixtures  such 
as; cell lysates, conditioned media, serum, plasma and tissue. They have been used with 
some success to detect biomarkers and SELDI based proteomics is used to detect 
peptides and small proteins (less than 20 kDa). 
SELDI is a modified form of MALDI based on a chip which was developed by 
Ciphergen. The sample is spotted onto the chip which has a modified surface with 
different chemical functionality, allowing some proteins to bind while others are washed 
away. The sample that is retained on the chip surface has appropriate matrix applied to it 
and measured directly in the MALDI MS. The chromatographic surface operates as a 
separation step and the sample is decreased in complexity. The chip surfaces available 
include: CM10 (weak-positive ion-exchange), H50 (hydrophobic surface – this is similar 
to reverse phase separation), IMAC30 (metal-binding surface- this can be loaded with 
different metal salts such as copper sulphate), and Q10 (strong anion exchange). Surfaces 
can also be used in conjunction with antibodies (for immuno-MS).  
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Figure 1-5 A basic diagram of the SELDI/MALDI system. Samples are spotted on to a 
SELDI chip with its retentate surface and processed with matrix. A laser ionises the 
peptides from the sample/matrix crystals on the spot. These ions are accelerated down an 
electric potential and down a flight tube to the detector. The m/z can be determined by 
the time taken to travel the flight tube and the kinetic energy of the ions in the electric 
field. Relative peak intensities from the MALDI can be used as a semi quantitive 
measurement of the protein presence in the sample. 
 
 
 
A chemical matrix is required for MALDI investigation of samples. The sample is 
acidified using a weak organic acid such as tri fluoroacetic acid (TFA) and is either laid 
under, in or on the matrix which is always in a molar excess (compared to the sample). 
The matrix helps to produce intact gas-phase ions from biomolecules such as proteins and 
oligonucleotides or large inorganic compounds and synthetic compounds; it does this 
through absorbing the laser light energy which is then transferred causing the target 
substrate to vaporise. It is vital to use the correct one; there are a number of matrices for 
protein/ peptide analysis such as alpha cyano-4-hydroxycinnamic acid ( CHCA). Matrix 
properties must include vacuum stability, ability to co-crystallise with analytes, be stable 
in solvents such as acetonitrile (ACN), able to cause co-desorption of the analyte when 
laser stimulated, and be able to absorb the laser wavelength. 
Chip
Flight tube Detector Mass/Charge (m/z) 
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1.2 Cancer 
Cancer is the result of many complex changes occurring in a “normal” cell, 
progressing through to malignant and potentially metastatic. The 6 hallmarks of cancer as 
outlined in Hanahan and Weinburg’s review in 2000 are shown in Figure 1-6 below.  
Cells commonly become cancerous when they acquire irreparable DNA damage, 
changing the sequence of genes which code for important regulatory proteins. After 
replication the mutations are passed down to the next generation of cells which can lead 
to deregulated growth, tumour progression and invasion through the basement membrane. 
 
Figure 1-6 The 6 hallmarks of cancer (adapted from Hanahan & Weinburg, 2000) 
 
 
 
Accumulations of successive DNA mutations arise over the course of a person’s 
life time (somatic gene changes) which is why age is often a risk factor in cancer. Also, 
lifestyle factors such as diet, alcohol, stress and tobacco have all been implicated in either 
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causing or increasing the risk of cancer.  The environmental exposure to chemical 
carcinogens and the ultra-violet rays of the sun have also been shown to result in DNA 
damage and result in cancer. There are examples of gene mutations that are hereditary for 
instance BRCA1 and BRCA2 which are tumour suppressor genes involved in DNA 
repair of double stranded breaks. Mutations in these genes can cause instability of the 
human genome. Women that have heterozygous germ-line mutations in BRCA1 or 
BRCA2 have a substantially increased risk of highly penetrative breast cancer and 
ovarian cancer. Patients that are positive for this mutation can chose to have pre-emptive 
mastectomies or preventative Tamoxifen treatment (Reding et al., 2010).  
1.3 Breast Cancer 
Breast cancer is now the most common cancer in the United Kingdom with 
approximately 125 women diagnosed each day. In 2008 around 12,000 women and 70 
men died from breast cancer. (CRUK – “cancerstats -key facts.” Updated Nov 2010).   
The incidence of breast cancer increases with age (around 80% of diagnosed cases are in 
women over the age of 50) and there are other risk factors; such as obesity, high socio-
economic group, alcohol use, expression of BRCA1 or BRCA2, ethnicity, early 
menarche, and childbirth late in life. 
There are many types of breast cancer; ductal carcinoma in situ (DCIS) and lobular 
carcinoma in situ (LCIS) are early, non-invasive types. There is also invasive lobular and 
invasive ductal carcinoma, or more rare types such as inflammatory breast cancer, 
medullary breast cancer, mucinous breast cancer, metaplastic breast cancer and papillary 
breast cancer. The stage and grade of a tumour, as well as the presence of oestrogen 
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receptor, progesterone receptor and ErbB2 are used to decide the treatment options for 
the patient. The patient can be classed as “triple negative” where they do not express any 
of these 3 receptors. 
A unique feature of oestrogen receptor positive breast cancer is the dependence on 
the endogenous steroid oestrogen. This is a feature that can be, and is, frequently used in 
the prevention of development of tumours and in the treatment of them. Manipulation of 
the oestrogen receptor can be carried out using therapeutic agents such as selective 
oestrogen receptor modulators (SERMs) (section 1.5.1), selective oestrogen receptor 
down regulators (SERDs) (section 1.5.2), luteinizing hormone-releasing hormone 
(LHRH) inhibitors (section 1.5.3), aromatase inhibitors (AI) (section1.5.4) or using 
physical ablation of the ovaries. 
When this project started in 2007, the majority of oestrogen receptor positive 
breast cancer patients in the United Kingdom received Tamoxifen either pre or post 
surgery, however, the use of AI’s has significantly increased in post menopausal women. 
The TEAM (Coombes and Kilburn, 2011) and BIG 1-98 (Kelly and Buzdar, 2010) trials 
have since reported that there is still value in patients being treated with Tamoxifen 
(2.5years) prior to a switch to AI therapy for post menopausal women. For women with 
breast cancer Tamoxifen is still a standard component of therapy. 
1.4 Oestrogen and oestrogen receptors 
Oestrogen is an important regulator in the development and progression of breast cancer 
and also in the development of normal breast. More than a century ago, Scottish surgeon 
George Beatson performed an oophrectomy and noted this procedure induced regression 
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of breast cancer which was later proven to be due to a reduction in systemic oestrogen 
levels (Stockwell, 1983). Oestrogen mainly originates in the ovaries in pre-menopausal 
women, whereas in post menopausal women the main source is in the aromatisation of 
androgens in adipose tissue. This accounts for the difference in therapeutic regimen 
between the two groups of women.   
Oestrogen functions by activating two nuclear steroid receptors: ER  and ER . 
Both receptors bind oestrogen and initiate gene transcription through ERE (oestrogen 
response elements) in oestrogen target tissues but have distinct functions and tissue 
distribution (Sommer and Fuqua, 2001). In most breast carcinomas (~70%) ER  is highly 
expressed which results in the increased rate of proliferation without differentiation or 
apoptosis. ER  is exclusively epithelial (Saunders et al 2002 and Speirs et al 2004) 
whereas the distribution of ER  in breast cancer is exclusively nuclear but expressed in 
multiple cell types (stromal fibroblast, endothelial and immuno-infiltrating cells) its 
expression has also been shown to correlate with an increase in aggression of the tumour 
(Younes and Homna, 2011). ER  expression has been reported to range from 26% to 
94%, the lowest of which was in a Japanese study, this implicates that the expression 
could be related to ethnicity. When Caucasian cohorts of patients were compared, the 
range was less extensive at 74%-94% (Speirs, 2004). The expression of ER in the breast 
has been well described although its usual function, clinical value in carcinogenesis, and 
its relevance to the pathological diagnosis of breast cancer, is yet to be determined 
(Speirs, 2004). 
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Oestrogen receptors that are not bound to ligand are inactive and usually 
sequestered in multi-meric protein complexes organised around the molecular chaperone 
heat shock protein 90 (HSP90). ER signalling pathways can be classed into 4 main 
mechanisms of action: Classical, ERE independent, ligand independent and non-genomic 
Figure 1-7). 
Classically the cytoplasmic ER translocates into the nucleus upon ligand binding. 
In the cytoplasm, the receptor dimerises, transcription factors and co-activation proteins 
are recruited, and the target genes are then activated through an oestrogen response 
element (ERE). Oestrogen activates genes that are involved in survival and cell 
proliferation amongst other actions (Elliston et al., 1990; Frasor et al., 2003 and Wilson et 
al., 2006). Oestrogen bound ER interaction with Fos and Jun, which dimerise and become 
part of the activator protein-1 (AP-1) complex modulating gene expression. This ligand 
bound ER gene modulation can also occur with GC box bound specificity protein -1 (SP-
1) this is ERE independent modulation.  ER can act independently of oestrogen by being 
phosphorylated on multiple residues (see Figure 1-8) within the receptor after growth 
factor activation. The phosphorylation of ER leads to the dimerisation of the receptor, 
DNA binding and ultimately activation of transcription (Murphy et al., 2011; Le Goff et 
al., 1994 and Chen et al., 1999).  
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Figure 1-7.  A simplified view of the 4 mechanisms by which oestrogen can exert its 
action upon a cell (roles and names of co-factors have been omitted).  1, Classical 
pathway: This is a genomic, ligand dependent mechanism; where estradiol (E2) bound 
dimers bind to the EREs (in lilac) in target promoter genes – this leads to an up regulation 
or down regulation of gene transcription and resulting in the oestrogenic effects being 
seen in the cell. 2, ERE independent pathway: This is also a genomic, ligand dependent 
mechanism where oestrogen bound ER dimers bind to alternative gene response elements 
such as AP-1 through Fos and Jun association and thus lead to gene transcription. 3, 
Ligand independent mechanism: This is a genomic ligand independent mechanism where 
the phosphorylation and subsequent activation of the ER, following growth factors and/or 
signalling molecules stimulation leads to target gene transcription. 4, the non-genomic 
ligand dependent mechanism; this is where the estradiol binds to a membrane associated 
receptor  activating intracellular signalling generating rapid oestrogenic effects in the cell. 
Figure adapted from Hall et al., 2001 
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Figure 1-8  Shows a basic example of ER  and its regions A/B - Activating factor 1 
domain (AF1), C -DNA binding domain (DBD), D – Hinge domain, E- Ligand binding 
domain,  and F domain. Multiple phosphorylated sites can be seen in the light blue boxes 
below the ERα domain where they have been identified by a variety of approaches. S118 
and S167 (highlighted with a red box) have been associated with Tamoxifen resistance. 
Figure adapted from Murphy et al., 2011. 
 
 
 
 
Oestrogen can also activate membrane bound ER and cause a rapid oestrogen signalling 
response through non-genomic activation (Levin et al., 2005 and Song and Santen, 2006). 
The non-genomic simulation of the oestrogen receptor is a rapid response to the ligand 
binding and its response in the cell is independent of the gene transcription. Oestrogen 
receptors act through a complex interplay of signalling cascades; such as insulin-like 
growth factor 1 receptor (IGF-1 R) (Song et al., 2010), EGFR (Fox et al., 2008), G-
proteins, Src, and PI3K (Wu et al., 2011). 
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1.5 Therapeutic agents 
Development of new therapeutics for breast cancer has resulted in new agents 
directed against certain molecular targets such as c-met (Eder et al., 2009), HSP90 (Wang 
et al., 2011), or angiogenesis related targets such as VEGFR2 (De Luca and Normanno, 
2010), signalling pathways such as mTOR (O’Regan and Hawk, 2011) all of which could 
prove to aid in treatment of the heterogeneous disease and a more unique patient 
treatment regimen. Presently, the majority of these new therapeutic agents are not 
clinically available and most are at preliminary laboratory stage of investigation. The 
therapeutic agents in clinical practice are detailed below and can be seen in Figure 1-9. 
 
Figure 1-9 Endocrine therapeutic agents can be used to treat ER positive breast cancer. 
The treatment regimen usually differs between pre and post menopausal women. In pre-
menopausal women the LHRH agonists work by blocking the production of oestrogen by 
the ovaries. SERMs such as Tamoxifen can also be used to partially block the oestrogen 
receptors. In post menopausal women AIs stop the enzyme aromatase from working and 
this prevents the conversion of androgens to oestrogens. SERMs can also be used in post-
menopausal women and also SERDs can be used to prevent ER mediated cell replication 
by potentially binding and degrading the oestrogen receptor.  
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1.5.1 Tamoxifen & Selective oEstrogen Receptor Modulators  
Tamoxifen (Nolvadex) is a selective oestrogen receptor modulator (SERM) that is 
classed as a partial antagonist due to having oestrogenic effects in some tissues such as 
the endometrium and bone, and anti-oestrogenic effects in tissues such as breast and the 
mammary epithelium. In breast cancer, oestrogen has been shown to promote 
development of the disease (as described above in section 1.4), so the interference in its 
action can be used to help slow/stop the progression of breast cancer. Tamoxifen is a 
hormonal treatment licensed as a first line adjuvant therapy in the treatment of early 
oestrogen-receptor positive breast cancer in the UK (NICE guidelines). In the UK, 5 
years of Tamoxifen therapy has become standard adjuvant hormonal treatment for 
postmenopausal women with early, oestrogen-receptor-positive breast cancer. Over the 
decades that Tamoxifen has been available it has become the most widely used endocrine 
therapy for ER+ women. It has been proven that the use of Tamoxifen significantly 
improves the survival of women with early stage breast cancer (Clark, 2006). Tamoxifen 
also provides protection against bone fractures in postmenopausal women, due to its 
oestrogenic effects in bone (Section 1.4) and it lowers serum cholesterol levels. The side 
effects associated with long term use of Tamoxifen have been associated with vaginal 
bleeding, endometrial thickening, and increased risk of endometrial cancer and thrombo-
embolic events.  
Patients may initially respond to the Tamoxifen, but unfortunately, almost all 
patients eventually acquire resistance over the course of the therapeutic regimen and the 
disease progresses. Several mechanisms of Tamoxifen failure have been suggested, some 
of which will be discussed further in section 1.7.  
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1.5.2 Selective Estrogen Receptor Down-regulators 
Selective oestrogen receptor down regulators (SERDs) such as fulvestrant, bind the 
oestrogen receptor and abrogate oestrogen signalling in cells. Fulvestrant has been shown 
to have no agonistic activity (unlike SERMs such as Tamoxifen) and therefore it does not 
preserve bone density of patients, but conversely does not increase the risk of blood clots 
or increase the risk of endometrial cancer. Fulvestrant may provide a beneficial effect in 
the treatment of oestrogen receptor positive patients that are Tamoxifen resistant, though 
it is mainly used for the treatment of postmenopausal women. Use in premenopausal 
women has also been suggested as beneficial by in an adjuvant setting (Young et al., 
2008). 
1.5.3 Luteinising Hormone Releasing Hormone agonists 
Luteinising Hormone Releasing Hormone (LHRH) agonists (such as goserelin) are 
another strategy in adjuvant endocrine therapy for pre menopausal women. They work by 
temporarily suppressing the synthesis of ovarian oestrogen; this is done by desensitising 
the hypothalamus/ pituitary/ ovarian axis (Huirne and Lambalk, 2001). This is used rather 
than the permanent effects of oopherectomy or radiotherapy that were traditionally used. 
LHRH agonists have proved to be a reliable and reversible agent to the ablation of 
ovarian oestrogen synthesis. The role of LHRH agonists in the treatment of breast cancer 
patients remains unclear as it was deemed that not enough evidence was available to 
compare LHRH agonists directly to (Goel et al., 2009). However, it has been indicated in 
the literature that the combination of treatments, LHRH agonist and Tamoxifen, is 
~ 35 ~ 
 
superior to the treatment of LHRH agonist treatment alone in women who are 
premenopausal with advanced breast cancer (Klijin et al., 2001).  
1.5.4 Aromatase Inhibitors 
Aromatase inhibitors (AIs) are a class of drugs that work by stopping the biosynthesis of 
oestrogen from the circulating androgens in tissues such as the breast and adipose tissue. 
This biosynthesis is carried out using the enzyme aromatase and the drug works by 
inhibiting this enzyme. AIs such as anastrozole, letrozole and exemestane have been 
shown in the literature and in trial data to be a superior treatment to Tamoxifen in the 
treatment of advanced breast cancer in post menopausal women (Nabholtz and Gligorov, 
2006; Mouridsen, 2007 and Coombes and Kilburn, 2011). Other trials have shown very 
similar efficiency for sequential regimens with AI and Tamoxifen and a combined 
regimen might reduce side effects of the treatments (Van de Velde, 2011). AI’s are not an 
effective treatment for pre-menopausal women with an intact hypothalamus/ pituitary/ 
ovarian axis and can potentially only be safely used in this group of patients if the axis is 
suppressed (either by LHRH agonists, surgery, or radiotherapy). Tamoxifen in 
combination with chemotherapy and Tamoxifen in combination with LHRH agonists 
remain the only proven endocrine intervention in the treatment of women with pre-
menopausal breast cancer. There are now known to be cases of AI resistance (Ma et al., 
2011) and the literature supports the hypothesis that the acquisition of resistance is 
predominantly mediated by cellular signalling events that lead to the constitutive 
activation of ER and growth factor miscommunication (Santen et al., 2005; Riggins et 
al., 2005 and Masri et al., 2008). 
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1.6 Mechanisms of Tamoxifen action 
Tamoxifen is a non-steroidal triphenylethylene derivative and works by binding to the 
oestrogen receptor. It works strongly as an anti-oestrogen within mammary epithelial 
cells, but does also act as an oestrogenic in some tissues such as bone. It was originally 
screened as a contraceptive agent that was effective in rats but not humans. In the early 
1970’s Tamoxifen was shown to be useful for clinical palliative care for advanced breast 
cancer and approved for the treatment of post menopausal patients with metastatic breast 
cancer in 1973 (UK) and 1977 (USA). 
The mechanism by which Tamoxifen works in the treatment of breast cancer is 
complex. Its principal mechanism of action is stopping the proliferation of the cells that is 
initiated by oestrogen stimulation (cytostatic); this action is mediated by the drug 
competing with oestrogen and subsequently binding to the oestrogen receptor in 
mammary epithelia to form a nuclear complex that decreases DNA binding and 
oestrogenic effects (see Figure 1-10). Tamoxifen and its metabolites such as 4-hydroxy 
Tamoxifen (4-OH Tamoxifen) (see Figure 1-11) bind to oestrogen receptors with a 
similar affinity to that of oestrogen, and have been shown (Dowsett et al., 2005) to 
saturate the ER present in post-menopausal women (99.9% saturation).  
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Figure 1-10. The action of Tamoxifen (T) compared to the action of Estradiol (E). When 
stimulated with E the ER dimerises and both AF1 and AF2 are active. The receptor dimer 
moves to the nucleus Estrogen Response Element (ERE). AF1 and 2 recruit co-activators 
and E stimulated tumour growth is activated. When Tamoxifen is added the receptor 
dimerises, AF1 is active however, AF2 is blocked.  The receptor dimer moves to the ERE 
however due to AF2 blockage only AF1 is able to recruit co-activators and this 
subsequently leads to partially inactivated transcription. Adapted from Buzdah et al., 
2004. 
 
Often genes that are down regulated upon oestrogen signalling are transcriptional 
repression genes and pro-apoptotic genes and conversely the genes that are up-regulated 
are ones that are related to pro-growth and survival (Frasor et al., 2003). Up regulation of 
these genes is mediated by activating function 1 (AF-1) and activating function 2 (AF-2), 
these are regions located on ER  (ER  does not possess an AF-1 region, (Kong et al., 
2003) which assist in the recruitment of co-regulatory proteins. 
Tamoxifen competes with oestrogen; it binds to ER and the receptor dimerises, 
however, AF-2 is not activated (Figure 1-10) as AF-2 activation is hormone dependent. 
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AF-1 action is not reliant on ligand binding but is mediated by phosphorylation and 
therefore retains activity, thus leading to only partially inactivated transcription. Genes 
that only require the action of AF-1 are still transcribed, and the preference for AF-1 or 
AF-2 in different tissues such as the bone, uterus and breast, goes some way to explaining 
the selectivity of Tamoxifen efficacy in different tissues. 
 
 
 
Figure 1-11 Tamoxifen and its metabolites in human treatment. Tamoxifen is given at 
20mg per day. It is metabolised by the cytochrome P450 family. The main metabolites 
that have a high affinity for oestrogen receptors are 4 Hydroxy Tamoxifen (4OH 
Tamoxifen) and Endoxifene. Selective Serotonin Reuptake Inhibitors (SSRIs) have the 
ability to bind to the CYP2D6 preventing the hydroxylation of the Tamoxifen and N-
desmethyltamoxifen preventing the formation of these important metabolites. (Jordan, 
2007). 
 
An alternative mechanism for Tamoxifen’s anti-proliferative action is the 
production of transforming growth factor beta (TGF It has been suggested that the 
anti-oestrogen signal transduction pathway involves sequential activation of p38 and 
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TGF pathways in order to control the growth inhibition (Buck et al., 2004). Moreover, 
activation of TGF  has also been shown in ER negative cells (mesenchyme and stromal 
cells) which suggest this interaction does not rely wholly upon the oestrogen receptor, 
and could be a possible explanation for some effectiveness seen in cells negative for 
oestrogen receptor (Charlier et al., 1995). Some studies have also shown that circulating 
levels of IGF-1 can be lowered by exposure to Tamoxifen; this may abrogate the action 
of the potent mitogen on the breast cancer cells and aid in the suppression of the cancer 
growth (Ho et al., 1998). Therapeutic concentrations of Tamoxifen have also been 
reported to inhibit protein kinase C (PKC) and calmodulin-dependent cAMP 
phosphodiesterase enzymes; this could impact upon the proliferation of the cells and 
Tamoxifen’s anti tumour activity as these proteins are known to have a role in growth 
regulation (O’Brian et al., 1990).  
 
1.7 Mechanisms of acquired Tamoxifen resistance 
The development of therapeutic anti-oestrogens such as Tamoxifen has proven to be 
effective in the treatment of hormone responsive breast cancer but has led to the 
discovery of a very real clinical problem: antioestrogen resistance. This type of resistance 
is now a common feature of the treatment and therefore limits the anti-oestrogen’s 
therapeutic success. Some hormone responsive patients do not respond to treatment with 
Tamoxifen; this is called intrinsic or de novo resistance. Patients that are initially treated 
successfully with Tamoxifen frequently acquire resistance over time, often relapsing to a 
more metastatic state. Acquisition of resistance to Tamoxifen plausibly involves 
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carcinoma cells developing further elaborate changes; it is unlikely that one mechanism 
will fully elucidate the mechanism of resistance.  
 
Altered ER and ER signalling 
The effects of Tamoxifen are largely mediated via the oestrogen receptor, and expression 
of oestrogen receptor is the decisive factor which treatment is based on therefore it is 
natural to imagine that a loss or decrease in ER expression in the cell could confer the 
acquisition of Tamoxifen resistance. One cause of intrinsic resistance is decreased or 
absence of ER expression due to the hyper methylation of ER genes. However, a decrease 
in the ER level of expression only affects a minority of resistant cancers (15-20%), and 
does not appear to be involved in acquired resistance (Guiterrez et al., 2005). This was 
further confirmed when AI was given as a follow up treatment to patients who had 
relapsed on Tamoxifen, as most responded to AI (see section 1.5.4) treatment, or to the 
SERD (see section 1.5.2) Fulvestrant,  which suggests that the ER continues to be 
functionally active in many Tamoxifen resistant breast cancers (Howell, 2002).   
Early studies suggested that mutations in the oestrogen receptor could confer 
resistance, but, this has now been shown to be present in only 1% of ER positive breast 
cancers (Clarke et al., 2003; Riggins, 2007 and Herynk and Fuqua, 2004). Mutations have 
been generated in laboratories which can confer resistance, some of which have been 
detected in patients for instance, Fuqua et al., 2000 found that a single amino acid 
substitution was found in approximately one third of the hyperplastic breast lesions 
investigated, (changing K303 to L303). Further investigation showed that this mutation 
lead to a hypersensitive ER that was able to bind co-activators in the presence of low 
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oestrogen. It was found to enhance ER mediated cellular growth by modulating the cross-
talk between ER and pathways that down regulate ER signalling (Barone et al., 2010). 
Altered regulation such as this could assist in acquisition of resistance to hormone 
therapy, however, the occurrences of mutations are few and often resistance occurs 
without the presence of mutations. It is therefore unlikely that mutations of the oestrogen 
receptor fully explain the mechanism of Tamoxifen resistance.  
A truncated form of ER , ER 36, has also been discovered to correlate with 
diminished responsiveness to Tamoxifen in the presence of the full form of ER  (Shi et 
al., 2009). 
The transient methylation of the ER  at arginine position 260 (R260) aids in the 
formation of multi-meric complexes containing PI3K, FAK, Src (tyrosine kinase) and 
ER  (via a protein known as protein arginine N-methyltransferase 1 – PRMT1); these 
complexes activate Akt which is known to be associated with endocrine therapy response 
(Le Romancer et al., 2008). 
  
 
Altered expression of co-regulatory proteins  
Co-regulatory proteins (activator and repressor) have very important roles to play in the 
transcription mediated by the ER. Altered patterns and expression of these proteins could 
contribute to Tamoxifen resistance.  
 Co-activators include the p160 steroid receptor family which function to stimulate 
the ER activity via an interaction with AF-2. The family includes AIB1, SRC-1 and TIF2 
(Webb et al., 1998). The co-activator AIB1 has been shown in the literature to be over 
expressed in over 50% of breast cancers (Anzick et al., 1997) it has also been shown to 
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have a pivotal role in MCF7 cells (List et al., 2001) which are the cells used in this study. 
It has been shown to be a predictive factor of Tamoxifen sensitivity; high expression of 
AIB1 correlates with a worse patient outcome (Alkner et al., 2010). It has also been 
proposed that it could provide a limiting factor in non-oestrogen driven, EGF stimulated 
growth through EGFR and ErbB2 in Tamoxifen resistant cells in culture (Zhao et al., 
2009). Other literature has provided an insight into how AIB1 and Paired Box 2 (PAX2) 
compete for regulation of ERBB2. Increased expression of AIB1 outcompetes PAX2 
binding, which would normally repress ERBB2 transcription, and therefore directly 
results in increased expression of ErbB2 (Hurtado et al., 2008). Increased ErbB2 protein 
activation has been indicated as a possible mechanism of Tamoxifen resistance (for more 
detail see below – RTKs). 
Another co-activator, PELP1, has been reported to have a role in resistance to 
Tamoxifen. It has been shown to function as a scaffold protein modulating the interaction 
of Src and the ER leading to the downstream activation of MAPKs, such as the ERKs, 
Src and the promotion of PI3K through oestrogen signalling (Gururaj et al., 2007).   
 
Aberrant growth factor signalling 
The modification and/ or altered expression and activation of several growth factors, 
growth factor receptors, and their downstream signalling molecules have been implicated 
in Tamoxifen resistance. Growth factors mediate their diverse biological actions; such as 
cellular proliferation, migration, metabolism and differentiation by acting upon receptors 
such as Receptor Tyrosine Kinases (RTK) on the cell surface. These receptors in turn 
activate many more signalling molecules such as the MAPK family (see below). RTKs 
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function in many critical roles within the cell, and their activity under normal 
circumstances is under tight control. When this control breaks down it results in aberrant 
signalling which can lead to tumourigenesis, and influence cell motility, invasion, 
angiogenesis, proliferation and survival. Aberrant signalling of some RTKs has also been 
linked with Tamoxifen resistance, including IGF-1R, EGFR and ErbB2 (Knowlden et al., 
2005).  
 Evidence suggests that abnormalities that occur in the EGFR and ErbB2 
signalling pathways could dramatically manipulate the way in which the cancer reacts to 
hormone action and ultimately, is thought to be critical to Tamoxifen resistant breast 
cancer growth in both patients and cell culture models (McClelland et al., 2001; 
Knowlden et al., 2003 and Hutcheson et al., 2003). Patients that express both ER and 
EGFR respond less well to Tamoxifen (Nicholson et al., 2002). ErbB2 over-expression is 
one of the better characterised mechanisms of Tamoxifen resistance.  
 Studies have shown that loss of transcriptional repressors alongside amplification 
of ERBB2 is the major factor responsible for this increase of ErbB2 expression. This loss 
of transcriptional repressors is mediated by Zinc finger transcription factor (GATA4) and 
X-linked Forkhead box P3 (FOXP3) tumour suppressor; a direct link between GATA4 
and FOXP3 and Tamoxifen resistance has not yet been established (Musgrove and 
Sutherland, 2009).  
Inhibition of ErbB2 using the inhibitor Trastuzumab (Herceptin) restored the 
inhibitory activity of Tamoxifen (Kurokawa et al., 2001). Herceptin alongside the EGFR 
inhibitor (Iressa) should theoretically provide us with useful tools in the treatment of ER 
positive breast tumours that are also positive for EGFR and/or ErbB2; such as in 
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Tamoxifen resistance. The results from a recent clinical trial showed that acquired 
resistance to Tamoxifen to be partially mediated through EGFR signalling which can be 
decreased using Iressa, (Gutteridge et al., 2010). 
The Insulin-like growth factor 1 receptor (IGF-1R) is part of the RTK super 
family. It has been considered to be a potential oncogene and plays a role in proliferation, 
cellular interactions, survival, and transformation (Casa et al., 2008). In the clinical 
setting the over expression of IGF1-R is seen frequently; it is phosphorylated in all breast 
cancers, and related to a poor outcome in patients (Fagan and Yee, 2008). It has been 
associated with Tamoxifen resistance in a number of ways: Cross talk between the 
IGF1R and ER signalling pathways (Fagan and Yee, 2008) when up-regulated IGF1R 
acts upon EGFR and ErbB2 (Massarweh et al., 2008 and Knowlden et al., 2005) and it is 
also thought that IGF1R may act in an ER independent manner where it continues to 
signal upon stimulation with IGF1 despite continuous suppression of ER transcription 
with Tamoxifen (Zhang et al., 2011). 
The Mitogen Activated Protein Kinase (MAPK) pathway has been implicated in 
the progression of cancer (Hanahan and Weinberg, 2000) and is also a known aberrant 
pathway resistance to endocrine therapy (Riggins et al., 2007). There are three major sub 
groups in the MAPK family: ERK, JNK, and p38 MAPK. Of these the ERKs are mainly 
involved in stimulation of cellular growth, usually activated via growth factors. JNK and 
P38 MAPK are activated via many different stimuli and the response (cellular growth or 
death) is dependent on the stimulus (cytokines, cellular stress, growth factors). Increased 
ERK phosphorylation and activation have been shown to lead to a reduced survival in 
breast cancer patients and acquisition of Tamoxifen resistance (Riggins et al., 2007). 
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Phosphorylation of Ser118 of the ER  has been shown to be induced by members of the 
MAPK (Joel et al., 1998), however, Weitsman et al., 2006 reported that the 
phosphorylation of Ser118 is not due to constitutive activation of MAPK pathway 
although the phosphorylation was reported to have a functional role in oestrogen 
regulated signalling. Ribosomal S6 Kinase (RSK), when activated by ERK1 and ERK2, 
has been shown to phosphorylate ER  at position Ser167 in the AF-1 domain (Joel et al., 
1998) see Figure 1-8. 
 Reactive oxygen species (ROS) induce cellular stress and can induce the 
activation of ERK and Akt signalling (Weitsman et al., 2009). Both of these signalling 
kinases have been implicated in the down-regulation of ER and also in the constitutive 
activation of ER  and therefore may contribute to the development of resistance to 
Tamoxifen (Weitsman et al., 2006).  
PI3K and Akt and their signalling pathways provide another viable mechanism of 
acquired Tamoxifen resistance. Akt is a signalling molecule and a downstream target of 
PI3K (Datta et al., 1999). Increased activation of Akt1 has been described as a potential 
contributing factor in the aggressive phenotype that is often seen in Tamoxifen resistant 
ER positive breast cancers and cell culture models (Jordan et al., 2004). Activation of Akt 
can promote cellular proliferation, and avoidance of cell death. Akt has been reported to 
phosphorylate Serine167 on the AF-1 (Figure 1-8) domain of the ER , consequentially 
instigating the ligand- independent activation of the receptor (Campbell et al., 2001) and 
subsequently has the potential to be a contributing factor in development of acquired 
Tamoxifen resistance. Increased expression and activation of p38 MAPK has been 
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observed in Tamoxifen resistant tumours, it has been described to be involved in 
TGF signalling (See section  1.6) and is also part of a paracrine signalling loop with the 
angiogenesis related protein Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) 
(Linderholm et al., 2011). 
The Src family of non receptor tyrosine kinases and their downstream targets have 
often been associated with breast cancer. They have been shown to be frequently over-
expressed (in particular Src) in breast cancer (Biscardi et al., 2000) and Tamoxifen 
resistance (Morgan et al., 2009). One substrate of Src, Cas, is a focal adhesion adaptor 
molecule which has been shown to have a role in Tamoxifen resistance when the protein 
was induced in vitro. An elevated activity of Src promotes motility and invasion in 
Tamoxifen resistant cells (Hiscox et al., 2006 and Hiscox et al., 2007). It has also been 
reported that the localisation of activated Src may be important, elevated levels located in 
the cytoplasm of breast tumours was significantly associated with a decreased patient 
survival whereas a nuclear expression of activated Src was associated with a more 
favourable response to endocrine therapy (Morgan et al., 2009).  
 
Pharmacological mechanisms 
A frequent mechanism of general drug resistance is altered efflux or influx of the drug, 
causing altered (often decreased) concentrations of the drug in the cell. This is a process 
that is often controlled by membrane pumps such as p-glycoprotein (MDR1) (Saeki et al., 
2005). It has been shown in the literature that patients with acquired Tamoxifen 
resistance show a lower concentration of Tamoxifen in serum (Johnston et al., 1993). In 
this study there were no significant differences seen in between the de novo resistant 
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group of patients and the acquired resistant group. When the drug concentration was 
measured in the tumour the concentration was lower which may imply that there is a 
connection between low concentrations of the drug in serum and tumour and acquired 
resistance (Johnston et al., 1993). 
 Tamoxifen is a pro-drug that is metabolised into many metabolites (see Figure 
1-11). It is therefore possible that altered metabolism of the drug could explain, at least 
partially, acquired resistance to Tamoxifen. It has been postulated that a large increase in 
oestrogenic metabolites of Tamoxifen could compete with the anti-oestrogenic 
metabolites for activation of the oestrogen receptor (Clarke et al., 2001). Yet it would 
require a very large shift to alter the levels of Tamoxifen in the tumour and the levels of 
metabolites in patient serum has been monitored over several years and indicate that the 
metabolites remain largely constant over the treatment regimen.  
 Often involved in de novo resistance, genetic polymorphisms of cytochrome P450 
enzymes CYP2D6 and CYP3A4 are used in the bio-activation of Tamoxifen to form its 
major metabolites (see Figure 1-11) could also play a role in acquired resistance. In 
plasma, endoxifen has been observed to have a large variability between patients. 
CYP2D6 is of particular interest as patients that have decreased CYP2D6 or genetic 
variants, have lower endoxifen concentrations (Stearns et al., 2003). Increased endoxifen 
levels have been reported to circumnavigate resistance associated with increased ErbB2 
expression (Goetz, 2009). Investigation of variants of CYP2D6 could lead to a more 
personalised drug regimen by predicting outcomes of Tamoxifen therapy, although this 
proposal remains controversial (Kuderer & Peppercorn, 2009).  
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Cell cycle regulators 
Tamoxifen is a cytostatic; the presence of Tamoxifen in culture leads to G1 phase 
specific arrest consequently leading to decreased proliferation and growth (Dowsett et al., 
2006). Key cell cycle regulators such as Cyclin D’s, Cyclin E’s and Myc are often over 
expressed in cancer and are frequently observed with a decrease of p21 or p27 expression 
which act as inhibitors of cyclin dependent kinases (CDKs) concomitantly. These 
observations have been associated with Tamoxifen resistance. Abukhdeir et al. showed in 
2008 that breast epithelial cell lines that had the p21 gene deleted displayed a growth 
proliferative response when treated with Tamoxifen. The cell cycle inhibitor p27 has 
been reported to mediate the G1 arrest when Tamoxifen is used, however, it has been 
shown that activation of the MAPK pathway and decreases the expression of the p27 
protein which was suggested to be a contributing factor in Tamoxifen resistance 
(Donovan et al., 2001). Src has also been shown to regulate p27 stability through 
phosphorylation (pY74 and pY88) leading to decreased p27 expression (Chu et al., 
2007).  
Growth factors have been shown to induce cell cyclin D1 expression and it has 
also been shown to interact with several transcription factors such as ER and signal 
transducer and activator of transcription 3 (STAT3) (Ishii et al., 2008 and Coqueret et al., 
2002). The over expression of cyclin D1 is frequent and is seen in approximately 50% of 
breast cancers (Zwijsen et al., 1997).  
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Figure 1-12 This figure shows the phases of a cell cycle. G1 phase. G0 phase (shown as 
an out-of-cycle state that cells might enter at a point in G1) S phase, G2 phase and M 
phase are also shown. Cyclin–cyclin-dependent kinase (CDK) complexes are shown, 
their position demonstrating where they are active. Tamoxifen is known to act through 
G1 phase specific arrest. From: Coller, 2007. 
 
 
 
Myc is an activator of RNA polymerase II transcription (Hynes and Stoelzle, 
2009) influencing a wide range of cell functions such as cell cycle, protein synthesis and 
apoptosis. Myc is involved in normal mammary development but is also frequently 
deregulated in mammary tumours. This deregulation is caused by multiple mechanisms 
including altered signalling pathways, genetic amplification, and altered transcriptional 
activity. ER , among others, binds the Myc promoter, and stimulate transcription. ErbB2 
activation via ER  has been shown to stimulate ERK and PI3K/Akt pathways, increasing 
RNA and protein Myc expression (Hynes and Stoelzle, 2009). Musgrove et al., 2008 
showed that the over expression of Myc was associated with a Tamoxifen resistance 
phenotype and was accompanied by a repression of p21 (tumour suppressor) allowing the 
cyclin E1-CDK2 (Figure 1-12) complexes to facilitate the proteolysis of p27 (decrease in 
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p27 expression has been associated with Tamoxifen resistance, detailed above). 
Tamoxifen resistant cells consistently express high levels of cyclin E1 and CDK2 (Louie 
et al., 2010). The over expression of Myc and cyclin D1 have been reported to be 
associated with Tamoxifen resistance in vitro which is now becoming more apparent in a 
clinical setting (Caldon et al., 2006 and Butt et al., 2005). There is also evidence that 
cyclin E1 over expression and inactivation of the retinoblastoma (RB) tumour suppressor 
facilitates a decreased clinical response to the treatment, probably via decreased 
expression of p27 (Chu et al., 2008). 
 
Cellular survival and Apoptosis 
One way in which cells potentially acquire resistance to Tamoxifen is avoiding drug-
induced cell death (apoptosis). Initiation of apoptosis through the mitochondrial pathway 
is shown in Figure 1-13. Studies have shown that cross-talk between the apoptotic 
effectors of Tamoxifen, the tumour necrosis factor (TNF) pathway and the increased 
survival signalling pathways such as Akt/PI3K and NF-KappaB have been associated 
with the evasion of Tamoxifen induced cell death (deGraffenreid et al., 2004). 
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Figure 1-13 This figure shows the initiation of apoptosis through the mitochondrial 
pathway. Pro-apoptotic BCL2 family proteins, for example; BAX, BID, BAD and BIM 
are important mediators of these signals. Apoptosis through mitochondria can be 
inhibited on different levels by anti-apoptotic proteins, including the anti-apoptotic BCL2 
family members BCL2 and BCL-XL and inhibitors of apoptosis proteins (IAPs), which 
are regulated by SMAC/DIABLO (second mitochondria-derived activator of 
caspase/direct IAP binding protein with low pI). Another way is through survival signals, 
such as growth factors and cytokines that activate the phosphatidylinositol 3-kinase 
(PI3K) pathway. PI3K activates AKT, which phosphorylates and inactivates the pro-
apoptotic BCL2-family member BAD. (Igney and Krammer, 2002) 
 
 
 
 It has been shown that inhibition of NF-KappaB expression can restore 
sensitivity to Tamoxifen in resistant cells and can also further sensitise the MCF7 
(Tamoxifen sensitive) cells to 4-OH Tamoxifen. These data suggest that this effect is not 
dependent on cell cycle or autophagy (Nehra et al., 2010). It is thought that the 
mechanism, through which NF-KappaB inhibition restores the cell’s sensitivity to the 
drug is through a reduction in BCL2 expression and subsequent induction of the capsize 8 
caspase 8, initiating Tamoxifen driven apoptosis (Nehra et al., 2010). 
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There is mounting evidence in the literature that an increased expression of anti-
apoptotic molecules (such as the BCL2 and BCL-XL) and a decrease in pro-apoptotic 
molecules (for example Caspase 9 and BAK) are observed in Tamoxifen resistant cell 
models and patients (Riggins et al., 2005). The attenuation of response to Tamoxifen 
could be due to the acquisition of pro-survival pathway activations (such as PI3K/Akt via 
ER  RTK activation).  
The BCL-2 homology-3 (BH3)-only, pro-apoptotic regulator PUMA (p53 up 
regulated modulator of apoptosis) has been identified recently as an oestrogen target gene 
(Roberts et al., 2011). In response to oestrogen stimulation PUMA is highly down-
regulated in many breast cancer cell lines. Also, patients with low PUMA mRNA 
expression correlated with a poor patient prognosis in ER positive, Tamoxifen treated 
patients indicating that PUMA may contribute to the mediation of apoptotic response to 
Tamoxifen. There is therefore an increasingly convincing body of evidence justifying 
investigation of new therapeutic approaches that target apoptotic pathways to modulate 
response to endocrine therapy.  
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1.7.1 Aim of this project 
Establish and characterise a robust cell model of Tamoxifen resistance and 
ascertain the phenotype of the cells. This was done through chemical selection, exposing 
the MCF7 (ER  positive) cells to increasing concentrations of Tamoxifen (4 OH 
Tamoxifen) over a period of time. The phenotype of these cells was compared to an 
established Tamoxifen resistant cell line (TAMR), developed in Cardiff, using proteins 
previously shown to be altered in resistance such as ERK1/2 and PKC These marker 
proteins were used throughout the project to ensure that there was no phenotypic drift 
over time. After a robust cell model of Tamoxifen resistance was established, the aim was 
the identification of alterations in protein expression and/ or phosphorylation between 
parental MCF7cells and the models of Tamoxifen resistance. Any altered expression and 
phosphorylation was assessed through thorough proteomic investigation; utilising 
technologies such as antibody arrays and mass spectrometry in conjunction with the best 
available labelling strategy for the instruments and software available in our laboratory.  
Following the identification of altered proteins; further investigation and 
determination of their biological significance in Tamoxifen resistance was investigated. 
This was done using functional assays to measure characteristics such as proliferation 
used alongside siRNA used to determine if decreasing the expression of the protein of 
interest effects the characteristics of the cells. Novel mechanisms of Tamoxifen resistance 
that have not hitherto been investigated may be identified, increasing our understanding 
of the cell biology and ultimately possibly allowing the development of novel therapeutic 
approaches to decrease the occurrence of Tamoxifen resistance. 
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2 Materials and Methods 
All chemicals were from Sigma-Aldrich unless otherwise stated. 
2.1 Cell culture:  
All cell culture work was carried out in a class II biological hood under sterile working 
conditions. All general tissue culture plastic used was from Corning and sterile for single 
use. Cell lines were grown in incubators set to controlled conditions, 5% CO2 humidified 
atmosphere at 37˚C. Cells were counted on a glass haemocytometer. 
2.1.1 Cells 
MCF7 are a mammary cell line originally acquired from a metastatic pleural effusion. 
TAMRBU are cells which were derived from MCF7 cells using pharmacological 
selection (section 2.1.2), resulting in a resistant phenotype. The MCF7 and TAMR were a 
kind gift from the Tenovus Center for Cancer Research at Cardiff University. TAMRBU 
were developed for the purpose of this project (Chapter 3). All cell lines express 
oestrogen receptor and are adherent. All cells were routinely tested for the presence of 
Mycoplasma. 
2.1.2 Establishment of the Tamoxifen resistant (TAMRBU) cell line. 
The Tamoxifen resistant cell line (TAMRBU) was established by the MCF7 parental cell 
line (sensitive to Tamoxifen) being continually exposed to 4-OH Tamoxifen (10
-7
M) 
diluted in ethanol and added freshly into experimental media (Table 2-1) for the routine 
maintenance of these cells for a period of 8 months. During this time the cells were 
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passaged when necessary.  For the initial 3 months of the TAM treatment regimen the 
cells exhibited a substantial growth inhibition and some cell death. Subsequently, the 
cells became more proliferative until similar growth rates to the parental MCF7 cells 
were achieved. 
2.1.3 Charcoal stripping the FCS 
Charcoal stripped FCS (csFCS) was prepared as follows:  A charcoal/dextran solution 
was prepared using activated charcoal (11.1%) and dextran C (0.06%) This mixture was 
then mixed vigorously for 1 hour. FCS was adjusted to pH 4.2 using 4M HCl and allowed 
to equilibrate for 30 mins at 4˚C. 5ml of charcoal solution was added to every 100ml of 
FCS and incubated over night (16 hours) with gentle agitation at 4˚C. The charcoal was 
removed from the FCS using centrifugation at 12,000g for 45 mins followed by filtration 
using Whatman number 4 papers to remove more traces of the charcoal. The FCS was 
readjusted to pH7.2 using 5M NaOH and filtered again using a 0.2µM membrane syringe 
filter in a class-2 culture hood to remove any micro-organisms and fine charcoal 
impurities. This was stored at -80˚C until required. 
2.1.4 Sterile cell culture solutions 
Phosphate buffered saline (PBS); 137mM sodium chloride, 2.7mM potassium chloride, 
4.3mM disodium hydrogen phosphate and 1.47mM potassium dihydrogen phosphate. pH 
7.4. Stored at room temperature (rt). 
Trypsin EDTA purchased as a 1x solution from Invitrogen.  
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2.1.5 Routine seeding from stock 
Cells were removed from the gas phase of the liquid nitrogen (LN2), warmed quickly at 
37˚C, added to a T25 flask with pre-warmed appropriate growth medium (Table 2-1). 
The cells were then left overnight (16hours) to attach, the media was removed, the cells 
washed in warmed PBS (2.1.4) and fresh media added.  
2.1.6 Cell Passage 
Cells were passaged approximately once a week upon reaching 90% confluency.  
The culture medium was aspirated the cells washed with warmed PBS. Trypsin / EDTA 
(3ml) (2.1.4 above) was added to the flask, rocked gently and placed in the 37˚C 
incubator for 5 mins until the cells were rounded and detached. 8 mls normal media 
(Table 2-1) was added to the cells to inactivate the trypsin and centrifuged at 1350g for 
5mins at rt. The supernatant was aspirated and the cell pellet re-suspended in 10 ml of 
culture medium. 2.5 ml of the re-suspended cell mixture was then added to a T75 flask 
with 7.5 ml of culture medium added and placed in an incubator. The media was changed 
every four days, until required or until 90 % confluent.   
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 Media FCS 
(vol/vol) 
Penicillin 
(10IU/ml) 
Streptomycin 
( g/ml) 
Glutamine 
(4mM) 
4-OH 
Tamoxifen 
(10
-07
M) 
DMSO 
(vol/vol) 
Normal – 
MCF7 
RPMI 1640  
(phenol red) 
Yes - 5% Yes Yes No No 
Normal – 
TAMR & 
TAMRBU 
RPMI 1640 
(no phenol red) 
Yes-5% 
Charcoal 
Stripped 
Yes Yes Yes No 
Experimental RPMI 1640 
(no phenol red) 
Yes-5% 
Charcoal 
Stripped 
Yes Yes No No 
SILAC RPMI 1640 
(no phenol red) 
 
Yes-5% 
Dialysed 
Charcoal 
Stripped 
Yes Yes MCF7 
 
No 
TR 
 
Yes
* 
No 
MCF7 “Heavy” 
(C
13
Lys) 40mg/L 
(C
12
Arg) 200mg/L 
TR “Light” 
(C
12
Lys) 40mg/L 
(C
12
Arg) 200mg/L 
No 
Freezing RPMI -1640 (phenol red) Yes  50% No Yes No Yes 10% 
 
Table 2-1 The media used for culturing the cell lines for the purposes of normal culture, experimental, SILAC and cryopreservation. 
All media used was RPMI 1640 from Invitrogen with the exception of the SILAC media where it was purchased from Geneflow. All FCS 
was from PAA, with the exception of the SILAC media where dialysed serum was purchased from Invitrogen and then charcoal stripped 
(2.1.3). To avoid the unwanted mild oestrogenic properties of the phenol red, phenol-red free media was used in experiments. It was also 
necessary to use steroid-depleted charcoal stripped foetal calf serum (csFCS) in experiments. The serum is dialysed for SILAC as it 
removes all unwanted amino acids that would otherwise “contaminate” the heavy and light preparations. 
*Tamoxifen was removed from the media 7 days prior to the experiment.
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2.1.7 Stable Isotope Labelling of proteins with Amino acids in Cell culture 
(SILAC) 
MCF7 cells and TAMRBU cells were washed thoroughly in PBS and then MCF7 cells 
grown in “heavy” media and TAMRBU in “light” media (Table 2-1). Cells were cultured 
routinely in the “heavy” or “light” media for at least 6 population doublings to ensure 
near 100% incorporation of the [
13
C] or [
12
C] isotope of the amino acid (Isotopic 
equilibrium see 5.1). Both MCF7 and TAMRBU cells grown in SILAC media showed an 
initial slowing of growth.  
2.1.8 Cryopreservation. 
Cells were trypsinised as in section 2.1.6; the pellet was re-suspended gently in freezing 
media (Table 2-1) so that the cells are at a density of 10
6 
cells per ml. The re-suspended 
cells were then aliquotted into 1ml cryotubes (Nunc) and placed in “Mr. Freeze” (Nunc) 
at -80˚C overnight and then the cryotubes were then transferred to the LN2 for storage at  
-140˚C. The “Mr. Freeze” and the DMSO help to reduce the formation of ice crystals in 
the cells and therefore reduce cell death during the cryopreservation process.  
2.2 Protein Chemistry 
2.2.1 Lysis of cells 
The cells were lysed using NP-40 lysis buffer (detailed below) with gentle agitation for 
30 minutes at 4˚C, samples were sonicated (sonicating bath for 10 minutes for mass 
spectrometry experiments, a series of 5 second pulses using the sonicating probe for 
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Western blots) followed by another 10 mins at 4˚C with gentle agitation. Samples were 
centrifuged at 10, 000 x g for 30 minutes and the supernatant collected. 
Nonidet-P40 (NP-40) Lysis buffer: 20 mM Tris HCl pH 8, 137 mM NaCl, 10% glycerol 
(v/v),1% nonidet P-40 (Igepal)(v/v) and 2 mM EDTA. All chemicals used were from 
Sigma –Aldrich. Protein inhibitor cocktail tablets (Roche) and PhosSTOP phosphatase 
inhibitor tablets (Roche) were added on the day of lysis. 
2.2.2 Determination of protein concentration; BCA assay 
25 µL of each of the BSA standard (0-1000µg/ml) and 1:10 dilutions of unknown 
samples were pipetted, in triplicate, into a 96 well flat bottomed plate. The BCA working 
reagent was prepared at 50 parts BCA reagent A to 1 part reagent B (Pierce). 200 µL 
working reagent was added to each well and the plate mixed using the microplate mixer 
for 1 minute. The plate was then incubated at 37˚C for 30 minutes and cooled to room 
temperature before reading at 562nm.  
2.2.3 Sodium Dodecyl Sulfate -polyacrylamide gel electrophoresis (SDS-
PAGE) 
Selections of pre-cast gels (Invitrogen) were used for SDS-PAGE. The use of these was 
especially important for mass spectrometry experiments as they were free from 
contaminating proteins. Gels used included 10, 12, or 1 well 4-12% Bis-Tris gels, 10 well 
3-8% Tris acetate gels, and 4-20% Tris Glycine gels. Typically, 4-12% Bis-Tris gels were 
used as they provided good separation of proteins, separating as low as 3KDa using MES 
running buffer.  
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The buffers used are as follows:  
3-(N-morpholino) propanesulfonic acid (MOPS) Buffer: MOPS 50mM, Tris Base 50mM, 
0.1% SDS, 1mM EDTA, pH 7.7. 
2-(N-morpholino) ethanesulfonic acid (MES) Buffer : MES 50mM, Tris Base 50mM, 
0.1% SDS, EDTA 1mM, pH 7.3. 
Tris-Acetate buffer (Invitrogen): Tris Base 50mM, Tricine 50mM, 0.1% (v/v) SDS, pH 
8.2  
Sample loading buffer: Lithium Dodecyl Sulphate (LDS): 10% (v/v) Glycerol, Tris Base 
141mM, Tris HCl 106mM, 2% LDS, EDTA 0.51mM, Coomassie Blue G250 0.22mM, 
Phenol Red 0.175mM, pH 8.5. Reducing conditions were implemented on the day of use 
by adding 50mM dithiothreitol (DTT) to disrupt the disulphide bonds in the sample. 
2.2.4 Western blotting 
Samples were prepared in sample buffer (2.2.3) and separated using SDS PAGE as 
described previously (2.2.3). Western blotting was performed on either semi-dry or wet 
platforms, using apparatus from Geneflow and Invitrogen respectively. For semi dry 
method: PVDF membrane (Milipore) was used, proteins were transferred for 90 minutes 
with 100 mA constant current and a maximum setting of 25 Volts or 60 minutes with 30 
Volt constant, and  170 mA to 110 mA using the wet method. The PVDF membrane 
washed briefly in TBS-T then incubated, with gentle agitation, with an appropriate 
blocking solution for 60 minutes (powdered non fat skimmed milk (Marvel) 5% w/v in 
TBS-T or, for phospho- antibodies 5% BSA in TBS-T). The membrane was then 
incubated with the appropriate primary antibody in either milk or BSA (dependant on the 
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manufacturer’s directions), overnight (16 hours) at 4˚C. This was followed by 3x 5 
minute washes and 1x 15 minute wash in TBS-T and then incubation in the appropriate 
secondary antibody conjugated to horse-radish peroxidase (HRP) for 60 minutes, 
followed by 3x 5 minute washes and 1x 15 minute wash in TBS-T. All excess liquid was 
drained from the membrane and a 1:1 mixture of ECL Western blotting detection reagent 
(GE Healthcare) (125μL/ cm2 PVDF) was added for 1 min. Excess reagent was removed 
and autoradiography film (GE Healthcare) was used to develop the blot for an 
appropriate time. The working dilutions and sources of the antibodies can be found in 
Table 2-5. 
 
Buffers and solutions used for Western blots: 
Tris Buffered Saline (TBS): 50 mM Tris HCl at pH 7.4 and 150 mM NaCl. TBS-T was 
used with the addition of Tween-20 detergent at a final concentration of 0.1%. 
 Transfer buffer: NuPAGE transfer buffer: Bicine 25mM, Bis-tris (free base) 25mM, 
EDTA 1.0mM, Chlorobutanol 0.05mM, pH 7.2. Methanol at 10%, this was removed for 
the larger receptor proteins such as EGFR. When transferring two membranes using the 
wet method, the methanol content was increased to 20%. 
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2.3 Proteomics (mass spectrometry) 
2.3.1 Preparation of samples for analysis by reverse- phase (RP) High 
performance Liquid Chromatography (HPLC) and Electrospray 
ionisation mass spectrometry (ESI MS) 
 
Cell lysates were run on SDS-PAGE gel and then stained using colloidal coomassie. 
Colloidal coomassie stain: 0.08% Coomassie Brilliant Blue G250 (CBB 250), 1.6% 
orthophosphoric Acid, 8% ammonium sulphate, and methanol added on the day of 
staining to a final concentration of 20%. The gel was placed in a plastic sandwich box 
with the stain and was agitated for a minimum of 6 hours to overnight (16 hours) at rt. 
The gel was then de-stained in 1% acetic acid (analytical grade - Fisher Scientific) until 
non- stained areas of the gel developed a clear appearance. 
After de-staining the SDS PAGE gel the sample lane was cut into gel pieces, (40 
bands/pieces of a 1 well gel for SILAC experiment) this was done on a clean glass plate 
with a sterile scalpel blade. To minimise contamination from keratins/dust the excision 
and processing took place in a positive pressure hood.  
Gel pieces were washed twice with 500µl of 50% acetonitrile/50mM ammonium 
bicarbonate for 20-45mins at 37°C with agitation. The gel pieces were then dried down 
using a vacuum drier and 250µl of 50mM DTT (made up in 10% acetonitrile/50mM 
ammonium bicarbonate) added and incubated at 56°C for 1 hour, after which the 
supernatant removed. 100mM Iodoacetamide (250µl) (made up in 10% 
acetonitrile/50mM ammonium bicarbonate) was added and then incubated at rt in the 
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dark for 30 minutes after which the supernatant was removed. The gel piece was then 
washed 2x in 500µl of 10% acetonitrile in 50mM ammonium bicarbonate for 15-30 mins 
at room temperature with agitation and the bands thoroughly dried using the vacuum 
dryer. Promega trypsin (sequencing grade, modified, porcine) was prepared by adding 
200µl of the provided trypsin resuspension buffer (dilute acetic acid used to lower the 
pH) to 20µg of trypsin to give a 200µg/ml stock solution. Immediately prior to use this 
was diluted 1 in 8 with 10% acetonitrile/50mM ammonium bicarbonate.  This raises the 
pH and activates the trypsin, and is subsequently used in rehydrating the dried gel slices 
with 50µl for 1 hour (rt). 20µl of 10% acetonitrile/50mM ammonium bicarbonate was 
added to ensure that there is sufficient liquid to completely rehydrate the gel piece these 
were incubated at 37°C overnight. Supernatants were collected and 30µl 3% Formic acid 
in water was added and incubated at 37°C for 1hour. Supernatants were collected again 
and added to the previous supernatant. Another 30µl 3% Formic acid was added and 
incubated at 37°C for 30 mins and supernatants were again collected. Supernatants were 
put in snap cap tubes and run straight away or stored at -80ºC. 
2.3.2 Separation of peptides by reverse phase HPLC and direct detection 
using electro spray ionisation mass spectrometry 
The gradient of the solvents used in the reverse phase HPLC was over 2 hours and can be 
seen in Figure 2-1 below, details of software and equipment associated with the use of 
ESI MS can be found in Table 2-2. Peptides were rapidly retained on a C18 trap column 
and unbound material was washed through to waste. Next the valve switching the flow 
was directed to the C18 analytical column and the ion trap and the peptides are eluted 
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from the column using the gradient of solvents see Buffer A and B in Table 2-2 and 
detailed in Figure 2-1 (flow rate of 1μL a minute). This is detailed in Section 1.1.2.  
 
Figure 2-1. Reverse phase HPLC gradient used in the separation of peptides. 
Buffer A = 100% water, 0.1% Formic acid. Buffer B =5% water, 95% ACN, 0.1% formic 
acid. 
 
2.3.3 Database searching 
The RAW MS/MS data was searched against an indexed non-redundant human fasta 
database (NCBI) to establish identification  of peptides and proteins using 
TurboSEQUEST search within the Thermo Electron Company software, 
BioWorksBrowser 3.1 SR1©. The data was searched with an Xcorr value of 1.5 for 
singly charged peptides, 2.0 for doubly charged and 2.5 for triply charged peptides. Xcorr 
(Cross correlation) is a means of measuring the similarity between the RAW peptide data 
and the peptide contained within the database so that an increasing Xcorr value indicates 
that the identification is more accurate. Data that did not reach these criteria were 
removed from the resulting analysis. 
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95% B
2
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h
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0
Re-equilibriation of the column
Elution The remainder of the 
peptides that were not removed from the 
column during the gradient
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Equipment / information Supplier 
Autosampler  Surveyor (Thermo Finnigan) 
   
HPLC  Surveyor MS pump (Thermo Finigan) 
   
Ion Trap Mass spectrometer  LCQ DECA XP Plus (Thermo Finnegan) 
   
Software  Xcalibur ™ 1.3 SR1 © Thermo 
  Electron corporation 
Sample vials  11mm PP vial crimp/snap 
250mandrel (national scientific 
company) 
   
Peek Tubing  50μm diameter tubing (Altech) 
C18 trap column  Dionex 
C18 analytical column  150 x 0.18mm 5μm BioBasic C18 
KAPPA 
   
Buffer A  100% water, 0.1% Formic acid 
Buffer B  5% water, 95% ACN, 0.1% formic 
acid 
   
Flow rate at detection  1μL per minute. 
Water HPLC grade (ChromoNorm) 
Acetonitrile (ACN)  HPLC grade (LGC promochem) 
Formic Acid  100% stock 
 
Table 2-2 Table of equipment and general information useful to the process of 
proteomics using a mass spectrometer. 
 
2.3.4 SILAC labelling efficiency 
A flask of “heavy” labelled cells (6 population doublings) was lysed in NP-40 lysis buffer 
(section 2.2.1), run on a 1D SDS PAGE and stained (sections 2.2.3 and 2.3.1). The 
colloidal coomassie gel can be seen in Figure 5-1. From this gel, 3 bands were excised 
(outlined in red) and digested using the method outline in section 2.3.1 The identified 
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peptides from the excised bands were manually scanned for the presence of K# (# = 
heavy) residues. Not all peptides have a K residue present in a trypsin digestion as trypsin 
can cut peptides at both K or R residues (see section 1.1.2). All peptides with an absence 
of K were excluded from the calculation. All peptides with a K residue were counted and 
a percentage of labelled to non-labelled was calculated. 
2.3.5 Manual Quantitation of isotopically labelled peptide pairs in SILAC 
Cells grown in SILAC media (heavy or light Lysine) outlined in Table 2-1 were prepared 
as in section 2.1.7 and 2.2.1 and analysed using the mass spectrometer. Using the 
BioWorks software and the TurboSEQUEST search allowed for the heavy and light 
modification to be taken into account and identifications of peptide sequences from their 
proteins of origin. This allowed the heavy and light version of the same protein to be 
identified and thus quantified using the XPRESS function. The XPRESS function 
calculates the relative abundance of SILAC pairs using the calculated ion current (XIC) 
for each peptide. This was then confirmed using Xcalibur 3.1 for each pair manually and 
averaged if there was more than one labelled peptide pair identified in the protein.   
2.4 Antibody based proteomics 
2.4.1 Proteome Profiler; phospho MAPK 
The phospho- MAPK array (R & D systems) was used to determine the relative levels of 
phosphorylation of the three main families of Mitogen Activated Protein Kinases; the 
(ERKs) Extra-cellular signal Related Kinases, (JNKs) c-Jun N-terminal Kinases, and the 
P38 family. It uses capture and control human antibodies that have been pre-spotted on to 
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a nitrocellulose membrane in duplicate. Cell lysates from TAMRBU, TAMR and MCF7 
were prepared as described below (section 2.4.2). The array was blocked for one hour 
with the provided buffer and the samples added and left overnight at 4˚C with gentle 
rocking. The array was then washed 3x for 10 mins (provided wash buffer) and the 
detection antibody cocktail added which was incubated with the array for 2 hours. The 
detection cocktail was removed and the array washed as previously described, 
streptavadin horse radish peroxidase was added at 1:2000 (diluted with array buffer) and 
incubated for 30 mins with gentle rocking. After briefly washing the array ECL detection 
agent was added and the arrays wrapped in plastic wrap and exposed to autoradiography 
film. All densitometry was read using a BioRad GS800 reader and all analysis was 
completed using MiniTab 15 using t-tests or one way unstacked ANOVA. The box plots 
show the median value and the range. 
2.4.2 Cell lysate preparation for MAPK, RTK and apoptosis arrays. 
Cells were grown to 80% confluence in a T75 flask and rinsed with PBS and lysed with 
the lysis buffer provided although cell lysates for RTK array were prepared using the NP-
40 lysis buffer (section 2.2.1) .The cells were solubilised at a concentration of 1x10
6 
cells 
per ml of lysis buffer by agitating gently for 30minutes, microcentrifuged at 14 000 x g 
for 5 mins and the supernatant transferred into a clean microcentrifuge tube. The protein 
concentration was determined using a BCA assay (section 2.2.2). 200μg of protein was 
used and a 5:1 ratio with the provided array buffer 2/3 solution. Thawed lysates were 
always kept on ice.  
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2.4.3 Proteome Profiler; RTK (Receptor Tyrosine Kinase) 
The RTK proteome profiler was used to determine the relative protein phosphorylation 
levels of 42 receptor tyrosine kinases. This array uses capture and control antibodies 
developed using cell lines, or where this was not available, recombinant protein. They are 
spotted in duplicate onto nitrocellulose membranes. The array was assayed as in section 
2.4.1. 
2.4.4 Proteome Profiler; Apoptosis 
The apoptosis array was used to detect the relative levels of expression of 35 apoptosis 
related proteins using antibodies that selected using cellular extracts expressing the 
protein target. They are spotted in duplicate onto nitrocellulose membranes. The array 
was assayed as in section 2.4.1. 
2.5 Functional Assays  
Once Western blots had confirmed the identity of proteins found using MS (see Western 
blotting section 2.2.4 and antibodies used in the study Table 2-5), functional assays were 
used to determine the functionality of any interesting proteins that were differentially 
expressed or modulated between the resistant cell lines and the parental. The main assays 
used for this purpose were: the cell growth assay using AlamarBlue (Invitogen) and an 
adherence assay, in combination with temporal knock downs of the protein of interest 
using siRNA, detailed below. 
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2.5.1 Adherence assay 
The adhesion assay was used to investigate the difference in adherence between the 
parental and resistant lines and if siRNA transient knockdowns of the proteins of interest 
affected the adherence. A 96 well plate was coated with 0.1% gelatin or left with no 
attachment factor and left for 1 hour at 37˚C. The wells were washed in 0.1% BSA in 
RPMI1640 2x, then blocked with 0.5% BSA in RPMI1640 for 45minutes at 37˚C and 
washed with PBS. MCF7 and TAMRBU cells were detached from the T75 flask using 
enzyme free cell dissociation buffer (Invitrogen) and counted. 10,000 cells in 50μL were 
added per well then incubated for 45minutes. After the incubation period the plate shaker 
was used to shake at 1500rpm for 10 seconds. Wells were washed with PBS 3 times and 
then fixed with 4% formaldehyde (Pierce) for 15 minutes and subsequently washed with 
0.1% BSA in RPMI. Crystal violet (5mg/ml in 2% Ethanol) was added for 10 minutes, 
aspirated and washed with dH2O. The plate was inverted to dry completely. Once dry 2% 
SDS solution was added to each well and incubated on the plate shaker at room 
temperature for 30 minutes. The concentration of crystal violet released from the 
adherent cells was assayed on the BioRad 680 microplate reader at 550nM.  
2.5.2 AlamarBlue™ Assay for cell growth assay. 
The amount of fluorescence produced in this assay is reflective of the number of living 
cells present, as this corresponds to the cells metabolic activity. Damaged and non-viable 
cells have a lower metabolic activity, and thus, generate a proportionally lower signal 
than healthy cells. The assay incorporates a specially selected oxidation-reduction 
(REDOX) indicator (Figure 2-2), that both fluoresces and undergoes colorimetric change 
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in response to cellular metabolic reduction. Fluorescence was monitored at 560 nm 
excitation wavelength and 590 nm emission wavelengths. 
 
Figure 2-2 The REDOX reaction of the resazurin sodium salt, the indicator in 
AlamarBlue™. From: Invitrogen product manual. 
 
 
AlamarBlue™  reagent (Invitrogen) was added to cells that had been plated at least 6 
hours, at a concentration of 10% of the sample volume and incubated for 6 hours at 37ºC. 
The resulting fluorescence was read on a plate reader or fluorescence spectrophotometer.   
2.5.3 Invasion assay 
For the invasion assay BD Matrigel Matrix (phenol red free) was used as a representative 
basement membrane in which the cells could invade. The Matrigel matrix was thawed, 
diluted 1:2 with cooled culture media and mixed to ensure homogeneity. Cooled pipette 
tips were used to apply a thin layer (10µL) of matrigel to the (pre cooled) 12µm Millipore 
filter insert and warmed at 37°C for 1 hour. Cells were detached using cell dissociation 
buffer (Invitrogen) and counted. 400µl of cells (1x10
5
 cells/ml) were seeded on top of the 
filters and immersed into the feeder wells of a 24 well plate containing 600µL of full 
culture media (Table 2-1) and incubated for 24hours at 37°C which allows for the 
invaded cells to attach to the underside of the filter immersed in the feeder tray. Cells that 
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had not invaded (on top of the filters) were removed using a sterile cotton bud. Alamar 
blue was added to the media in the filter tray to a final concentration of 10% and the plate 
further incubated at 37°C for 6 hours. 200µL of conditioned culture medium was 
transferred into a flat bottomed 96 well plate and the fluorescence monitored at 560 nm 
excitation wavelength and 590 nm emission wavelengths. The % alamar blue reduction 
of invaded cells was normalised to the % of alamar blue reduction of an equal number of 
cells in the feeder tray with no filter in normal media. 
2.5.4 siRNA protocol 
siPORT NeoFX (Ambion) was used as the siRNA transfection agent for siRNA assays. It 
uses a lipid-based formulation to efficiently transfect adherent cells as they are 
subcultured. 1 hr or less before transfection, MCF7 and TAMRBU cells were trypsinised 
and re-suspended in normal growth medium (Table 2-1) at a suitable concentration as 
outlined below in Table 2-3 and set aside at 37°C in the incubator while the transfection 
complexes were prepared as below in Table 2-3 different assays were carried out on 
different plate sizes (e.g. proliferation 96well and invasion 24well). 
The reagents were all brought up to room temperature. The diluted siPORT 
NeoFX agent into OPTI-MEM I (Invitrogen) medium and the Diluted RNA in OPTI-
MEM I medium were then mixed and incubated at rt for 10 mins to allow transfection 
complexes to form. This mixture was added to the well of a culture plate and the cells 
were gently added on top. The complexes were mixed gently by tilting the plate and then 
incubated for at least 48 hours. To ensure the knock down was achieved, Western blots 
were performed and densitometry data was gathered (section 2.2.4.) 
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Table 2-3 Number of cells used in siRNA transfections in differing well plate formats. 
 
 
Table 2-4 A, B & C.  Directions for preparation of the transfection complexes and cell 
volume needed. 
A Diluted siPORT NeoFX agent into OPTI-MEM I medium  
 
 
 
B Diluted siRNA in OPTI-MEM I medium as follows 
  
C Cell volume needed and final transaction volume required. 
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Table 2-5 List of Antibodies used in the study. 
 
 
Antibody / protein  Company WB  dilution 
Primary EGFR 
 
Santa Cruz 1:1000 
Primary ER  
 
Santa Cruz 1:500 
Primary ERK1+2 
 
Abcam 1:2000 
Primary p-ERK1+2 
(Thr202/Tyr204) 
 
Cell Signalling Technology 1:1000 
Primary PKC  
 
BD Bioscience 1:2000 
Primary p-PKC  
(Thr 505) 
 
Cell Signalling Technology 1:1000 
Primary Akt 
 
Cell Signalling Technology 1:1000 
Primary p-Akt  
(Ser 473) 
 
Cell Signalling Technology 1:1000 
Primary IQGAP1 
 
Upstate/Milipore 1:1000 
Primary Cortactin 
 
Upstate/Milipore 1:1000 
Primary Talin-1 
 
Cell Signalling Technology 1:5000 
Primary Cathepsin D Santa Cruz 1:5000 
Primary Ribophorin II 
 
Santa Cruz 1:2500 
Primary   Actin Abcam 1:50,000 
Primary GAPDH Ambion 1:2000 
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3 Development of the Tamoxifen resistant cell line 
TAMRBU 
3.1 Introduction 
Tissue samples are often difficult and/or painful to obtain, and breast tissue is a fatty 
tissue which can complicate sample preparation for proteomics. An alternative is cell 
culture. Cell lines are an important tool in scientific research, and tissue culture is a 
routine laboratory technique. In 2000, historians of science Meyer Friedman and Gerald 
W. Friedland named it one of the 10 greatest discoveries in medicine “It made possible 
the study of living organisms at the cellular and even the molecular level and the 
development of modern vaccines ... and abetted the search for the causes of cancer (and 
AIDS).  Indeed, because of tissue culture, more has been learned about the basic 
mechanisms of disease in the past 50 years than in the previous 5,000" (Freidman and 
Freidland, 2000). Though using cells in culture is known to have disadvantages such as 
the cells are not in situ and are therefore are not growing in the 3D architecture of the 
body or are they subject to paracrine stimulation; it does have the advantage of 
simplifying the sample with the presence of only one cell type, as opposed to the stromal 
cells, endothelial cells and “normal” non- cancerous epithelial cells that would be present 
in a small biopsy. Obtaining a biopsy of tissue is also normally an invasive procedure and 
therefore the use of cell culture as a tool to study disease models has proven to be useful. 
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MCF7 cells are one of the most widely used cancer models in the world, retaining 
functional oestrogen receptors that are able to process oestrodiol effectively. They were 
used as the parental cell line to establish both the TAMR and the TAMRBU cell lines. 
MCF7 are an adherent, epithelial mammary cell line originally derived from a female 
breast cancer patient with metastatic disease via pleural effusion. Initially, MCF7 cells 
respond to the growth inhibitory effects of Tamoxifen, however the MCF7 cell line, with 
constant exposure to Tamoxifen over a period of time can provide a sub-population that 
can circumvent the effects of Tamoxifen and go on to develop the resistant phenotype 
allowing for the development of an experimental Tamoxifen resistance model. The use of 
this cell culture model to investigate the issue is well established.  
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Figure 3-1 Model of Tamoxifen resistance 
Above is a simplified model showing the development of resistance. Of all breast 
carcinoma cases, the majority (approximately 75%) are oestrogen receptor positive. Of 
the oestrogen receptor positive patients that take Tamoxifen, approximately 30% do not 
respond to treatment (de novo resistant). Approximately 70% of patients that take 
Tamoxifen initially respond to the treatment, the majority of which will have acquired 
Tamoxifen resistance during the course of their 5 year treatment.  
 
 
ER+ (75%)
Acquired Resistance
ER- (25%)
De novo Resistance
30%
Responsive
70%
MCF -7
TAMR / 
TAMRBU
Tamoxifen
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3.2 Results 
To develop a meaningful Tamoxifen resistant cell line it is necessary to mirror the 
clinical path to resistance, see Figure 3-1. The morphological changes of the MCF7 cell 
line can be seen as it goes through the chemical selection process and develops into the 
resistant phenotype sub-line TAMRBU (Figure 3-2). Using Tamoxifen continuously in 
culture selects for the resistant phenotype as the cells adapt to the drug’s presence. 
Initially the time taken for the cells to become confluent was increased dramatically from 
5 days to 4 weeks (with regular changes of media) as the majority of cells were 
phenotypically more rounded and many had died/detached from the flask surface. The 
time taken to reach confluence was used as a rough measure of cell growth/survival in the 
presence of Tamoxifen. With continuous exposure, the time taken for the cells to reach 
confluence in the flask decreased, after a period of 20 weeks the cells were proliferating 
at a similar rate to the parental MCF7 cells but in the presence of Tamoxifen, and the 
cells were deemed resistant as shown in the graph in Figure 3-3.  
3.2.1 Determination of the relative protein concentration of oestrogen 
receptor in the MCF7, TAMR and TAMRBU cell lines. 
In order for a breast cancer patient to be treated with Tamoxifen they are screened for the 
presence of oestrogen receptor  as it is the target receptor. It has been previously shown 
that the majority of patients that go on to develop acquired Tamoxifen resistance have 
cells that are still expressing functional oestrogen receptors (Henryk and Fuqua, 2007). 
Therefore, it was important to determine that the models of resistance used in this study 
are oestrogen receptor positive.  To verify that we could detect this in the TAMR and 
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TAMRBU cell lines, the oestrogen receptor positive MCF7 cells were compared to the 
TAMR and TAMRBU cell lines using Western blot analysis (Figure 3-4). The blots were 
additionally probed for  Actin as a control for overall proteins expression level loading 
accuracy. The Rf values were determined for this and some other characterisation 
proteins to confirm protein size. 
Rf = distance protein migration\solvent front 
It was seen that the resistant cell lines both expressed ER ; the protein was shown to be 
expressed but to a lesser extent than in the parental MCF7 line.  
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MCF7
Plus 10-7M 4 OH Tamoxifen
2 days 7 days 14 days
Plus 10-7M 4OH Tamoxifen
28 days 42 days 56 days 70 days
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Figure 3-2 Investigating morphological changes occurring while developing the Tamoxifen resistant cell line TAMRBU.  
Images were taken the microscope on bright field mode (x10). The MCF7 cells were grown in media containing 5% csFCS with 
Tamoxifen present as a chemical selection process in T25 flasks and images were taken periodically of the development of resistance 
from the MCF7 cells to the TAMRBU cells. Over a period of 10 weeks the cells began to grow well in the presence of Tamoxifen. This is 
depicted in graphical form in Figure 3-3. 
 
 
 
Plus 10-7M 4OH Tamoxifen
98 days 126 days 140 days133 days
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Figure 3-3 Time line of the development of the resistant cells TAMRBU. 
 
3.2.2 Determination of the relative protein concentration of 
“characterisation” proteins. 
3.2.2.1 Characterisation proteins  
These proteins were selected as they had previously been shown to be differentially 
expressed between MCF7 and TAMR cells. They were used in this project to conform the 
establishment of the TAMRBU cell model but also as a characterisation panel to monitor 
the quality of the cell culture model in subsequent experiments throughout this study thus 
ensuring that the incidence of cell drift was avoided.  
 
Legend for Figures 3-4 to 3-11.Western blot analysis was carried out on whole cell 
extracts taken from MCF7, TAMR and TAMRBU cell lines. These were grown to 80% 
confluence in media containing 5% csFCS. The SDS PAGE gels were 4-12% Bis – Tris 
gradient gels, and blotted with primary antibodies (Table 2-5.) All blots were probed for 
actin as a loading control and all densitometry was carried out on the Bio-Rad G800 
densitometry reader. The resulting blots were normalised to  actin and illustrated as a 
percentage of the loading control concentration. All experiments were carried out 
independently five times (with the exception of p-Akt at n=3, Figure 3-11) which were 
carried out and show standard error of the mean. 
**Phospho PKC  (Thr505), Figure 3-9, the densitometry was measured on the upper 
band only. The lower band was presumed to be a degradation product as known to be 
liable to break down. 
MCF7 plus TAM                    Time to confluence        
(days)                                                 (days)
0 4
2 28
7 28
14 28
28 21
42 10
56 10
70 8
98 7
126 7
133 4
140 4
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Figure 3-4 Relative ER protein expression between the MCF7 parental cell line and 
the TAMR and TAMRBU, Tamoxifen resistant cell lines.  
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Figure 3-5 Relative EGFR protein expression between the MCF7 parental cell line 
and the TAMR and TAMRBU, Tamoxifen resistant cell lines.  
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Figure 3-6 Relative ERK1+2 protein expression between the MCF7 parental cell line 
and the TAMR and TAMRBU Tamoxifen resistant cell lines.  
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Figure 3-7 Relative ERK1+2 protein phosphorylation between the MCF7 parental 
cell line and the TAMR and TAMRBU Tamoxifen resistant cell lines.  
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Figure 3-8 Relative PKC  protein expression between the MCF7 parental cell line 
and the TAMR and TAMRBU Tamoxifen resistant cell lines.  
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Figure 3-9 Relative p-PKC  protein phosphorylation between the MCF7 parental cell 
line and the TAMR and TAMRBU Tamoxifen resistant cell lines.  
 
 
 
M
C
F
7
T
A
M
R
T
A
M
R
B
U
Phospho-PKC
(Thr505)
0
20
40
60
80
100
120
140
160
180
MCF7 TAMR TAMRBU
Cell types
%
 
ac
ti
n
~ 88 ~ 
 
 
 
 
 
Figure 3-10 Relative Akt protein expression between the MCF7 parental cell line and 
the TAMR and TAMRBU Tamoxifen resistant cell lines. 
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Figure 3-11 Relative Akt (Ser473) protein phosphorylation between the MCF7 
parental cell line and the TAMR and TAMRBU Tamoxifen resistant cell lines (N=3). 
 
 
 
 
 
M
C
F
7
T
A
M
R
T
A
M
R
B
U
p-Akt (Ser 473) 
0
20
40
60
80
100
120
140
160
MCF7 TAMR TAMRBU
Cell types
%
ac
ti
n
~ 90 ~ 
 
3.2.3 The effect of long term removal of Tamoxifen from the culture growth 
media. 
The changes seen in the cells when they have acquired Tamoxifen resistance should be 
the effect of acquiring resistance rather than the short term effect of Tamoxifen presence 
in the culture media. To verify this, TAMRBU cells were cultured in the presence of 
Tamoxifen or the absence of Tamoxifen for 1, 2, 3, 4, 5 and 6 weeks. The cellular 
proteomes from the TAMRBU cells, along with MCF7 control cells, were extracted and 
the lysate was run on a SDS PAGE gel and then Western blotted, investigating the 
stability of the EGF receptor expression. (Figure 3-12). Western blot analysis was 
performed and was additionally probed for  Actin as a control for overall proteins 
expression level loading accuracy.  
The level of EGFR expression in the resistant cell line was consistently up 
compared with the MCF7 parental cell line and was stable in the presence of Tamoxifen 
and when Tamoxifen was withdrawn on a long term basis. This was not tested on other 
characterisation proteins, but does infer that the proteins expressed from the TAMRBU 
cells are stably expressed and are not affected by the presence or absence of Tamoxifen.  
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Figure 3-12 Effect of Tamoxifen and its absence from the growth media on stability of 
the relative expression of EGFR over a period of 6 weeks. 
Western blot analysis was carried out on whole cell extracts taken from MCF7 and 
TAMRBU breast cancer cells. The cells were grown to 80% confluence in media 
containing 5% csFCS with Tamoxifen present (W/) and Tamoxifen absent (W/O) over 
varying period of time, cells were passaged at 80% confluence when necessary. The 1D 
SDS PAGE gels were 4-12% Bis-Tris gradient gels, and the blotted membranes were 
probed with primary antibodies for EGFR and  Actin.  
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3.2.4 Investigation into the growth patterns of the cell culture models 
MCF7 should not thrive in an environment where Tamoxifen is present. To investigate 
cell growth; AlamarBlue™ (Invitrogen) was used. The amount of fluorescence produced 
in the assay is reflective of the number of living cells present as it corresponds to the cells 
metabolic activity. Damaged and non-viable cells have a lower metabolic activity, and 
thus, generate a proportionally lower signal than healthy cells. AlamarBlue was used to 
determine the effect of different treatments on MCF7 and TAMRBU cells. The effect of 
Tamoxifen, oestrodiol, and Tamoxifen and oestrodiol in combination, as shown in Figure 
3-13; ethanol was the vehicle, so the effect of ethanol was also investigated. The results 
indicate that the TAMRBU and MCF7 cells were stimulated by the addition of oestrodiol 
to the media: thus inferring the oestrogen receptor is functional in both cell models. The 
TAMRBU cell line appears to proliferate more in the presence of Tamoxifen in the 
media, but the MCF7 cells growth is significantly subdued to an average of 50% of the 
growth of MCF7 cells with no treatment. When used in combination Tamoxifen and 
oestrodiol seem to effect the MCF7 cells as they do not grow as effectively as the cells 
that have had no treatment but consistently grow more than MCF7 that have been solely 
subjected to Tamoxifen.  The effect of the vehicle was minimal on both cell lines. The 
proliferation rate of the Tamoxifen resistant TAMRBU cells and the MCF7 sensitive cells 
independent of the treatments did not differ significantly between the cell lines.  
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Figure 3-13 Alamar blue assay used for the measurement of proliferation. 
 
Alamar Blue proliferation assay was carried out on MCF7 and TAMRBU (BU) cells. 
Prior to the experiment the cells were grown to 80% confluence in media containing 5% 
csFCS with Tamoxifen absent for a period of 3 days. Optimisation of plating density had 
been carried out and subsequently 10,000 cells per 0.32cm
2 
were chosen as the optimum 
number of cells to receive an adequate reading on the plate reader after a period 72 hours. 
Treatments: ETOH vehicle, TAM= Tamoxifen 10
-7
M, E2= Oestrodiol 10
-9
M, and 
TAM&E2= Both Tamoxifen 10
-7
M and Oestrodiol 10
-9
M. 
Results above are derived from 5 independent experiments normalised to cells with no 
treatment ± SEM. 
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3.3 Discussion 
The development of the Tamoxifen resistant cells “in house” enabled us to follow the 
process that the Tenovus Centre for Cancer Research in Cardiff had used to develop their 
resistant cells – this was seen as good practice and carried the added benefit of producing 
a robust cell line, which behaved similarly to the TAMR cell line but with a lower 
passage number. The characterisation profiles of the two cell lines were very similar or 
followed the same trend. Some proteins were more highly expressed in the TAMRBU 
cells and this was putatively explained by the lower passage number of the cells. The 
TAMRBU cells after a period of 20 weeks proliferated at a similar rate to TAMRs and 
MCF7 cell lines, and grew well in the presence and in the absence of Tamoxifen. The 
results indicate subsequent to the removal of the Tamoxifen from the media, that the cells 
were not reliant on the presence of the drug to grow and the Western analysis determined 
that the absence of Tamoxifen over a period of 6 weeks did not attenuate the increase in 
expression of the EGF receptor, inferring the presence/absence of the drug was not 
altering the receptor expression in a short term manner but rather, this was a stable 
change in the cells generated by acquired resistance to Tamoxifen. 
The characterisation of the two Tamoxifen resistant cell lines shows that they are 
consistent with the previously published characteristics (ability to proliferate in the 
presence of Tamoxifen, and high level of expression of specific proteins such as EGFR) 
and therefore a robust and reproducible model to be used in the subsequent experiments 
discussed in the following chapters - 4, 5, and 6.  
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4 Antibody based proteomic investigation 
4.1 Introduction 
Several commercially available antibody arrays were used to investigate the potential 
proteomic differences in expression / phosphorylation status of many proteins between 
MCF7 and Tamoxifen resistant cells. Antibody arrays enable multiplex high-throughput 
protein expression profiling. They do not provide complete global assessment of the 
proteins in the sample as mass spectrometry does, but provide the ability to analyse over 
30 proteins at once (depending upon the array), many focussed on a particular group of 
proteins such as Mitogen Activated Protein Kinase family. The arrays used in this study 
were chosen specifically for their signalling pathway focus MAPK, or the protein family 
focus such as Receptor Tyrosine Kinase (RTKs) and apoptosis. All of these arrays 
contained at least one protein that had been previously described as altered in Tamoxifen 
resistance. 
 
Figure 4-1 Example of Proteome profilers. An example of the differences seen between 
Tamoxifen sensitive (A) and Tamoxifen resistant cells (B) using a proteome profiler 
array (R and D systems). 
A
B
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Many different samples can be measured on antibody arrays including tissue 
lysates, cell lysates, conditioned media, and in some cases serum and plasma. Cell lysates 
from the MCF7, TAMR and TAMRBU were used on the selected antibody arrays. All 
densitometry analysis was read using a BioRad GS800 reader and all analysis was 
completed using MiniTab 15 using t-tests or one way unstacked ANOVA. The box plots 
show the median value and the range. Detailed methodology of the antibody arrays is 
located within the material and methods chapter (section 2.4). 
4.2 Human phospho- MAPK proteome profiler 
This array analysed the phosphorylation status of all three of the major MAPK families as 
well as additional intercellular protein kinases such as Akt, p70 S6 Kinase, and GSK-3. 
The full details of the proteins used on the array can be seen in Table 4-1 and an example 
of the array can be seen in Figure 4-1. The array included a positive and negative control 
as detailed in Table 4-1 and the average reading of the negative controls was subtracted 
from the densitometry values. The MAPK proteome profiler was assayed on three 
independent occasions on three separate cell populations. Significance of results and fold 
change seen in the MAPK profiler is summarised in Table 4-2. 
4.2.1 Controls 
The three positive control spots were analysed on each array for each of the three 
replicates. These were then analysed using a one way ANOVA (unstacked) giving a P 
value of 0.880. These data enable confidence in the arrays as they do not differ 
significantly between experiments.  
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Figure 4-2 Box plot showing the positive control spots; no significant difference can be 
seen between the cell lines and between the three replicates. 
 
Table 4-1 MAPK proteome profiler antibody array. 
 
Target Protein/Control  Phosphorylation Site Detected 
Positive control  / 
Negative control  / 
ERK 1  T202/Y204 
ERK 2  T185/Y187 
JNK 1  T183/Y185 
JNK 2  T183/Y185 
JNK 3  T221/Y223 
JNK pan  T183/Y185, T221/Y223 
P38   T180/Y182 
P38   T180/Y182 
P38   T180/Y182 
P38   T183/Y185 
RSK1  S380 
RSK2  S386 
MSK2  S360 
Akt1  S473 
Akt2  S474 
Akt3  S472 
Akt pan  S473, S474, S472 
GSK3 /   S21/S9 
GSK3   S9 
HSP27  S78/S82 
P70S6K  T421/S424 
 
A table showing the antibodies spotted onto the MAPK proteome profiler antibody array; 
including the targeted sites of phosphorylation, and alternative nomenclature. Table 
adapted from the R and D systems product sheet. 
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4.2.2 Densitometry analysis of the MAPK proteome profiler: ERK 1 and 
ERK 2. 
As we have already shown ERK (extracellular signal-regulated kinase) 1 and 2 to have 
increased phosphorylation in the resistant cell lines using Western blotting (Figure 3-6). 
These proteins acted as an internal control for this array experiment. ERK1 and ERK2 
phosphorylation on the antibody array was obviously increased in resistance and a one 
way un-stacked ANOVA analysis of both gave a p value of less than 0.001 between the 
MCF7 and resistant lines (Figure 4-3). A paired t-test showed both TAMR and 
TAMRBU to have significantly increased phosphorylation of ERK1 when compared to 
MCF7 cells, but not significantly different to each other, (P=0.457). The increase in 
phosphorylation was 55.1% in TAMR and a 61.6% in TAMRBU from the MCF7 
parental line (Table 4-1). ERK2 was also increased in the resistant lines significantly in t-
test (TAMR, P=0.007 and TAMRBU, P=0.008). They do slightly differ from each other 
as the TAMRBU showed marginally lower phosphorylation than the TAMR, this 
however was not significant (P=0.171).  The phosphorylation is increased by 76.5% in 
TAMR and 54.6% in TAMRBU from the MCF7 parental line (Table 4-2). 
 
Figure 4-3 Box plots of the phosphorylation of ERK1 and ERK2. A comparison of 
MCF7, TAMR and TAMRBU. It shows that both the resistant cell lines have increased 
phosphorylation of both proteins. ERK1, P=<0.001. ERK2, P=<0.001. N=3. 
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4.2.3 Densitometry analysis of the MAPK proteome profiler: JNK family. 
The density of the pixels on the proteome profiler was inconsistent for the JNK family of 
proteins, so although there was a general trend of increased phosphorylation for the JNK 
family members assayed only JNK1 showed a statistically significant increase (Figure 
4-4).  JNK1 showed an increase of 11.9% (TAMR) and 6% (TAMRBU) when compared 
with the phosphorylation of JNK1 in MCF7 cells. This was a statistically significant 
using ANOVA (P=0.003), and t-test comparison between the MCF7 and TAMR gave a P 
value of 0.001, whilst between MCF7 and TAMRBU gave 0.076. The resistant lines did 
not significantly differ from each other (P=0.111).  
JNK2 showed a 5.1% (TAMR) and 5.8% (TAMRBU) increase in 
phosphorylation, however, the difference between MCF7 and TAMR values gave a P 
value of 0.371 whereas MCF7 and TAMRBU gave a P value of 0.022. TAMR and 
TAMRBU did not differ significantly (P=0.911). JNK3 showed increased 
phosphorylation in both resistant lines (TAMR; 14.3%, TAMRBU; 15.6%) in comparison 
to MCF7. However, the ANOVA and individual t-tests did not indicate any significance 
as the MCF7 results was so variable. Total (or pan) JNK phosphorylation showed a 
minimal increase in phosphorylation (TAMR; 2.1%, TAMRBU; 4.5%) the values did not 
reach significance (Table 4-2). 
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Figure 4-4 Box plots of the JNK family of MAPK. JNK1 is shows a statistically 
significant difference in phosphorylation between the three cell populations with an 
ANOVA  P value of 0.003, however the JNK2, JNK3 and total JNK (JNK pan) shows no 
overall significant difference. * indicates significance P<0.05. N=3 
 
4.2.4  Densitometry analysis of the MAPK proteome profiler: p38 family.  
These data (Table 4-1 & Figure 4-5) show the p38 family had increased phosphorylation 
in both resistant cell lines when ANOVA is performed: p38  has a P value of 0.001, 
p38  the P value is 0.026, whilst p38  and p38  have P values of less than 0.001. The 
increases in phosphorylation seen between the MCF7 and resistant lines are very apparent 
with p38  increased by 25.4% (TAMR) and 39.0% (TAMRBU), p38 increased by 
24.9% (TAMR) and 26.4% (TAMRBU), p38 increased by 24.1% (TAMR) and 36.8% 
(TAMRBU) and p38 increased by 38.6% (TAMR) and 40.7% (TAMRBU). The 
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differences seen between the MCF7 and either resistant line were all significant and there 
was no statistically significant difference between TAMR and TAMRBU, see Table 4-2.  
 
 
Figure 4-5 These Box plots for the p38 family of MAPK show the three cell lines and 
an increase in phosphorylation in both resistant cells. p38  has a P value of 0.001, for 
p38  the P value is 0.026, whilst p38  and p38  have P values of less than 0.001. N=3. 
 
 
 
4.2.5 Densitometry analysis of the MAPK proteome profiler: RSK1 and 
RSK2. 
RSK1 demonstrated an increased phosphorylation of TAMR and TAMRBU compared to 
MCF7(115.1% & 23.2% respectively).These increases are seen to be significant by t-test 
with P=values at 0.040 (TAMR) and 0.017 (TAMRBU). The resistant lines were not 
significantly different from each other with a P value of 0.289. The ANOVA gave a P 
value of 0.017. The RSK2 isoform showed no significance with ANOVA (0.229). The 
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median expression of RSK2 remained similar across the three cell lines. None of the 
values reached significance (see Table 4-2). 
 
Figure 4-6 Box plots of the RSK1 and RSK2 protein phosphorylation. The ANOVA 
result for each plot is RSK1 P= 0.017 and RSK2 P=0.229. N=3 
 
 
4.2.6 Densitometry analysis of the MAPK proteome profiler: Akt 1, 2, 3 and 
total.  
Akt1, 2, 3 and total illustrated a general trend of increased phosphorylation in resistance 
with Akt1 showing the largest percentage increase compared with MCF7 cells with a 
43.9% (TAMR) and 49.9% (TAMRBU) increase. T-tests indicated that the increase was 
significant with P values of 0.026 and 0.044 respectively and there was no significant 
difference between the two resistant lines (0.728). Akt2 showed a smaller increase in 
phosphorylation (10.4%; TAMR and 17.8%; TAMRBU) and neither of these increases 
reach significance on t-test analysis (Table 4-2). Akt3 demonstrated a similar increase in 
phosphorylation (11.4% TAMR; 13.5% TAMRBU) but TAMRBU was significantly 
different to MCF7 by t-test analysis (0.008). Akt pan (total) showed a marked increase in 
phosphorylation, with TAMR increased by 50.8% and TAMRBU 56.4%. The ANOVA 
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suggests a high degree of variance (P= less than 0.001) and the t-tests performed between 
MCF7 and TAMR (P=0.001) and MCF7 and TAMRBU (P=0.014) showed that these 
increases were significant. The t-test between the resistant lines indicated that there was 
no difference between them, with respect to Akt phosphorylation (P=0.559). 
 
Figure 4-7 These Box plots for Akt 1, 2, 3 and total (pan) show the three cell lines 
MCF7, TAMR and TAMRBU and an increase in phosphorylation in both resistant cells 
compared to the parental. Akt1has a P value of 0.003, Akt2 0.009, Akt3 0.004 and Akt 
pan less than 0.001. N=3. 
 
4.2.7 Densitometry analysis of MAPK proteome profiler: GSK3 /  and 
GSK 
The protein phosphorylation of GSK3  and GSK3  in Tamoxifen resistant cells 
showed a small decrease when compared to the MCF7 cells. GSK3  densitometry 
displayed a 3.3% decrease (TAMR) and a 7.9% decrease (TAMRBU). ANOVA analysis 
indicated that there was a significant variance within the data (P=0.037) but individual t-
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tests did not produce significant values. GSK3  showed a 9.8% decrease (TAMR) and a 
7.4% decrease (TAMRBU). ANOVA did not suggest that there was a significant variance 
in these data (P=0.402) the individual t-tests did not give significant results. See Table 
4-2 for values. 
 
 
 
Figure 4-8   Box plots of GSK3 /  and GSK3  phosphorylation between MCF7, 
TAMR and TAMRBU cells. ANOVA analysis indicates that GSK3 /  is significant 
(P=0.037) and GSK3  is not (P=0.402). N=3. 
 
 
4.2.8 Densitometry analysis of the MAPK proteome profiler: P70S6K and 
HSP27. 
The proteome profiler array data showed increased phosphorylation of P70S6K in both of 
the resistant cell lines (TAMR; 14.7%, TAMRBU; 39.2%) compared to MCF7. The 
ANOVA P value for P70S6K of less than 0.001 indicated that there was a very 
significant amount of variance between the groups. The individual t-test between MCF7 
and TAMR gave a P value of 0.055 and between MCF7 and TAMRBU the P value was 
0.006. The t-test between the resistant cell lines implied that the difference clearly seen in 
Figure 4-9 between TAMR and TAMRBU was significant (P=0.032). 
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HSP27, as shown in Figure 4-9, had an increased level of phosphorylation in the 
Tamoxifen resistant cells (TAMR; 4.8%, TAMRBU; 24.5%). This increase was not 
statistically significant when comparing TAMR and MCF7 cells, however, it was very 
significant in the MCF7 and TAMRBU t-test analysis (P=0.006). There was also a 
difference seen between the resistant lines (P=0.032). The statistically significant 
differences seen between resistant lines for both HSP27 and P70S6K was partly due to 
the variance seen in the TAMR cell line across the three replicates, but could also imply a 
degree of clonal variance between the resistant cell lines or perhaps result from the lower 
passage number of the TAMRBU cells, discussed further in section 4.5.1. 
 
 
 
 
Figure 4-9 The Box plots above show the phosphorylation of P70 S6 Kinase and Heat 
shock protein 27. The proteins both show an increase in the phosphorylation in the 
resistant cell lines. The ANOVA P value for P70S6K was less than 0.001 and for HSP27, 
0.004. N=3.  
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Table 4-2        A summary of the MAPK antibody array results.  
 
 
Protein Significance 
M:T 
Significance 
M:B 
Significance 
T:B 
ANOVA 
M:T:B 
Normalised Fold 
change % 
Proteins 
of 
interest 
 
M T B 
ERK1 0.000 0.013 0.457 0.000 100 155.1 161.6 * 
ERK2 0.007 0.008 0.171 0.000 100 176.5 154.6 * 
JNK1 0.001 0.076 0.111 0.003 100 111.9 106.0  
JNK2 0.371 0.022 0.911 0.273 100 105.1 105.8  
JNK3 0.173 0.211 0.597 0.267 100 114.3 115.6  
JNK pan 0.447 0.230 0.092 0.260 100 102.1 104.5  
p38  0.011 0.017 0.053 0.001 100 125.4 139.0 * 
p38  0.132 0.006 0.885 0.026 100 124.9 126.4  
p38  0.004 0.007 0.093 0.000 100 124.1 136.8 * 
p38  0.002 0.024 0.777 0.000 100 138.6 140.7 * 
RSK1 0.040 0.017 0.289 0.017 100 115.1 123.2 * 
RSK2 0.715 0.126 0.380 0.229 100 97.3 107.9  
MSK2 0.052 0.150 0.443 0.056 100 120.3 127.0  
Akt1 0.026 0.044 0.728 0.003 100 143.9 149.9 * 
Akt 2 0.053 0.074 0.113 0.009 100 110.4 117.8  
Akt 3 0.093 0.008 0.503 0.004 100 111.4 113.5  
Akt pan 0.001 0.014 0.559 0.000 100 150.8 156.4 * 
GSK3 /  0.392 0.066 0.222 0.037 100 96.7 92.1  
GSK3 0.402 0.564 0.277 0.402 100 90.2 92.6  
HSP27 0.332 0.006 0.032 0.004 100 104.8 124.5  
P70S6K 0.055 0.001 0.032 0.000 100 114.7 139.2  
 
 
M=MCF7, T=TAMR, B=TAMRBU. Significance indicates P value obtained using a 
student paired t-test analysis between the cell lines. ANOVA is the P value obtained from 
one-way unstacked ANOVA analysis of variance between all three cell lines. Fold 
change in phosphorylation is normalised to the MCF7 levels and displayed as a 
percentage. Proteins of interest are proteins that have reached significance in both 
resistant cell lines. Significance is reached when p≤0.05. 
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4.3 Human phospho- Receptor Tyrosine Kinase (RTK) proteome 
profiler  
This array was used to detect changes in pan tyrosine phosphorylation of 42 receptor 
tyrosine kinases between the MCF7, TAMR and TAMRBU cellular lysates. Full details 
of the proteins and controls used on this array are included in Table 4-3.  The RTK 
proteome profiler was assayed on three independent occasions on three separate cell 
populations. Significance of results and fold change seen in the RTK profiler are 
summarised in  
Table 4-4. 
4.3.1 Controls 
The array included a positive and negative control as detailed in Table 4-3 and the 
average readings from the negative controls were subtracted from the densitometry 
values. The densitometry values for the three (duplicated) positive phospho-tyrosine 
antibody spots were averaged for each of the array replicates and ANOVA analysis 
suggested no statistical variance (P=0.555). The t-tests carried out between the cell lines 
did not reach significance, see Table 4-4 for values. 
 
Figure 4-10 Box plot showing the densitometry values for the positive phospho 
tyrosine control spots. ANOVA analysis gives a P value of 0.555. N=3.  
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Table 4-3 A table showing the proteins, and their families spotted onto the Human 
Phospho-Receptor Tyrosine Kinase Proteome profiler array, alongside controls.  
 
Proteins spotted on to the RTK Proteome profiler antibody array. 
+ Control ROR2 
EGFR TIE1 
ErbB2 TIE2 
ErbB3 TrkA 
ErbB4 TrkB 
FGFR1 TrkC 
FGFR2a VEGFR1 
FGFR3 VEGFR2 
FGFR4 VEGFR3 
Insulin R MuSK 
IGF-1R EphA1 
AxI EphA2 
Dtk EphA3 
Mer EphA4 
HGFR (met) EphA5 
MSPR EphA6 
PDGFRa EphA7 
PDGFRb EphB1 
SCFR EphB2 
Flt-3 EphB4 
M-CSF-R EphB6 
c-RET  
ROR1  
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4.3.2 Densitometry analysis of EGF receptor family members. 
EGFR has long been reported to be elevated in TAMR cells. We therefore used EGFR as 
a “characterisation protein” in chapter 3 and again show the expression of this protein to 
be increased by array analysis. The phosphorylation of this receptor was increased by 
80.9% (TAMR) and 88.2% (TAMRBU) using this RTK array. ANOVA analysis 
suggested a high degree of statistically significant variance (P= less than 0.001). The t-
test values for EGFR, as listed in Table 4-4,  showed a high degree of statistical 
significance between the MCF7 cell line and both TAMR and TAMRBU, but there was 
no significance between the two resistant lines (P=0.643). 
ErbB2 also had a high degree of statistical significance using ANOVA (P= 
0.001). The phosphorylation of ErbB2 was increased by 159.4% (TAMR) and 164.4% 
(TAMRBU) compared to MCF7. These were statistically significant changes as the t-test 
showed, TAMR; P=0.001, and TAMRBU; P=0.002. There were no differences between 
the resistant cell lines TAMR and TAMRBU, P=0.617. 
ErbB3 (ANOVA, P=0.189) and ErbB4 (ANOVA, P=0.125) showed an increase in 
phosphorylation in the Tamoxifen resistant cell lines (see Table 4-4) but due to the 
variability seen in ErbB3 and ErbB4 TAMR samples, the increase was not significant. 
When a paired t-test was performed between the MCF7 and the TAMRBU cells, the 
outcome was significant with ErbB3 having a P value of 0.042 and ErbB4 (0.013). 
When a paired t-test was performed between the two resistant cell lines they showed no 
significant difference (ErbB3; P= 0.710, ErbB4; P=0.892). 
 
 
~ 110 ~ 
 
 
 
Figure 4-11 The phospho-RTK data for EGFR (p= less than 0.001), ErbB2 (p= 0.001), 
ErbB3 (p=0.189) and ErbB4 (p=0.125). All of these proteins show an increase in 
phosphorylation in the Tamoxifen resistant cell lines but due to the variability seen in 
ErbB3 & ErbB4 TAMR samples the increase was not significant. 
 
4.3.3 Densitometry analysis of Eph Receptors. 
The densitometry analysis for the EphB receptors 1, 2, 4 and 6 is shown in Figure 4-12.  
EphB2, 4 and 6 showed marginal increases in phosphorylation; however, as these 
changes were small and the data variable, there was a lack of statistical significance by 
ANOVA. Nevertheless, a t-test showed that the difference between the phosphorylation 
of MCF7 and TAMRBU for EphB4 (4.8% increase) was significant (P=0.026). 
Comparing the two resistant lines, no significantly difference in EphB2 and EphB4 
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phosphorylation was seen, but for EphB6 a significant result was seen (P=0.034). 
Moreover, EphB1 showed a more marked increase in phosphorylation (TAMR; 48.0%, 
TAMRBU, 31.1%), which illustrated statistical significance with a P value of 0.047 
(ANOVA). Individual t-tests showed TAMR phosphorylation to be significantly higher 
than in MCF7 cells (P=0.045) and TAMRBU nearly reached significance (P=0.051).  
The EphA receptor analysis is shown below in Figure 4-13. EphA1 showed a 
statistically significant increase in phosphorylation when compared to the MCF7 parental 
line (89.6%; TAMR, P=0.014 and 108%; TAMRBU, P=0.013). The full statistical data 
can be seen in Table 4-4. Similarly, EphA2 exhibited an increase in phosphorylation in 
both resistant lines although the magnitude of change was smaller (TAMR; 18.3%, 
TAMRBU; 20.1%). An unstacked ANOVA analysis suggested that there was a degree of 
variance in the samples (P=0.049) which was confirmed in t-test analysis, TAMR P= 
0.016 and TAMRBU, P=0.085, both compared to MCF7 cells.   
In marked contrast EphA3 showed little increase in phosphorylation and was not 
significant in any analysis. Both EphA4 and EphA5 showed increases in phosphorylation 
in the resistant cells (EphA4 - 40.3%;TAMR and 33.7% TAMRBU) but when a t-test was 
performed it did not prove to be statistically different, due to intra assay variation. 
Interestingly, EphA6 and EphA7 showed a decrease in phosphorylation in resistance 
(EphA6 -2.4%; TAMR and 10.6%; TAMRBU). However, this did not reach significance 
in EphA6 (P=0.172 for MCF7 compared to TAMR and 0.088 for MCF7 compared to 
TAMRBU). Whereas it did not for EphA7, comparing MCF7 and TAMRBU cells 
produced a P value of 0.050 (difference= -14.8%). 
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Figure 4-12  Densitometry analysis of the EphB receptors, these box plots show a 
marginal increase in most of the EphB receptors with EphB1 showing the most increase 
in phosphorylation, which is statistically significant with a P value of 0.047. However the 
others do not show significance by ANOVA; EphB2 is 0.134, EphB4 0.193 and EphB6 
0.770. N=3. 
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Figure 4-13 Box plots showing densitometry analysis of EphA receptors. Only EphA1 
and EphA2 show any significantly significant differences between resistance and MCF7 
with P values of less than 0.001 and 0.049 respectively. N=3. 
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4.3.4 Densitometry analysis of Vascular Endothelial Growth Factor 
Receptors 1, 2, and 3. 
The VEGF receptors 1, 2 and 3 all showed a trend of increased phosphorylation in the 
resistant cell lines (VEGFR1; 9.5% and 8.4%, VEGFR2; 59.6% and 77.4%, VEGFR3; 
35.8% and 24.6% - for TAMR and TAMRBU compared to MCF7 in each case). Of these 
increases in phosphorylation, VEGFR2 was statistically significant by t-test (TAMR, 
0.020; TAMRBU 0.010) as was VEGFR3, with P values of 0.028 (TAMR) and 0.048 
(TAMRBU). The resistant lines were not statistically different from each other 
(VEFGR2; 0.348 and VEGFR3; 0.127). 
 
 
Figure 4-14 The VEGF receptor family of RTKs. Box plots showing densitometry 
analysis of VEGF receptors family (1, 2 and 3)  producing P values of 0.077, less than 
0.001 and 0.001 respectively using ANOVA. N=3. 
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4.3.5 Densitometry analysis of Fibroblast Growth Factor receptors 
(FGFRs) 1, 2 , 3 and 4. 
FGFR1 and FGFR4 showed no significant difference between any of the cell lines (see 
Table 4-4).  FGFR3 exhibited a statistically significant increase in phosphorylation 
between the MCF7 and TAMRBU lines with a 35.4% increase (P=0.042). FGFR2a 
presented a statistical difference using ANOVA analysis of variance (P= less than 0.001) 
which was also conveyed when analysed using t-tests; MCF7 and TAMR (less than 
0.001), MCF7 and TAMRBU (0.002) and TAMR with TAMRBU (0.008). 
 
Figure 4-15 FGF receptor family densitometry data. These box plots show the FGF 
receptor family (1, 2 , 3 and 4), P values from ANOVA are as follows; 0.835, less than 
0.001, 0.007, and 0.130, respectively. (N=3). 
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4.3.6 Densitometry analysis of Platelet Derived Growth Factor receptors 
(alpha and beta). 
The densitometry values in the MCF7 sample for PDGFR  showed considerable 
variance, and the phosphorylation was relatively similar between cell lines with no 
statistical variation, see Table 4-4. The PDGFR  however, showed a much more marked 
change in phosphorylation between MCF7 and resistant lines (TAMR; 17.4% and 
TAMRBU; 36.9%) though only the difference between MCF7 and TAMR reaches 
significance (P=0.017), due to the TAMRBU assay variance.  
 
 
Figure 4-16 Densitometry analysis of the PDGFR alpha and beta. The ANOVA 
analysis of variance does not show significance (P=0.875 and P=0.142 respectively) 
However the increase in phosphorylation between TAMR and MCF7 is significant 
(P=0.012) and denoted by *. N=3. 
 
4.3.7 The densitometry analysis of TIE1 and TIE2 receptors. 
The TIE1 receptor showed an increase in phosphorylation, which was significant in 
TAMR cells, (see Table 4-4 for values). TIE2 receptor showed a marked increase of 
tyrosine phosphorylation (49.9% and 87.0%) in both the TAMR and TAMRBU cell lines. 
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These increases were statistically significant by t-test giving P values of 0.032 and less 
than 0.001. 
 
Figure 4-17 The TIE receptor phosphorylation data. Box plots showing the difference 
in phosphorylation of the TIE receptor family. ANOVA values indicate a degree of 
significance P=0.064 and P ≤0.001 respectively. N=3. 
 
4.3.8 Densitometry analysis of ROR1 and ROR2 receptors. 
ROR receptor 1 showed statistically increased phosphorylation in the TAMR and 
TAMRBU cell lines compared to the MCF7 parental cell lines with the TAMR cells 
showing the greatest increase (23.4%), (Seen in Figure 4-18 and Table 4-4). In contrast, 
ROR2 receptor only reached significance when TAMR and MCF7 were compared by t-
test analysis (P=0.008). 
 
Figure 4-18. Densitometry data for ROR1, ROR2; the TAMRs show a greater increase in 
phosphorylation than TAMRBU. ANOVA analysis provides P values of 0.013 for ROR1 
and 0.574 for ROR2. N=3. 
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4.3.9 The densitometry analysis of TrkA, B and C receptors. 
TrkA receptor phosphorylation exhibited no statistical difference between any of the cell 
lines. Interestingly, TrkB showed a statistical difference with a 9.3% decrease in 
phosphorylation between TAMRBU and MCF7, with a P value of 0.030.  This is in 
contrast to TrkC which showed a 12.4% increase in phosphorylation of the TAMRBU 
cells when compared to MCF7, which is also statistical when analysed by t-test P=0.035. 
 
 
Figure 4-19 Densitometry analysis of TrkA, B and C. The box plots show the varying 
degree of phosphorylation between the parental and resistant lines giving ANOVA 
analysis P values of 0.145, 0.017 and 0.062. N=3. 
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4.3.10 Densitometry analysis of M-CSF receptor (c-fms) phosphorylation 
The phosphorylation of this proto-oncogene related protein was increased by 12.7% and 
14.2% in TAMR and TAMRBU respectively, compared with phosphorylation of the 
receptor in MCF7 cells. These increases were statistically significant (P=0.014, TAMR 
and P=0.003 TAMRBU). There was no statistical difference between resistant lines 
(P=0.573).  
 
Figure 4-20 Densitometry analysis of M-CSF receptor tyrosine phosphorylation between 
MCF7 and Tamoxifen resistant cells. ANOVA analysis performed gave a P value of  
0.046. N=3. 
 
4.3.11  Densitometry analysis of Hepatocyte Growth Factor Receptor 
HGF receptor phosphorylation was increased by 28.3% in TAMR and 29.9% in 
TAMRBU. Both of the increases seen were statistically significant (0.008 and 0.017 
respective P values by t-test). 
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Figure 4-21. The densitometry analysis of HGFR and the differences in tyrosine 
phosphorylation seen between the MCF7 and resistant lines. ANOVA analysis (P≤0.001). 
N=3. 
 
4.3.12 Densitometry analysis of TAM family of receptors: Tyro3 (Dtk), AxI 
and Mer 
AxI receptor phosphorylation did not change significantly between cell lines. However 
Dtk and Mer showed marked increases in phosphorylation in both TAMR and TAMRBU. 
Dtk showed 91.1% increase in the TAMR and a 99.8% increase in the TAMRBU cells. 
These data were significant statistically; t-test showed P values of 0.026 and 0.003 
respectively. The increase in Mer was not as large at 62.5% TAMR and 56.2% TAMRBU 
but still a marked increase. These were also statistically significant using t-test analysis 
with P values of 0.026 and 0.002 for TAMR and TAMRBU. The resistant lines did not 
significantly differ from each other. 
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Figure 4-22 Densitometry analysis of the TAM family of receptors, showing a marked 
increase in phosphorylation in the resistant lines for Dtk and Mer receptors giving 
ANOVA P values of 0.001 and  less than 0.001 respectively. N=3. 
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Table 4-4  A summary table of results from the RTK array.  
 
Protein 
  
Significance 
M:T 
Significance 
M:B 
Significance 
T:B 
ANOVA 
M:T:B 
Normalised Fold 
change % 
M T B 
+ Control 0.521 0.112 0.893 0.555 / / / 
EGFR * 0.028 0.002 0.634 0.000 100 180.9 188.2 
ErbB2 * 0.001 0.002 0.617 0.000 100 259.4 264.4 
ErbB3 0.256 0.042 0.710 0.189 100 119.9 115.3 
ErbB4 0.221 0.013 0.892 0.125 100 122.8 125.0 
FGFR1 0.271 0.056 0.105 0.835 100 97.4 102.5 
FGFR2 * 0.000 0.002 0.008 0.000 100 199.3 238.8 
FGFR3  0.062 0.042 0.533 0.007 100 130.7 135.4 
FGFR4 0.259 0.084 0.156 0.130 100 103.7 115.7 
Insulin R 0.078 0.232 0.648 0.655 100 106.9 110.0 
IGF-1R 0.399 0.009 0.425 0.126 100 109.5 117.4 
AxI 0.689 0.049 0.438 0.765 100 101.4 104.8 
Dtk * 0.026 0.003 0.461 0.001 100 191.1 199.8 
Mer * 0.026 0.002 0.513 0.000 100 162.5 156.2 
HGFR * 0.008 0.017 0.793 0.000 100 128.3 129.9 
MSPR  0.076 0.010 0.222 0.030 100 188.0 136.7 
PDGFR  0.609 0.922 0.576 0.875 100 103.0 100.8 
PDGFR  0.017 0.160 0.408 0.142 100 117.4 136.9 
SCFR 0.189 0.111 0.403 0.070 100 112.7 108.8 
Flt-3 0.146 0.063 0.981 0.077 100 113.6 113.8 
M-CSF-R * 0.014 0.003 0.573 0.046 100 112.7 114.2 
c-RET * 0.011 0.143 0.636 0.036 100 123.1 119.8 
ROR1 * 0.030 0.030 0.071 0.013 100 123.4 105.7 
ROR2 0.008 0.509 0.142 0.574 100 108.8 102.4 
TIE1 0.004 0.178 0.213 0.064 100 116.0 108.5 
TIE2 * 0.032 0.000 0.052 0.000 100 149.9 187.0 
TrkA 0.175 0.942 0.151 0.145 100 113.5 99.9 
TrkB  0.098 0.030 0.180 0.017 100 95.6 90.7 
TrkC 0.648 0.035 0.173 0.062 100 102.1 112.4 
VEGFR1 0.205 0.041 0.762 0.077 100 109.5 108.4 
VEGFR2 * 0.020 0.010 0.348 0.000 100 159.6 177.4 
VEGFR3 * 0.028 0.048 0.127 0.001 100 135.8 124.6 
MuSK  0.050 0.163 1.000 0.050 100 143.5 143.5 
EphA1 * 0.014 0.013 0.507 0.000 100 189.6 208.2 
EphA2  0.016 0.085 0.702 0.049 100 118.3 120.1 
EphA3 0.229 0.914 0.178 0.865 100 105.7 100.1 
EphA4 0.126 0.231 0.476 0.154 100 140.3 133.7 
EphA5 0.280 0.664 0.154 0.286 100 122.3 110.3 
EphA6 0.172 0.088 0.179 0.451 100 97.6 89.4 
EphA7 0.467 0.050 0.060 0.078 100 97.6 85.2 
EphB1 * 0.045 0.051 0.061 0.047 100 148.0 131.1 
EphB2 0.231 0.250 0.589 0.134 100 110.7 108.1 
~ 123 ~ 
 
EphB4 0.410 0.026 0.638 0.193 100 103.2 104.8 
EphB6 0.421 0.067 0.034 0.077 100 104.6 112.2 
 
M=MCF7, T=TAMR, B=TAMRBU. Significance indicates P value obtained using a 
student paired t-test analysis between the cell lines. ANOVA is the P value obtained from 
one-way unstacked ANOVA analysis of variance between all three cell lines. Fold 
change in phosphorylation is normalised to the MCF7 levels and displayed as a 
percentage. * denotes significant proteins of interest, significance reached when p≤0.05. 
 
4.4 Human Apoptosis proteome profiler array 
The human apoptosis proteome profiler analysed the expression of thirty five apoptosis 
related proteins, full details of which can be seen in Table 4-5, so that they could be 
compared between the cell lines. The apoptosis proteome profiler was assayed on 2 
independent occasions on TAMRBU and MCF7 cell populations, the TAMR and 
TAMRBU had followed similar trends on the previous antibody arrays and so due to 
financial constrainsts it was deemed reasonable that only the TAMRBU and MCF7 cells 
be analysed using the apoptosis array. The statistically significant results are displayed 
below graphically, all other results are summarised in Table 4-6. 
4.4.1 Controls 
The array included positive and negative controls as detailed in the table below. 
The average reading of the negative controls was subtracted from all densitometry values. 
As the experiment had only been carried out at two independent occasions the 
conclusions drawn cannot be relied on as truly significant. The statistics were carried out 
using the individual spots as independent values rather than averaging them as was done 
in the MAPK and RTK profilers, although not strictly correct this gave an indication of 
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which protein expression differs in resistance. “Significance” of results and fold change 
can be seen in the apoptosis array summary Table 4-6 
 
Figure 4-23 the box plot showing the positive control values between experiments. 
ANOVA shows a P value of 0.485 and t-test 0.560. 
 
 
Table 4-5 A table of the proteins that are targeted on the apoptosis array proteome 
profiler 
 
Protein Targets of the Apoptosis Proteome Profiler 
HSP70 HO-1/HMOX1/HSP32 
HSP27 HSP60 
HO-2/HMOX2 Bcl-2 
HTRA2/Omi Bcl-x  
Bad Bax 
Livin Pro-Caspase-3 
PON2 Cleaved Caspase-3  
p21/CIP1/CDNK1A Catalase  
p27/Kip1 cIAP-1  
Phospho-p53 (S15) cIAP-2  
Phospho-p53 (S46) Claspin  
Phospho-p53 (S392) Clusterin  
Phospho-Rad17 (S635) Cytochrome c  
SMAC/Diablo TRAIL R1/DR4  
Survivin TRAIL R2/DR5  
TNF RI/TNFRSF1A FADD  
XIAP Fas/TNFRSF6  
HIF-1   
Negative Control Positive control 
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4.4.2 Densitometry analysis of some members of the Bcl family  
The Bcl family has many members including Bcl-2 (B cell lymphoma -2), BAX (Bcl-2 
like protein 4), BAD (Bcl-2 antagonist of cell death) and Bcl-X (Bcl-2 like protein 1) 
which were on the apoptosis proteome profiler. The Bcl-2 protein had decreased 
expression in the resistant cell lines (11.8%) this was a statistically significant decrease 
with P values from ANOVA and t-test giving 0.010 and 0.032 respectively. The BAD 
protein also showed a significantly decreased expression when compared to the MCF7 
cells (20.1%) with P values of 0.014 and 0.041 from ANOVA and t-test analysis. BAX 
also showed a statistically significant decrease (21.7%). In keeping with the increased 
growth of the resistant cell lines ANOVA gave a P value of 0.004 and t-test gave 0.016. 
Bcl-X, however, showed a statistically significant increase (18.9%), P values were 0.004 
(ANOVA) and 0.008 (t-test). 
 
Figure 4-24 Box plots showing the general decrease in expression of the Bcl family of 
proteins in Tamoxifen resistant cell line, TAMRBU. The Bcl-X protein however, shows 
an increase. The differences are all statistically significant using ANOVA. 
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4.4.3 Densitometry analysis of catalase 
The protein catalase shows a marginal, yet statistically significant, increase in Tamoxifen 
resistant cell lines (3.1%). The P value from ANOVA is 0.022 and from t-test 0.011. This 
is a small increase, which though interesting, may be artefactual due to the lack of 
replicate experiments n=2. 
 
 
 
 
 
 
4.4.4 Densitometry analysis of the inhibitors of apoptosis proteins 
c-IAP1 (cellular-Inhibitor of Apoptosis Protein 1), c-IAP2 (cellular-Inhibitor of 
Apoptosis Protein 2) and X-IAP (X linked -Inhibitor of Apoptosis Protein) all showed a 
statistically significant increases in the Tamoxifen resistant cell line TAMRBU when 
compared with MCF7 cells.  The c-IAP1 shows the most marked increase at 48.3% (P 
less than 0.001 ANOVA; P=0.001 t-test), X-IAP was increased by 20.2% (P less than 
0.001 ANOVA, P=0.007 t-test) and c-IAP2 by 17.4% (P=0.008 ANOVA, P=0.008 t-test).   
 
Figure 4-25 Box plot showing the statistically significant increased expression of catalase 
(P=0.011, t-test; P=0.022, ANOVA) 
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Figure 4-26 Densitometry analysis box plots, showing a statistically significant increase 
in IAP expression in resistance (Table 4-6). 
 
 
4.4.5 Densitometry analysis of HIF1 
HIF1  (Hypoxia inducible factor 1 alpha) shows a statistically significant increase in 
Tamoxifen resistant cells (18.5%) when compared with the sensitive parental cells 
MCF7. ANOVA analysis shows high variance (P value = less than 0.001) and t-test 
shows P=0.003. This result is interesting as the cells were not under hypoxic conditions, 
the flasks of cells (before harvesting lysates) were grown in the same incubator and the 
cells were at a similar cell density.  
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Figure 4-27 Densitometry analysis of HIF1  showing a statistically significant increase 
expression in resistance. 
 
 
4.4.6 Densitometry analysis of Heat shock protein 70 (HSP70) 
Heat Shock Protein 70 was one of three Heat Shock Proteins (HSP) that were spotted on 
the apoptosis array; however, HSP70 was the only one that showed a significant change 
in expression, (P=0.003 ANOVA, P=0.011t-test) with an increase of 16.5% in TAMRBU 
compared to the MCF7 cells. 
 
Figure 4-28 The densitometry analysis of the Heat shock protein 70 expression showing 
high levels in both cell lines but significantly increased in TAMRBU. 
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4.4.7 Densitometry analysis of Paroxanase 2 expression 
PON2 (Paroxanase 2) showed a statistically significant increase of 15.9% in resistant 
cells (TAMRBU) when compared with the MCF7. ANOVA (P=0.006) and t-test 
(P=0.001). 
 
Figure 4-29.  Densitometry analysis of the PON2 antioxidant protein showing a 
significant increase in expression in resistance. 
 
 
4.4.8 Densitometry analysis of RAD17 phosphorylated at Serine 635 
The cell cycle checkpoint protein RAD17 illustrated an increase in phosphorylation 
(34.5%) in resistance when compared with the MCF7 cells. This was significant with 
both ANOVA (0.032) and t-test (0.009). 
 
Figure 4-30 Densitometry analysis box plots showing a statistically significant increase in 
phospho RAD17 in acquired resistance. 
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4.4.9 Densitometry analysis of SMAC/DIABLO protein 
SMAC/DIABLO protein showed a decrease in expression in resistant cells in comparison 
with MCF7 cells (31.9%). This was a marked decrease that was statistically significant 
ANOVA showing P value of less than 0.001 and t-test 0.001. The protein is involved 
with the BCL2 family of proteins and also the inhibitors of apoptosis. This result is 
discussed in more detail below (Discussion; section 4.5). 
 
Figure 4-31 Box plots showing the densitometry analysis of SMAC DIABLO protein. 
The resistant line is significantly decreased when compared with the MCF7 parental line. 
 
4.4.10 Densitometry analysis of Survivin protein expression 
Survivin, exhibited an increase of 20.5% which was statistically significant with both 
ANOVA (P=0.004) and t-test (P=0.046).  
 
Figure 4-32 the box plot showing the increased expression of survivin expression in 
resistance, this is statistically significant in both ANOVA and in t-test. 
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Table 4-6 A summary table of results from the apoptosis proteome profiler array 
 
Protein Significance ANOVA Normalised Fold change % 
 M:B M:B M B 
Positive control 0.560 0.485 / / 
HIF-1 * 0.003 0.000 100 118.5 
HO1/HMOX1/HSP32 0.395 0.640 100 102.8 
HSP60 0.030 0.478 100 104.8 
Bcl-2 0.032 0.010 100 88.2 
Bcl-x * 0.008 0.004 100 118.9 
Bax * 0.016 0.004 100 78.3 
Pro-Caspase-3 0.151 0.189 100 96.1 
Cleaved Caspase-3  0.103 0.458 100 98.1 
Catalase  0.011 0.022 100 103.1 
cIAP-1 * 0.001 0.000 100 148.3 
cIAP-2 * 0.008 0.008 100 117.4 
XIAP * 0.007 0.000 100 120.2 
Claspin  0.655 0.573 100 102.4 
Clusterin  0.154 0.042 100 102.4 
Cytochrome c  0.844 0.817 100 100.9 
TRAIL R1/DR4  0.096 0.147 100 91.9 
TRAIL R2/DR5  0.091 0.135 100 93.7 
FADD  0.140 0.081 100 93.4 
Fas/TNFRSF6  0.590 0.605 100 98.5 
HSP70 * 0.011 0.003 100 116.5 
HSP27 0.180 0.069 100 111.4 
HO-2/HMOX2 0.289 0.777 100 103.2 
HTRA2/Omi 0.353 0.500 100 97.4 
Bad * 0.041 0.014 100 79.9 
Livin 0.416 0.383 100 105.3 
PON2 * 0.001 0.006 100 115.9 
p21/CIP1/CDNK1A 0.557 0.604 100 102.2 
p27/Kip1 0.795 0.712 100 101.7 
Phospho-p53 (S15) 0.245 0.604 100 98.3 
Phospho-p53 (S46) 0.421 0.344 100 105.1 
Phospho-p53 (S392) 0.202 0.309 100 104.9 
Phospho-Rad17 (S635) * 0.009 0.032 100 135.4 
SMAC/Diablo * 0.001 0.000 100 68.1 
Survivin * 0.046 0.004 100 120.5 
TNF RI/TNFRSF1A 0.690 0.622 100 100.8 
     
M=MCF7, B=TAMRBU. Significance indicates P value obtained using a student paired 
t-test analysis between the cell lines. ANOVA is the P value obtained from one-way 
unstacked ANOVA analysis of variance between both cell lines. Fold change in 
phosphorylation is normalised to the MCF7 levels and displayed as a percentage. 
Proteins of interest are highlighted *. Significance reached when p≤0.05. 
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4.5 Discussion 
Several mechanisms, proteins and pathways have been implicated in the development of 
Tamoxifen resistance including EGFR, ERK1/2, and FGFR. The antibody arrays used in 
this chapter were specifically chosen to include some of the proteins previously shown 
(by us and others) to have an involvement in acquired resistance to Tamoxifen therapy. 
This is useful as they were used as positive controls for the array experiments. Utilisation 
of Antibody arrays in this project was a useful tool as they offered an opportunity to 
screen a whole pathway simultaneously whilst providing a targeted approach to 
proteomic evaluation of the mechanisms of acquiring resistance.  
4.5.1 MAPK 
MAPKs are involved in important cellular pathways mediating cell proliferation, 
and cell survival pathways. Expression and activation of these pathways have been shown 
to play an important role in the development and progression of cancer (Keshet and 
Seger., 2010) and other findings show that it also has a role to play in Tamoxifen 
resistance (Hutcheson et al., 2003). Recent data in the literature suggests that the proteins 
in the complex MAPK signalling pathways can modulate oestrogen receptor activity 
(Yamnik and Holz, 2010). Using this MAPK focussed array has enabled us to see that 
several members of the MAPK family have modulated activity in the Tamoxifen resistant 
cell lines, see Table 4-2. 
We previously showed increased phosphorylation of ERK1 and ERK2 in the 
TAMR and TAMRBU cell lines by Western blotting (Figure 3-7) and the proteome 
MAPK profiler mirrors this increase, this gives confidence in the array data as the ERKs 
act as an internal validation of the data.   
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The p38 Mitogen-activated Protein Kinases (MAPKs) are a family of four related 
Serine /Threonine kinases which can be activated by pro-inflammatory cytokines as well 
as environmental stresses. All four of the p38 family members, alpha, beta, gamma, and 
delta, are phosphorylated at specific threonine and tyrosine positions. Once activated, p38 
phosphorylates a number of targets, inducing nuclear transcription factors. The whole 
family shows statistically significant increases (TAMR; 25.4%, 24.9%, 24.1% and 
38.6%; TAMRBU; 39%, 26.4%, 36.8% and 40.7% for , , ,  respectively). Although 
these data show only small increases this still may affect the balance of signalling in the 
cell. Total p38 MAPK has also been shown in the literature to have a role in resistance 
(within an autocrine loop with VEGF/VEGFR2 and p38 (Aesoy et al., 2008)) and 
Linderholm et al., 2011 have suggested the use of p38 as a potential biomarker of 
intrinsic Tamoxifen resistance. This study reported this finding for total p38 however the 
data in this Thesis suggest that there are some differences seen between the isoforms. 
Akt 1, 2 and 3 are a family of serine/threonine protein kinases that are thought to 
have a role in multiple cellular processes; cell proliferation, inhibition of apoptosis, 
transcription and cell migration as well as tumourigenesis. They are often activated 
downstream of growth-factor receptors and PI3 Kinase. Akt has previously shown to 
have a role to play in acquired Tamoxifen resistance (Pancholi et al., 2008). The 
activation of Akt 1 by phosphorylation at Ser473 was shown by Western blotting in 
Figure 3-11. The MCF7 and TAMR displayed predominately Akt1, but also increased 
Akt 2 and 3 phosphorylation. It is worth noting that an increased expression of Akt3 has 
been shown in the literature to be associated with a more aggressive clinical phenotype 
(Nakatani et al., 1999). Interestingly, this isotype was shown to have an increased 
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phosphorylation in resistance, which reached statistical significance in the TAMR cells 
moreover, a cell line that had been stably transfected with constitutively active Akt was 
protected from apoptosis induced by Tamoxifen (Shin and Arteaga, 2006). Our 
Tamoxifen resistant cells show an increase in Akt activity and also showed anti apoptotic 
mediators (see section 4.5.3).  
RSK (90 kDa ribosomal S6 kinase) is an effector of both Ras/MEK/MAPK and 
PI3K/PDK1 pathways. There are four isoforms but only RSK1 and RSK2 are spotted 
onto this array and only RSK1 significantly increased. RSK can be
 
activated by ERK in 
response to growth factors, polypeptide hormones, chemokines and other stimulus. It has 
been shown to be over expressed in breast cancer (Yamnick and Holtz, 2010) but not 
specifically cited to have a role in Tamoxifen resistance. ERK response is up regulated in 
our Tamoxifen resistant cell lines (Figure 3-7) this is known to activate RSK so the 
increase in RSK1 phosphorylation seen on this array fits with this being a functionally 
important pathway in Tamoxifen resistance.  
MAPK antibody array showed major differences in ERK1 and 2, p38’s, and Akt 
as would be predicted but interestingly this array also identified other significantly altered 
proteins which are novel findings (see Table 4-2). 
4.5.2 RTK 
RTKs aid cells to interpret the diverse range of signals and stimulus that cells 
come in to contact with, ensuring cells respond to the external stimulus appropriately. 
The activation of these receptors in the cell is tightly controlled and allows the cell to 
respond to its environment effectively. Cancer evades the normal mechanisms that 
control the cell and the regulation of the response to external stimulus causing 
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uncontrolled proliferation. The aberrant signalling of RTKs and their role in human 
cancers has been well known for many years. The constitutive activation of many 
proteins in this family of receptors has been shown to be important in tumour 
proliferation and the progression of cancer. 
The receptors themselves are divided into sub families, according to their 
structural characteristics but all have a single trans-membrane domain separating the intra 
cellular tyrosine kinase region from the extra-cellular portion. Adaptor molecules allow 
for the activation of RTKs to be linked to downstream signalling pathways such as 
MAPK pathway (which is crucial for RTK induced cellular proliferation). 
The EGF receptor family members (which include EGFR, ErbB2, ErbB3 and 
ErbB4) are tyrosine kinase receptors involved in the regulation of cell growth and 
differentiation. Differential expressions of the EGFR family members have been shown 
in breast carcinomas to influence different clinical behaviours, (Knowlden et al., 2003). It 
is thought that acquired resistance
 
to anti-oestrogens such as Tamoxifen is facilitated by 
increased EGFR
 
expression which enables stimulation of proliferation and 
phosphorylation of the ER on specific serine residues (Gee et al., 2005). ErbB2 also 
showed a statistically significant increase in phosphorylation; this has been described 
before in Tamoxifen resistance (Gee et al, 2005). Patients whose tumours have increased 
amplification of ErbB2 often go on to develop resistance to therapy (Knowlden et al., 
2003) and often also have different responses to other therapeutic agents such as Taxanes 
(Mokbel and Elkak, 2001). In these patients Herceptin is an important treatment.  
Herceptin is a humanised IgG monoclonal antibody specific to the growth factor ErbB2 
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(aka HER2) and is used in ErbB2 amplified cancers such as some breast and also some 
upper gastrointestinal cancers. 
Eph Receptors represent the largest group of RTKs; their expression controls 
many cellular processes through binding of the ligand Ephrin. In a cancer environment 
the EphR’s have been shown to play a role in aberrant cell – cell communication. They 
are thought to influence cancer progression, though the mechanisms through which they 
do this are poorly understood due to the complexity of EphR signalling (Pasquale, 2010). 
Both increased and decreased EphR expression has been linked with cancer progression, 
leading to promotion of tumourigenesis, as well as inhibition of it (Truitt et al., 2010). 
Eph RTKs regulate attachment to extra cellular matrix in several cell types, including 
tumour cell lines, but have been shown to promote rounding and detachment from the 
matrix in some breast tumour cell lines, (Truitt et al., 2010). This expression and 
conflicting evidence that EphR’s are involved in many aspects of cancer development 
and progression seems to suggest that their bidirectional signals may contribute to this. 
They have been shown to affect growth, migration and invasion in cultured cancer cells 
and in vivo affecting tumour growth, metastasis, and angiogenesis. For these reasons, the 
Eph receptors could be promising new therapeutic targets in cancer.  It has been 
suggested in the literature that the over expression of EphA2 infers a more aggressive 
breast cancer phenotype, and decreases breast epithelial cells sensitivity to Tamoxifen 
(Brantley-Sieders et al., 2008 and Lu et al., 2003) More recently, Gokmen-Polar et al., 
2011 have shown that dual targeting of EphA2 and ER restores Tamoxifen sensitivity in 
ER/EphA2 positive breast cancer. Interestingly, EphA2 was shown to have increased 
phosphorylation in our resistant cells, this reached significance in TAMR (p=0.016), for 
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EphA1 however, the tyrosine phosphorylation was increased and again reached 
significance. This has not previously been shown in the literature, however, EphA1 
expression was shown to be increased in gastric cancer correlating with increased stage 
and invasion and a poor patient survival (Wang et al., 2010). 
There are five FGFRs (1, 2, 3, 4, and 5) that mediate FGF activity, each contains 
three Ig domains with acidic amino residues between the first and second of these 
residues. All of the receptors, bar FGFR5, have a cytoplasmic split tyrosine kinase 
domain. Alternative splicing leads to multiple forms of FGFR1, 2 and 3. The only 
receptor that showed a significantly altered phosphorylation was FGFR2a; this has not 
been shown before. However, Meijer et al., 2008 has shown that altered expression of 
FGF17 causes Tamoxifen resistance in vitro and that FGFR4 is involved in the 
acquisition of Tamoxifen resistance. Interestingly, FGFR4 showed an insignificant 
increase in expression in our experiments; although this may have been partly due to the 
low levels of expression detected and the variation in the MCF7 cells expression. Further 
investigation of this result (by Western blot) would be warranted. A recent paper has also 
suggested that an over expression/ amplification of FGFR1 has a causal role in the 
progression of treatment resistance in breast cancer (Turner et al., 2010) no evidence of a 
change of phosphorylation was seen in this study, expression of FGFR1 was not 
investigated. The FGF signalling pathway could be a valuable target in the treatment of 
breast cancer patients resistant to endocrine treatment, but further investigation into 
which receptors are increased is needed. 
The VEGFR family belong to the class III subfamily of receptor tyrosine kinases 
All three receptors in the family contain seven immunoglobulin-like repeats in their 
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extracellular domain and kinase insert domains in their intracellular region. They are 
perhaps best known for their role in regulating VEGF family-mediated vasculogenesis, 
angiogenesis, and lymphangiogenesis. VEGFR2 is thought to be the primary inducer of 
VEGF-mediated blood vessel growth, while VEGFR3 plays a significant role in VEGF-C 
and VEGF-D-mediated lymphangiogenisis. These are the two receptors that have 
statistically significant increases in tyrosine phosphorylation in our cell model. This is a 
potentially interesting result as the cells are epithelial in nature and the VEGFR family 
are endothelial receptors, although their expression has previously been described in 
MCF7 cells (Aesoy et al., 2008). The up-regulation of VEGFR2 phosphorylation (Figure 
4-14) and p38 phosphorylation (Figure 4-5) in this study has also been reported in the 
literature in acquired Tamoxifen resistance (Aesoy et al., 2008) who reported that MCF7 
cells with acquired Tamoxifen resistance have increased VEGF secretions and 
subsequently increased signalling through VEGFR2. It was elucidated that this increased 
signalling was acting through p38, the expression and phosphorylation of which was 
found to be increased in resistance, as we also report in this Thesis. Aesoy et al., 2008 
showed that inhibition of p38 in resistant cells led to a decreased proliferation of both 
resistant and sensitive cells and a connection (signalling loop) was established between 
VEGFR2 and p38 using knock downs of VEGFR2.  The p38 pathway is involved with 
growth, and VEGFR2 pathway is involved in angiogenesis and anti-apoptosis, 
modulation of these pathways may provide a way to overcome Tamoxifen resistance. Our 
data would fit well with such a model. 
Tie-2 is a receptor for the angiopoietins (ANG 1 and 2) and is involved in 
vascular stabilization and remodelling in endothelial cells both in physiological and 
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pathological conditions. The phosphorylation of Tie2 was found to be statistically 
increased in both resistant cell lines (Figure 4-17). Tie 2/Ang signalling has been found to 
regulate the survival and apoptosis of endothelial cells, control vascular permeability, and 
regulates capillary sprouting. In cancer, Tie2 was originally found to be over expressed in 
tumour blood vessels; however, it has been recently shown in the literature that Tie2 is 
also expressed outside the vascular partition in several types of cancer, including breast 
tumours (Martin et al., 2008).  Our results show a statistically significant increase in Tie2 
phosphorylation in both resistant cell lines and add weight to these findings and suggest 
that the role of Tie2 in tumour cells needs further exploration.   
HGF receptor (HGFR), a product of the proto-oncogene c-met, is a heterodimeric 
transmembrane glycoprotein that has tyrosine kinase activity and is activated by HGF. In 
this chapter it was shown to have increased phosphorylation in the Tamoxifen resistant 
cell lines (Figure 4-21). The receptor has been shown in the literature to have increased 
expression when MCF7 and T47D breast cancer cells are exposed to chronic doses of 
Fulvestrant, leading to the activation of HGF secreting fibroblasts and activation of a 
number of signalling proteins including Src, ERK1 and 2 and Akt, all of which contribute 
to a more aggressive phenotype in breast cancer cells (Hiscox et al., 2006). Here we show 
that Tamoxifen resistance also leads to statistically significant increases in HGFR 
activation. Modulation of cell motility, cellular adhesion, resistance to apoptosis and 
anchorage independent growth have all been associated with HGFR in cancer. Clinically, 
over expression of HGFR may confer a tendency for breast tumours to metastasise, as it 
allows the surrounding stromal cells (i.e. fibroblasts) to contribute additional stimulating 
signals. This would fit with the known increases seen in TAMR cells. 
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The Macrophage stimulating factor receptor (M-CSFR), shown to have increased 
phosphorylation in resistant cells (Figure 4-20), is the product of the c-fms proto-
oncogene. Abnormal expression has previously been shown in the breast, ovary and 
endometrium (Maher et al., 1998) whilst the activation of the receptor by the ligand has 
been reported to regulate invasion and anchorage independent growth in breast cancer 
cells. The increased phosphorylation of M-CSFR seen in this study would fit with these 
findings. M-CSFR has been investigated as a prognostic marker in ipsilateral breast 
cancer reoccurrence in clinical samples but showed no correlation between receptor 
expression and metastasis and was thought to be a poor prognostic marker (Maher et al., 
1998). 
Axl, Dtk, and Mer share a common ligand; GAS6 (Growth arrest specific 6). 
GAS6 has highest affinity for Axl, followed by Dtk, then Mer. Axl, Dtk and Mer are a 
sub family of receptor
 
tyrosine kinases whose extracellular domain contains motifs 
similar to those found in
 
many cell adhesion molecules, they have been implicated in 
tumourigenesis, cell survival, proliferation and adhesion. GAS6 has been shown to be 
regulated by oestrogen (Mo et al., 2007) and an ERE has been identified in the GAS6 
promoter. Axl was only shown to have significantly increased phosphorylation in 
TAMRBU cells and this was a marginal increase of 4.8%. The other two receptors 
showed greater phosphorylation and this was significant in both resistant cell lines (see 
Table 4-4). Less is known about these receptors and their role in cancer but they have 
been found to be over expressed in a number of human cancers (Linger et al., 2008). The 
clinical ramifications of the increases have not yet been elucidated so this represents a 
novel and interesting finding which requires further investigation as one could suggest 
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that an increase in the phosphorylation of these receptors of an oestrogen regulated ligand 
could represent a mechanism for evading oestrogen/Tamoxifen regulated growth.  
4.5.3 Apoptosis  
Apoptosis is the process of programmed cellular death, and it plays a critical role 
in normal processes whilst inappropriate apoptosis tends to lead to diseases, including 
cancer. It comprises of complex cascades that lead to cellular changes such as membrane 
blebbing, DNA degradation, chromatin condensation and ultimately the formation of 
apoptotic bodies that are cleared by phagocytosis (Elmore, 2007).  
Apoptosis and proliferation play an important role in normal breast development; 
the balance of these two mechanisms is therefore crucial in the determination of overall 
growth and regression of cancer cells and also in the cells response to therapeutics such 
as chemotherapy, radiotherapy and hormonal therapy such as Tamoxifen, as the action of 
these therapeutics, at least in part, is based on induction of apoptosis.  
The Bcl-2 family of proteins consist of both promoters and inhibitors of apoptosis. 
The pro-apoptotic Bad (Bcl-2-antagonist of cell death) is a pro-apoptotic protein and its 
expression was significantly decreased in TAMRBU, this was also the case of the pro-
apoptotic protein Bax (See section 4.4.2). These data would fit with the increased 
proliferation rate seen in the resistant cell model. Bax has been shown to be crucial for 
inducing the permeability of the outer mitochondrial membrane and therefore the release 
of the promoters of apoptosis such as SMAC/Diablo. Again, the decrease in expression of 
the proteins suggests that the TAMRBU cells are evading the apoptotic cascade in order 
to survive. However, the results for the pro-survival proteins Bcl-x and Bcl-2 was 
conflicting. There was an increase in Bcl-x protein but not of Bcl-2 (section 4.4.2). The 
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decrease in Bcl-2 also conflicts with reports in the literature (Planas-Silva et al., 2007) 
where it is implied that an increase is associated with a more aggressive phenotype and 
therefore an increase in our Tamoxifen resistance cell model would have predicted. This 
would be an interesting result to repeat and validate by Western blot.  
Heat shock proteins 27 and 70 have previously been associated with clinical 
resistance to Tamoxifen (Ciocca et al., 1998). HSP27 is an oestrogen-regulated protein 
and HSP70 is part of the chaperone machinery that works in the assembly and function of 
steroid receptors. In addition, HSPs have been shown in the literature to assist in 
protecting cells against stress, and their expression has been linked to drug resistance 
(Calderwood et al., 2006).  The HSP60 showed a small increase in expression in this 
study (see Table 4-7) and has also been shown to be up regulated in many cancer types 
including breast (Desmetz et al., 2008). The role of HSP60 in cancer is still poorly 
understood, and the relationship between HSP60 and Tamoxifen resistance is novel. 
As already mentioned, mitochondrial pro-apoptotic protein SMAC/Diablo 
expression in TAMRBU was statistically decreased (Figure 4-31). This is interesting as it 
is a likely promoter of apoptosis, reported to inhibit IAP activity (Fandy et al., 2008). 
During the process of apoptosis, Smac/DIABLO gets released into the cytosol of the cell 
and becomes bound to an inhibitor of apoptosis XIAP which acts as an antagonist to 
XIAP’s interaction with caspase 9. This action promotes caspase 9 activity, followed by 
caspase 3 and apoptosis commences. It has been shown in the literature (Mizutani et al., 
2005) that patients with metastatic disease Renal Cell Carcinoma have lower 
Smac/DIABLO levels than those with localised disease. It has also been shown that 
Smac/Diablo when artificially over expressed in cancer cells is able to enhance the 
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sensitivity of the cells to various therapeutic agents including Tamoxifen (Fandy et al., 
2008). 
The cellular IAPs (Inhibitor of Apoptosis) proteins were increased in the 
TAMRBU cell line (Figure 4-30). IAPs inhibit the activity of mature caspases. It has 
been speculated that cellular caspase activity may be restored by proteins such as 
SMAC/Diablo (Wilkinson et al., 2004) which links with the decrease in SMAC/Diablo 
expression seen in TAMRBU cells in this Thesis (see above). XIAP (X-linked inhibitor 
of apoptosis) is also a member of the IAP family. XIAP inhibits the activity of caspase 3, 
7, and 9 (Suzuki et al., 2001). However, no change in caspase expression was seen in 
these cells. 
Increased Survivin has been detected in most types of cancer but is rarely 
expressed in the “normal” equivalent tissue, so this could be a potential promising 
biomarker of cancer. It has been associated with markers of poor prognosis in breast 
cancer patients in the literature (Ryan et al., 2006) which would appear to support the 
increase seen in Tamoxifen resistance here (Figure 4-32). It has also been associated with 
a resistance to Tamoxifen induced apoptosis in MCF7 cells (Moriai et al., 2009). 
HIF1 was shown to be up regulated in TAMRBU cells on the apoptosis array 
(Figure 4-27). It is understood from the literature that HIF1  activates the transcription of 
many genes in prostate cells under hypoxic conditions; these include glucose transporters 
and vascular endothelial growth factor (Mori et al., 2010). Whilst these cells were 
certainly not hypoxic, the expression of this protein is the prime mechanism for induction 
of tumour angiogenesis (Quintero et al., 2004), and the up regulation is again in keeping 
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with the fact that the resistant cell lines are rapidly proliferating and therefore potentially 
would  lead to the growth of large tumours which need more vascularisation.  
 PON2 has recently been reported to contribute to tumourigenesis and evasion of 
apoptosis (Witte et al., 2011). PON2 was found to be over expressed in a number of 
human cancers including prostate, endometrium and liver; furthermore, its over 
expression was shown to be associated with resistance to various therapeutic agents such 
as imatinib, doxorubicine, staurosporine in leukaemic cell line models (Witte et al., 
2011). It was also suggested that high expression of PON2 lowered ROS and limited the 
formation of caspase activation; however, caspase 3 activation was not altered in 
TAMRBU cells (Table 4-6). Witte et al., 2011 reported that a decrease in JNK activation 
(Thr183 and Tyr185) was seen in cells that over expressed PON2, however, JNK 
activation was not significantly altered in TAMRBU cells (Figure 4-4). 
 
Antibody arrays have shown value in the discovery of proteins associated with 
Tamoxifen resistance as many of the proteins found to have altered expression or 
phosphorylation in Tamoxifen resistant cell lines are novel findings as shown in the 
summary Table 4-7.  
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Table 4-7. A table of all the proteins that were statistically different in the both 
Tamoxifen resistant cell lines (where applicable), whether the modulation has been 
described in resistance previously and the reference of the paper if it has. Phosphorylation 
is designated by (P) 
 
Protein Name 
 
Increased/ 
decreased in TR 
Previously found 
in TR? 
Reference 
EGFR (P) Increased YES Knowlden et al 2003 
ErbB2 (P) Increased YES Knowlden et al 2003 
FGFR2a (P) Increased NO  
Dtk (P) Increased NO  
Mer (P) Increased NO  
HGFR (P) Increased YES Hiscox et al 2006 
M-CSF-R (P) Increased NO  
ROR1 (P) Increased NO  
Tie2 (P) Increased NO  
VEGFR2 (P) Increased YES Svensson et al 2005 
VEGFR3 (P) Increased NO  
EphA1 (P) Increased NO  
EphB1 (P) Increased NO  
ERK1 (P) Increased YES Gee et al 2001 
ERK2 (P) Increased YES Gee et al 2001 
P38 (P) Increased YES Aesoy et al 2008 
RSK1 (P) Increased NO  
Akt (P) Increased YES Clark et al 2002 
HIF1  Increased YES Martinez-Outschoom et 
al 2010 
Bcl-2 Decreased NO  
Bcl-X Increased NO  
Bad Decreased YES  Cannings et al 2007 
Bax Decreased NO  
Catalase Increased NO  
cIAP1 Increased NO  
cIAP2 Increased NO  
XIAP Increased NO  
HSP70 Increased NO  
PON2 Increased NO  
p-RAD17 (S635) (P) Increased NO  
SMAC/Diablo Decreased NO  
Survivin Increased YES Moriai et al 2009 
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5 Mass spectrometry based proteomic investigation 
Quantitative proteomics has traditionally been based on 2D SDS PAGE but there are 
other emerging, relatively new technologies that can overcome some of the disadvantages 
of the 2DE (such as poor membrane protein analysis). These include labelling 
technologies and strategies such as ITRAQ, O18 labelling, ICAT and SILAC all of which 
were introduced in section 1.1.3 
SILAC is the approach that was chosen for this project. It is a form of metabolic 
labelling where one cell population is grown in a media containing a heavy labelled 
lysine and one in normal lysine (this is outlined in more depth in the methods section, 
2.1.7, and in the main introduction 1.1.3).  
The ability to use mass spectrometers to investigate cellular proteomes allows us 
to assess many proteins and their expression in one spatial time-point. This is a valuable 
tool in the field of Tamoxifen resistance providing the potential to discover novel 
changes.   
5.1 SILAC labelling and global proteomics  
5.1.1 Labelling efficiency. 
The SILAC experiment did not commence until the extent of labelling had been 
established (see section 2.3.4). This was done as a simple calculation. The % of K 
inclusive peptides with labelled K residues was 98%. This was a high incorporation of 
label and further cell population doublings were deemed unnecessary.   
~ 147 ~ 
 
 
Figure 5-1. 4-12% Bis-Tris gel to obtain the SILAC labelling efficiency. 
 
5.1.2 Shotgun global SILAC experiment 
Briefly, the cells were trypsinised (section 2.1.6) and counted. 5x10
6
 cells of each 
“heavy” and “light” respectively were counted and mixed into one tube which was then 
lysed using NP-40 lysis buffer (2.2.1) and a BCA assay completed to determine protein 
concentration. 200 g of protein lysate was loaded into a 4-12% Bis-Tris 1 well gel 
(Figure 5-2), run and stained with colloidal Coomassie. A paper stencil was used as a 
guide enabling 40 even, manageable slices to be cut manually from the gel; this enabled 
the proteins to be separated by their size before they were typically digested, with the 
largest proteins in slice 1 and smallest in slice 40.  
TAMRBU C12 LYS MCF7 C13 LYS
Excised bands
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Figure 5-2. 4-12% Bis-Tris one well gel used to separate the whole cell lysates from the 
mixed heavy and light labelled cells. This was then cut using this template to create 40 
gel bands to perform in-gel digestion on and extract peptides from.  
 
 
 
In total, 262 quantifiable proteins were identified using FASTA database 
(ipi.HUMAN.v3.51.fasta). Each protein included in the study had 2 or more peptides 
found, these peptides were only included if they reached an XCorr value of 1.5 for singly 
charged peptides, 2.0 for doubly charged and 2.5 for triply charged peptides. Data that 
did not reach these criteria were removed from the resulting analysis. Raw data is 
available in Appendix. 
 
The data from each slice was analysed and the Xpress ratio (ratio Heavy: Light) 
data was manually checked; due to the frequently seen irregularity in the software’s peak 
picking. The peaks that the software picked were often incorrect, an example of which is 
shown in Figure 5-3b, and subsequently each Xpress ratio was checked manually. 
 
SLICE 1
SLICE 40
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Figure 5-3 Examples of good (A) and poor (B) peak picking. The shaded grey area under 
the peak gives the value on which the Xpress ratio is based. 
 
 Of the 262 quantifiable proteins found in the global SILAC proteomic 
experiment, the difference between over expressed proteins and under expressed proteins 
are fairly evenly spread, with 25% down regulated and 29% up-regulated in resistance. A 
large proportion (46%) presented as neutral (no difference between heavy and light 
peptides). This can be seen in a pie chart below (Figure 5-4) and also in the formation of 
the waterfall plot (Figure 5-8) the average of the LogBase2 is 0.334 – showing a slight 
skew as more proteins are up-regulated. 
 
A B 
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Figure 5-4. 46% of the labelled proteins found were neutrally expressed between heavy 
MCF7 and light TAMRBU. There were marginally more up-regulated in resistance.  
 
The ontological data of the proteins found in this experiment was gathered from UniProt 
knowledge database. The cytoplasm is the largest (by volume) portion of the cell and 
therefore it is unsurprising that the largest proportion of the proteins found were 
cytoplasmic with 67% (Error! Not a valid bookmark self-reference. A). The ontology 
also showed that 19% of the proteins found were nuclear proteins.  Unfortunately there 
were few membrane proteins and no receptors found. This would have been interesting to 
collate with the data from the RTK antibody array (Section 4.3).  The functionality of the 
proteins found was also investigated and the Uniprot knowledge database was again used. 
This could not classify a function for 48% of the proteins and they were therefore labelled 
“unknown”. Enzymes accounted for 28% of the proteins found. This could be due to the 
higher metabolic rate/proliferation that is seen in the resistant cell lines (alamar blue 
assay – section 3.2.4). There were also kinases, phosphatases and transcription regulators 
found by the experiment. It has been estimated that 20% of the human genome encodes 
25%
46%
29%
Down Regulated Neutral Up Regulated
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for signalling proteins such as kinases, phosphatases and transcription factors (Taylor et 
al, 2004). The resistant cells are known to have aberrant signalling pathways and 
therefore it is good that the experiment identified some proteins in these groups.
 
Figure 5-5. Ontological information pertaining to the quantifiable protein identifications 
obtained using the global SILAC approach. A, shows the largest proportion of proteins 
identified were cytoplasmic. Part B shows of the total identified 42% did not specify role 
and were given the sub-group of “other”. Ontological information gathered from UniProt 
knowledge database. 
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Figure 5-6 Ontological Information of the proteins that are over expressed in the SILAC 
experiment. Of the proteins showing increased expression in resistance 59% were 
cytoplasmic, 20% nuclear, and 10% plasma membrane proteins. The fewest proteins were 
found to be associated with the extracellular space and 8% were of undesignated 
localisation. Nearly half of the proteins were of unknown specific function and 25% were 
enzymes. 
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Figure 5-7 Ontological information of the proteins that showed down regulation in 
TAMRBU using SILAC. The majority of the proteins with lower expression in 
TAMRBU were cytoplasmic (62%) and 50% of the down regulated proteins were 
classified as having no specific function, 18% were enzymes and 10% were peptidases.  
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Figure 5-8 A waterfall plot of the 262 quantifiable proteins that were identified, each 
blue bar represents a protein, the 5 red bars are the proteins that have been further 
validated by Western blot analysis. The blue line that crosses the bars represents the 
average (0.334). More proteins were over expressed in resistance. The Y axis represents 
LogBase2 of the ratio between heavy and light. 
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Table 5-1. A table describing 15 example proteins that showed increased expression in 
the Tamoxifen resistant cell model TAMRBU found using SILAC labelling MS 
approach. 
 
Protein name (plus abbreviation) Gene Accession Fold 
Change 
Log 2 
BCL2-Associated athanogene (BAG-1) 
 
BAG1 Q99933 7.14 2.84 
Calpain-1 CAPN1 
 
P07384 3.44 1.79 
Chloride intracellular channel 1 (CLIC-1) 
 
CLIC1 O00299 3.85 1.94 
Cortactin 
 
CTTN Q14247 
 
2.38 1.25 
Epithelial cell adhesion molecule (EpCAM) 
 
EPCAM P16422 
 
9.09 3.18 
Hepatoma-derived growth factor (HDGF) HDGF P51858 
 
2.17 1.12 
High-mobility group box 1 (HM Box-1) HMGB1 P09429 3.57 1.84 
IQ motif containing GTPase activating protein 1 
(IQGAP1) 
 
IQGAP1 P46940 
 
2.66 1.40 
Phosphatidylinositol-3,4,5-trisphosphate-dependent 
Rac exchange factor 1 (P-Rex) 
 
PREX1 Q8TCU6 
 
3.57 1.84 
Protein phosphatase 1, gamma isozyme (PP1 ) PPP1CC 
 
P36873 
 
1.63 0.86 
Prohibitin 
 
PHB P35232 
 
2.00 1.00 
Proliferation-associated 2G4, (PA2G4) PA2G4 Q9UQ80 
 
3.33 1.74 
Ribophorin - 2 
 
RPN2 P04844 
 
4.35 2.12 
Staphylococcal nuclease and Tudor domain containing 
1 (SND-1) 
 
SND1 Q7KZF4 
 
3.44 1.79 
Talin-1 
 
TLN1 Q9Y490 3.22 1.69 
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Table 5-2 A table that represents 15 example proteins that were down regulated in the 
TAMRBU resistance cell culture model compared to MCF7 are shown, as identified 
using SILAC and MS approach. 
 
Protein (Plus abbreviation) Gene Accession Fold 
Change 
Log 2 
 Actinin 4 
 
ACTN4 O43707 -1.6 -0.43 
AFG3-Like protein 2 
 
AFG3L2 Q9Y4W6 -4.16 -2.05 
Programmed cell death 6 interacting protein 
ALIX 
 
PDCD6IP 
 
Q8WUM4 
 
-1.5 -0.25 
Calponin-2 
 
CNN2 Q99439 -2.32 -1.22 
Cathepsin D 
 
CTSD P07339 -1.6 -0.69 
Centaurin 
 
ARAP3 D3DQE3 -1.56 -0.62 
Cytochrome C1 
 
CYC1 P08574 -1.5 -0.64 
Ezrin-radixin-moesin binding 
phosphoprotein-50 (EBP-50) 
 
SLC9A3R1 
 
O14745 
 
-5.55 -2.47 
Protein FAM49B (L1) FAM49B Q9NUQ9 
 
-6.66 -2.74 
Lamin B1 
 
LMNB1 P20700 -2.32 -1.21 
nuclear transcription factor, X-box binding-
like 1 
 
NFXL1 Q6ZNB6 -4.3 -2.40 
Nuclear migration protein NUDC 
 
NUDC Q9Y266 -3.57 -1.83 
SET 
 
SET Q01105 -2.08 -1.05 
Vigilin HDLBP 
 
Q00341 -2.27 -1.18 
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5.2 Western Blots of five candidate proteins found using MS 
SILAC 
Of the 262 proteins found using SILAC (see CD appendix) 5 were chosen for further 
validation using Western blotting. Validation of MS analysis is routinely used in the 
literature and it was seen as good practice before further, more functional work was 
carried out.  
The 5 proteins that were chosen for further study were selected for several 
reasons; IQGAP1 had been shown in the literature to be important in EGFR signalling 
and also ERK1 and 2 signalling, these are known to be key factors in Tamoxifen 
resistance acquisition. It also was quantified using over 10 peptide pairs giving more 
confidence in the data. Cortactin and Talin were shown in the literature to play a role in 
actin cytoskeleton reorganisation and attachment, and have been shown to interact with 
many proteins that are implicated in acquired Tamoxifen resistance in the literature. 
Ribophorin- 2 was chosen for further investigation as there was little known data for 
function of this protein with the exception of an increase of expression shown in 
docetaxel resistance and the quantitation from SILAC suggested that this protein also 
shown an increased expression in resistance (4.35 increase in TAMRBU). It was also 
seen as good practice to validate a protein that was decreased in resistance, for this reason 
cathepsin D was chosen.  
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5.2.1 Ras GTPase activating like protein 
Ras GTPase activating like protein (IQGAP1) is a protein that has many roles in the 
normal function of a cell, as discussed in detail in section 5.3.1. Here we found via 
SILAC that TAMRBU showed an increase in IQGAP1 of 166.8% (p = less than 0.001) 
compared to the expression seen in the MCF7 cells. This trend is also seen to a lesser 
extent (81.7%, p ≤0.001) in the Western blot densitometry analysis as can be seen in 
Figure 5-9.  
    
 
Figure 5-9 Composite showing A, the densitometry analysis of the Western blot (shown 
above chart) showing an 87.1% increase in TAMRBU pixel density (p<0.001 by students 
T test) when compared to MCF7. B, shows the comparison of the area under the curve 
(AUC) value for the quantitative peptides analysed in SILAC, this shows a 113.1% 
increase in the TAMRBU when compared to MCF7 with p value <0.001. 
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5.2.2 Src substrate Cortactin 
Over expression of cortactin has been associated with an increase in motility and has 
been frequently reported in many types of cancer which is discussed in more detail in 
section 5.3.1. Using SILAC, cortactin was shown to be increased by 138.4% in 
resistance, compared with MCF7 cells. There is no statistical analysis of this data as there 
were only 2 quantifiable peptide pairs found. In the Western blot analysis there was an 
increase seen in resistance, however it is to a lesser extent (33% increase in resistance) 
this was statistically significant (p=0.01) by student t-test. 
               
 
Figure 5-10 Composite showing A, the densitometry analysis of the Western blot (shown 
above chart) showing a 33% increase in TAMRBU pixel density (p=0.010 by students T 
test) when compared to MCF7. B, shows the comparison of the area under the curve 
(AUC) value for the quantitative peptides analysed in SILAC, this shows a 138.4% 
increase in the TAMRBU when compared to MCF7, there are no statistics available on 
the SILAC data as only two peptide pairs were found. * denotes statistical significance. 
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5.2.3 Talin-1 
Talin-1 is a protein involved in motility and potentially involved in Akt signalling which 
is discussed further in section 5.3.1. The SILAC data showed a 3.22 fold change increase 
in TAMRBU cells. This was calculated from one quantifiable pair of peptides for the 
protein so no statistics could be used. When Western blots were used to validate the 
result, TAMRBU showed a 90.6% increase in expression when compared to the 
expression seen in MCF7 (p=0.002). Both SILAC and Western blots showed an increase 
of expression of Talin-1 in resistance.  
            
 
Figure 5-11 Composite showing A, the densitometry analysis of the Western blot (shown 
above chart) showing a 90.6% increase in TAMRBU pixel density (p=0.002 by students 
T test) when compared to MCF7. B, shows the comparison of the area under the curve 
(AUC) value for the quantitative peptides analysed in SILAC, this shows a 222.6% 
increase in the TAMRBU when compared to MCF7, there are no statistics available on 
the SILAC data as only one peptide pair was found. * denotes significance. 
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5.2.4 Ribophorin 2 
The validation of Ribophorin 2 using Western blot analysis did not agree with the result 
from SILAC and therefore the result seen in SILAC that ribophorin was increased by 
155.6% was not validated. Indeed, the Western blot analysis showed a statistically 
significant decrease in expression (48.6%, p=0.019). 
 
         
 
 
Figure 5-12 Composite showing A, the densitometry analysis of the Western blot (shown 
above chart) showing a 48.6% decrease in TAMRBU pixel density (p=0.019 by students 
T test) when compared to MCF7. B, shows the comparison of the area under the curve 
(AUC) value for the quantitative peptides analysed in SILAC, this shows a 155.6% 
increase in the TAMRBU when compared to MCF7, there are no statistics available on 
the SILAC data as only two peptide pairs were found. 
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5.2.5 Cathepsin D 
Cathepsin D and its potential role in Tamoxifen resistance is discussed in detail in section 
5.3.2. Validation of the SILAC is shown in Figure 5-13; the TAMRBU showed a 37.6% 
decrease in Cathepsin D when compared to MCF7 cells. There was only one pair of 
quantifiable peptide pairs found for this protein and therefore statistics could not be 
performed. When Western blot densitometry analysis was performed it showed a 61.6% 
decrease in resistance (p=0.002). Thus both the SILAC and the Western blots show a 
decrease in expression. 
            
 
 
Figure 5-13 Composite showing A, the densitometry analysis of the Western blot (shown 
above chart) showing a 61.6% decrease in TAMRBU pixel density (p=0.002 by students 
T test) when compared to MCF7. B, shows the comparison of the area under the curve 
(AUC) value for the quantitative peptides analysed in SILAC, this shows a 37.6% 
decrease in the TAMRBU. There is no statistical data for B as there was only one pair of 
quantifiable proteins. * denotes statistical significance. 
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5.3 Discussion 
The SILAC labelling approach that was used in section 5.1 is a technique used to 
investigate different protein expression profiles using relative quantitation. SILAC as a 
labelling strategy is a tool for the quantitative analysis of global differential protein 
expression, and when used in combination with differential MS analysis; provides us with 
a powerful tool to identify and quantify complex protein samples. The majority of 
proteins found were cytoplasmic. There were no receptors found, we know that many 
receptors have altered expressed and modulation in acquired Tamoxifen resistance, this 
can however be explained by the ability of the mass spectrometers that were used in the 
analysis. The way in which a mass spectrometer analyses proteins is outlined in section 
1.1.2. Briefly, after fragmentation of the first ion it analyses the next most abundant and 
then the next, etcetera. The low abundant proteins may not be analysed as the time is 
taken up on the more abundant proteins in the sample which are analysed first. Newer 
instruments would be more sensitive as they are able to cycle more rapidly to reach less 
abundant peptides. The lysis buffer used on the SILAC labelled cells was identical to the 
lysis buffer used in preparation of lysates for Western blots; and large receptors such as 
EGFR were identified from the lysates using Western blot (Figure 3-5) indicating that the 
lysis protocol was not the issue.  The use of a multi dimensional HPLC run may have 
produced a less complex sample for the mass spectrometer to analyse. However, as the 
SILAC experiment provided us with a large number of leads to follow without this extra 
step, it was deemed unnecessary for this study. It may provide more leads to follow in the 
future (Section 7.2).  
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There was no cross over between the proteins found in the arrays and proteins 
found via SILAC, potentially due to the arrays being focussed on low abundance proteins 
such as receptors which the mass spectrometer used in this study could not detect.  
Ideally, some proteins would have been detected by both methods, thus acting as internal 
standards and providing further confirmation of hits. As there was no cross-over, Western 
blots were used as further validation of the SILAC results (see section 5.2). The 5 
proteins that had a Western blot carried out on them for validation purposes are 
highlighted in red, Figure 5-8.  
The importance of performing validation of the SILAC results is paramount to 
confirm the data and is reported widely in the literature. The SILAC method provides an 
opportunity to identify novel changes that occur between two cell populations. There are 
limitations to the experiment in this study; it was only carried out on one occasion and 
only heavy lysine was used to label the peptides. More recent studies use dual labelling 
with arginine and lysine giving a better coverage of the proteins identified. However, 
arginine has been shown to convert to proline, potentially affecting the quantification if 
labelling with arginine only, as the basis of the heavy isotope incorporation relies upon 
cellular metabolism, there are methods available to decrease/prevent this conversion 
(Lossner et al., 2011). 
A selection of proteins that showed differential expression between the MCF7 and 
the TAMRBU cells were chosen for further investigation in the literature, all proteins 
were chosen as they exhibited clear MS spectra and had quantitation scores that were the 
result of multiple peptide pairs (increased confidence), the quantitation scores were either 
above or below 1.5 fold change difference MCF7 to TAMRBU. 
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5.3.1 Over expressed proteins 
BCL-2 athanogene-1:  Fold change = 7.14 
BCL-2 athanogene-1 (BAG1) is a pro-survival, multifunctional protein that can associate 
with steroid hormone receptors, such as ER , and BCL-2 protein (described above in 
section 4.4.2) (Townsend et al., 2005). To this end, BAG1 is able to regulate oestrogen 
dependent transcription and also exhibits an anti-apoptotic action. It has the ability to 
directly interact with the chaperone protein HSP70 (which expression was shown in 4.4.6 
to be increased in TAMRBU cells). HSP70 is rapidly induced by the cell during times of 
cellular stress which may support the many functions that BAG1 participates in (Linman 
et al., 2005). BAG1 has been shown to be frequently over-expressed in breast cancer 
(Anderson et al, 2010) in which it plays an important but contentious function. High 
expression of BAG1 has been implicated in poor outcome for patients in some studies 
(Tang, 2002) but others have failed to confirm this observation. The implication of a high 
level of BAG1 in acquired Tamoxifen resistance could be very important. However, 
some studies have contradicted our data; for example, Millar et al., 2009 showed that 
improved patient responsiveness to Tamoxifen and a better patient outcome was 
associated with a high expression of BAG-1, this seems counter-intuitive as the protein is 
a known pro-survival anti-apoptotic protein. Furthermore, Tang et al., 1999 showed that 
BAG-1 is over expressed in clinical samples of invasive breast carcinomas and the over-
expression was associated with a shorter disease-free and decreased overall survival 
outcome of patients. 
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Calpain-1: Fold change = 3.44 
Calpain-1 belongs to a conserved family of cysteine proteinases first described in 1964. 
The activity of this family has been implicated in several fundamental cellular processes 
such as signalling, migration, apoptosis and cell survival (Huang and Wang, 2001). The 
expression of calpain-1 is altered during tumourigenesis and proteolysis of substrates 
such as FAK and Talin (Talin was also found to be over expressed using SILAC), as well 
as proto-oncogenes such as Myc; showing that it may have a role in pathogenesis. It has 
also been suggested in the literature that Src and EGFR stimulated cell motility is 
dependent of the activation of the calpain family (Carrager and Frame, 2002). The calpain 
family have been implicated in the protein tyrosine phosphatase 1B and src mediated 
induction of invadapodia (Cortesio et al., 2008). It has also been revealed to be involved 
in cortactin (also over expressed in TAMRBU) mediated actin reorganisation and 
laemellipodia and pseudopodia formation at the leading edge of the cell (Perrin, 2006). 
There has been recent evidence that the increased expression of Calpain-1 may 
influence the response to some therapies used in the treatment of cancer (Storr et al, 
2011). For example, it has been associated with a poor patient response to Trastuzumab 
therapy in ErbB2 positive breast cancer patients. Moreover, it has been shown that the 
inhibition of calpain-1 modulates signalling in several tumour types in particular ErbB2 
positive breast cancer (Kulkarni et al., 2010) and also prostate cancer where it facilitates 
signalling independent of androgen stimulation (Pelley et al 2006). Tamoxifen resistant 
cells show aberrant cell signalling and over express ErbB2 and here we have shown that 
calpain-1is also over expressed in the Tamoxifen resistant cells. Calpain activity has been 
revealed to be both pro-survival and pro-apoptotic, it is known to cleave caspases 10 and 
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7, and also Bcl-2 family members such as BAX. Evidence in the literature suggests that 
its survival activity is mediated through the p53 tumour suppressor and NF B Calpain 
is able to cleave p53 subsequently preventing p53 mediated apoptosis (Pariat et al., 1997) 
and also promote survival through the activation of NF B Calpain mediates the 
cleavage of the NF B inhibitor, I B , in response to tumour necrosis factor (TNF) 
(Han et al., 1999) and also through the activation of ErbB2 signalling via PI3K and Akt 
in breast cancer cells (Pianetti et al., 2001).The proteolysis of the inhibitor I B  can be 
suppressed by the over expression of the endogenous, ubiquitously expressed inhibitor of 
calpain, calpastin (Chen et al., 2000). The roles that calpain-1 has in cancer can be 
conflicting, and its influence exerted may depend on its cellular location.   
 
CLIC1: Fold change = 3.85 
The chloride channel family are a varied group of proteins that are thought to be involved 
in many cellular processes such as maintenance of intracellular pH, the regulation of cell 
volume and the stabilisation of the cellular membrane potential (Averaimo et al., 2010). It 
is reported that the protein localises primarily to the cell nucleus and displays both 
nuclear and plasma membrane chloride ion channel activity. CLIC1 is a member of the 
p64 family (along with parchorin). They are widely expressed channels with a reported 
ability to auto insert and self assemble as intracellular anion channels with a potential 
function in apoptosis and secretion of signalling proteins (Ashley, 2003). This is a 
controversial report as the receptors exist as a soluble protein and a membranous form 
and the way in which they transform from one to the other is yet to be elucidated. A 
differential expression of CLIC1 has not previously been described in breast cancer or 
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Tamoxifen resistance. However, it has been shown to be up regulated in gastric 
carcinoma (Chen et al., 2007), colorectal cancer (Petrova et al., 2008), gall bladder cancer 
(Wang et al., 2009) and nasopharyngeal carcinoma (Chang et al., 2009). Interestingly, 
CLIC1 has been associated with increased expression of multidrug resistance protein 
(MDR) in gastric cancer patients being treated with chemotherapeutic agents (Chen et al., 
2007). In endothelial cells the decreased expression of CLIC1 inhibited directed 
migration in wound healing assays (Tung and Kitajewski, 2010). 
 
Cortactin: Fold change = 2.38 
Cortactin is a src kinase substrate that is frequently over expressed in many types of 
cancer including; laryngeal cancer (Gibcus et al., 2008), colorectal cancer (Cai et al., 
2010), head and neck cancer (Timpson et al., 2007) and breast cancer (Bowden et al., 
2006). There are many reports that this increase in cortactin expression consistently 
correlates with a poor patient outcome by increasing the aggressive nature of the tumour. 
The way in which it does this is potentially by promoting the invasive nature of the cells, 
most likely through the formation of invadapodia and remodelling of the actin 
cytoskeleton but also it has been suggested that the promotion of metastasis is driven 
through the degradation of the extra cellular matrix by the cortactin expressing cancer 
cells (Clark et al., 2007).  
Over expression of cortactin has also been implicated in sustaining EGFR 
signalling by preventing the ligand induced breakdown of the receptor in cancer (van 
Rossum et al., 2005) and an increase in cortactin expression is associated with resistance 
to gefitinib (EGFR antagonist) in head and neck carcinoma (Timpson et al., 2007). 
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Notably, the cortactin expression is up in the Tamoxifen resistant cells in this Thesis, as is 
the expression and activation of EGFR (Figure 3-5 and Figure 4-11). 
The gene that encodes cortactin (EMS1) is frequently seen over expressed in 
breast cancers (Hui et al., 1998) and in cell lines (Campbell, 1996). EMS1 is on 
Chromosome 11q and this amplification is also seen in many cancers, with the region 
known to code for many oncogenes (including Cyclin D1). The increased expression of 
Cyclin D1 and its role in resistance has been reported in the literature (Kilker and Planas-
Silva, 2006) and is often co-localised together with cortactin (Lundgren et al., 2008) and 
may even function synergistically. 
One of the main functions of cortactin within the cell is in actin organisation. 
Arp2/3 is a molecule that is able to nucleate branched actin filament networks providing 
the cell with structural support as well as enabling vesicle trafficking and the persistence 
of protrusions such as invadapodia (Goley et al., 2006). The localisation of cortactin to 
such cellular protrusions raises the prospect of cortactin expression playing a role in 
motility in cancer. This has been investigated in a number of ways including transwell 
migration and wound closure assays, in conjunction with siRNA knock down of cortactin 
showing that cortactin over expression is closely linking to an increase in cell motility in 
cancer (Bryce et al., 2005 and Rothschild et al., 2006). This may be relevant as 
Tamoxifen resistant cells have a more metastatic phenotype (Hiscox et al., 2004) and will 
be investigated further in the next chapter.  
Cortactin is also known to be post translationally modified by numerous protein 
kinases (src, ERK, met, syk and pak). When the N-terminal region of cortactin is 
phosphorylated by pak at position Ser113, it decreases its actin binding potential 
~ 170 ~ 
 
(Martinez-Quiles et al., 2004). This raises the issue that phosphorylation of cortactin may 
be important to the functional role of the protein as well as its degree of expression. 
Further investigation of this, either through Western blotting or phosphoproteomics may 
provide more clues as to its function in Tamoxifen resistance. 
 
Epithelial Cell Adhesion Molecule: Fold change 9.09 
Epithelial Cell Adhesion Molecule (EpCAM) is an epithelial cellular adhesion membrane 
glycoprotein and is highly expressed in numerous carcinomas (Van de Gun, 2010) and 
frequently over expressed in human invasive breast cancer (Gostner, 2011) in which it 
has been reported to be a marker of poor prognosis (Gastl et al., 2000). It has been 
explored as a marker of cancer initiating cells (cancer stem cells) (Lugli et al., 2010) and 
has a controversial biological role, having been associated with increasing and also 
preventing metastasis and also acting as a tumour suppressor (Shiah et al., 2009 and 
Spizzo et al., 2011). The role of EpCAM in cancer needs further investigation to fully 
elucidate its role in the process of carcinogenesis although it is likely that expression, 
signalling of the protein and impact are linked to the stage, type, and possibly even the 
microenvironment. The expression levels of the EpCAM antigen shown by 
immunohistochemistry by Spizzo et al., 2002 correlated with a lower patient survival and 
this was decreased further when the patients also over expressed ErbB2 (as our cells do). 
There have been a number of trials of a monoclonal antibody (mAb) that targets EpCAM, 
one of which has recently been approved by the European Commission for the treatment 
of EpCAM positive patients (Schmidt et al., 2010).  
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A decrease of EpCAM  has previously been associated with induction of 
epithelial mesenchymal transition (EMT) in non small cell lung and head and neck cancer 
cells (Frederick et al., 2007) however, this does not fit  with our results as EMT like 
phenotype is displayed in Tamoxifen resistance cells (TAMR) (Hiscox et al, 2006) and 
also exhibited in TAMRBU cells but EpCAM is up regulated. In renal and thyroid cancer 
show up regulation of EpCAM to be associated with a better patient survival however in 
many other cancers (bladder, gall bladder, pancreas, ovarian, breast) increased expression 
of EpCAM is associated with a decrease in patient survival and in breast cancer it was 
also associated with large, less differentiated tumours, the presence of nodal metastasis as 
well as overall worse survival (Spizzo et al., 2004). Cimino et al., 2010 reported that 
there also was an increase in EpCAM in the metastasis site when compared to the 
matched primary site.  
 
Hepatoma derived growth factor (HDGF): Fold change = 2.17 
HDGF is a nuclear protein that has been shown to be mitogenic in a wide variety of cells 
(Yu et al., 2011). Its increased expression has been associated with poor prognosis in 
Nasopharyngeal carcinoma (NPC) (Wang et al., 2011) and also correlating with tumour 
progression, and poor patient disease free and overall survival in oesophageal cancer in 
Japan (Yamamoto et al 2007). Lee et al., 2010 showed that HDGF regulates the BAD 
mediated apoptotic pathway and the induction of VEGF secretion in gastric cancer cells. 
When the HDGF was silenced using shRNA pro-apoptotic BAD was induced and there 
was an inactivation of ERK, this in turn de-phosphorylated BAD at Ser112 and Ser136 
and this induced apoptosis. Down regulation of HDGF led to a decrease in cell 
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proliferation and a less invasive phenotype in gastric cancer cells. These results would be 
in keeping of our observation of increased HDGF, increase in BAD (Figure 4-24) and 
increased ERK activity in TAMRBU cells (Figure 3-7). Recently, Guo et al, 2011 
investigated the role of HDGF in breast and prostate cancer. They showed siRNA knock 
down of HDGF expression in MCF7 cells significantly decreased cell proliferation. This 
leads to the prospect that HDGF has a role in cell growth, invasion and avoidance of 
apoptosis all of which are known to be characteristic of resistance.  
 
High mobility group box 1: Fold change = 3.57  
High mobility group box 1 (HMGB1) also known as amphoterin is an architectural 
transcription factor, as it has the ability to bend DNA to regulate gene activity 
(Boonyaratanakornkit et al., 1998). It was shown to have increased expression in 
Tamoxifen resistant TAMRBU cells via SILAC in this Thesis. HMGB1 may be involved 
in EMT (Lynch et al., 2010) as HMGB1 expression induces morphological changes 
consistent with the EMT phenotype (decreased E cadherin and increased cell migration). 
This was seen in renal proximal tubular epithelial cells and may be induced, at least 
partly, by receptor for advanced glycation end products (RAGE) through the induction of 
TGF  secretion. HMGB1 has also been implicated in the process of autophagy, a tightly 
controlled process that occurs ubiquitously and contributes to the routine turnover of 
proteins in the cytoplasm. It can be induced by changes in environmental conditions such 
as drug treatment and nutrient depletion. Paradoxically, the process has also been 
implicated in cancer serving to protect the cell and also contribute to cell damage 
(Dagenhardt, 2006 and Eisenberg-Lerner and Kimchi, 2009).  Damage associated 
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molecular pattern (DAMP) molecules can initiate immune responses to damage, and also 
mediate autophagy contributing to drug resistance in cancer (Lui et al., 2011). HMGB1 is 
released in tumour cells after a dose of treatment cytotoxicity is induced. The release of 
HMGB1 activates autophagy through the PI3K-MEK-ERK pathway, in leukaemia and 
siRNA’s directed at these signalling pathway reverses the drug resistance (Tang et al., 
2010 and Yang et al., 2011). HMGB1 is a prototypical DAMP and subsequently acts on 
the DAMP receptors (i.e. RAGE) the sustained release of HMGB1 indicates that 
autophagy will also be sustained. (Lui et al., 2011). Interestingly, HMGB1 expression is 
regulated by transcription factors such as p53 and c-myc. It has DNA chaperone 
functionality allowing it to participate in fundamental processes such as DNA replication, 
transcription and repair. This is of particular interest as it is thought that HMGB1 
enhances the transcription factors involved in the progression of cancer such as p53 and 
p73 and also modulates the nuclear hormone receptors such as ER  (Ohmori et al., 
2011). 
Increased expression of HMBG1 has previously been shown to have a role in 
which cells develop drug resistance/exhibit phenotype of drug resistance; increased 
invasion and metastasis (mediated through HMGB1, Matrix metallo proteinases (MMPs) 
and RAGE), sustained angiogenesis (activated through HMGB1 and VEGF secretion), 
insensitivity to antigrowth signals (increased HMGB1 increases expression of Cyclin 
D1), self sufficiency growth signalling (increased HMGB1 and Akt, MAPK and NF B) 
and evasion of apoptosis (increased HMGB1, working through BCL-2 and c-IAPs) (Tang 
et al, 2010). 
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IQ motif containing GTPase activating protein: Fold change = 2.66 
IQ motif containing GTPase activating protein (IQGAP1) is a ubiquitously expressed 
scaffold protein that contains multiple protein interaction domains enabling it to interact 
with many molecules and proteins – such as Rac1, cdc42 and ErbB2. Interestingly 
IQGAP1 has been reported to play a role in the progression of cancer, in particular cell 
motility and invasion (Mataraza et al., 2003 and Mataraza et al., 2007). 
IQGAP1 more recently has been implicated in Trastuzumab resistance (White et 
al., 2011) who report that IQGAP1 is able to bind directly to the ErbB2 protein and is 
involved in signalling pathways associated with resistance. When over expressed 
IQGAP1 is knocked down, ErbB2 expression and phosphorylation is also decreased, 
causing a decrease in the proliferation that is often associated with breast cancer with 
over expressed ErbB2 receptors. When IQGAP1 expression was knocked down, p27 (a 
protein which binds to and prevents the activation of cyclins and subsequently controls 
the cell cycle progression at G1) is up regulated. White et al., 2011 showed that blocking 
this up-regulation reduces the growth inhibition caused by the knock down of IQGAP1, 
implying that IQGAP1 has a role in cell cycle progression in cancer. They also report that 
IQGAP1 was over expressed in trastuzumab-resistant breast cells, and the inhibition of 
IQGAP1 function restores functionality of Trastuzumab in ErbB2 over expressing cells. 
In this project we have shown that IQGAP1 is over expressed in TAMRBU cells, as is 
ErbB2 activity (Figure 4-11). In the next chapter we will investigate the effects of 
knocking down IQGAP1 with siRNA. 
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Phosphatidylinositol-3, 4, 5-trisphosphate-dependent Rac exchange factor 1: Fold 
change = 3.57 
Phosphatidylinositol-3, 4, 5-trisphosphate-dependent Rac exchange factor 1 (P-Rex1) is 
an essential protein implicated to have a role in fundamental cellular functions such as 
growth and motility. It has also been revealed to play a role in tumourigenesis in breast 
cancer through ErbB receptors (Sosa et al., 2010). It is an essential mediator of the small 
GTPase Rac1 and its mediators and effector proteins are established as mediators of 
mitogenic and motile signalling by RTKs in breast cancer (Sosa et al., 2010). Moreover, 
the over expression of P-Rex1 seen in our TAMRBU cells is also mirrored in the majority 
of human breast cancers and breast cancer derived cell lines (Montero et al., 2011). Qin et 
al., 2009 identify an increased expression of P-Rex1 in prostate cancer which promotes 
metastasis. There has been development of therapeutic inhibitors (Sosa et al., 2010 and 
Vigil et al., 2010) which could work well for patients with acquired Tamoxifen 
resistance, as a pharmacological inhibitor of Rac1 has been shown to reverse Tamoxifen 
resistance in resistant cell lines (Felekkis et al., 2005). 
 
Protein phosphatase 1 gamma: Fold change = 1.63
Protein phosphatase 1 gamma (PP1  is a ubiquitous serine/threonine phosphatase that is 
involved in regulating many cellular processes including protein synthesis and glycogen 
metabolism; it also has an essential role in cell division. PP1 has been shown in the 
literature to be over expressed in invasive DCIS when compared to mammary dysplasia 
and fibroadenoma, the same research group also implicated PP1 in the increased 
proliferation in breast cancer cell lines (Sogawa et al., 1997). As we have shown 
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PP1 was increased in TAMRBU cells using SILAC this change could be associated with 
an increased metabolic activity required for increased proliferation. 
It has also been show to be responsible for the de-phosphorylation of Histone H3 
after DNA damage (Shimada et al., 2010) and it has been shown to play a protective role 
in vascular smooth muscle cells against oxidative stress induced apoptosis. This apoptotic 
process begins with an increase in ROS (mitochondrial), leads to caspase 3/7 activation 
and DNA fragmentation, this decreased mitochondrial membrane potential in the cells 
and PP1γ expression and activity is decreased. When the PP1γ expression was decreased 
using siRNA it led to an increase in apoptosis, conversely, the over expression of PP1γ 
protected against apoptosis by attenuating the caspase 3/7 activation (Tchivilev et al., 
2008).
Prohibitin: Fold change = 2.00 
Prohibitin is a multifunctional protein and is implicated to have roles in proliferation, 
transcription and apoptosis (Theiss and Sitaraman, 2011). Prohibitins are mainly located 
in the mitochondria but can also be found in the nucleus (McClung et al., 1995). 
Prohibitin has been shown to interact with PI3K/Akt and transforming growth factor-β 
(TGF-β) as well as Ras/MAPK/ERK (Rajalingham and Rudel, 2005 and Mishra et al., 
2010). The proteins that prohibitin interacts with have all been implicated to have a role 
in Tamoxifen resistance. He et al., 2011 showed that prohibitin is regulated by oestrogen 
in murine uterine cells. When prohibitin expression was down regulated using shRNA in 
HELA cells there was a significant decrease in the rate of cell division which led to the 
degradation of a fusion protein (OPA1) which is a Dynamin-related GTPase required for 
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mitochondrial fusion and regulation of apoptosis. The morphology of the mitochondria 
did not alter; however, degradation of OPA1 reduced the ability of some cells to adhere 
to ECM and showed a decreased capability of anchorage independent growth (Sievers et 
al., 2010). 
 
Proliferation associated protein 2G4: Fold change = 3.33 
Proliferation associated protein 2G4 also known as ErbB3 binding protein 1 (EBP1) was 
increased in TAMRBU cells. The gene PA2G4 encodes for the EBP1 protein which is 
often associated with growth regulation of cells but also may be involved in ribosomal 
assembly and RNA processing. The increased expression of this protein in Tamoxifen 
resistance is surprising as it has been previously shown to have decreased expression in 
Tamoxifen resistance (Lu et al, 2011) and in hormone therapy refractory prostate cancer 
(Zhang et al., 2008). In effect, the result seen in our SILAC experiment is opposite to that 
seen in the literature. 
The literature describes EBP1 as a tumour suppressor, and also suggests that there 
is an important interaction with EBP1 and ErbB2 and 3 which contributes to the 
signalling that regulates growth. As has been discussed in section 4.5.2, Erb signalling in 
breast cancer plays a critical role in its progression. It has been reported that EBP1 
inhibits EGF stimulated breast cancer growth, contributing to Tamoxifen sensitivity by 
decreasing the expression of ErbB2 (Lu et al, 2011). It was also shown that expression of 
EBP1 accelerated the rate of ErbB2 degradation and that this process could be reversed 
by inhibiting proteosome action (Lu et al, 2011) Furthermore, knock down of EBP1 led 
to Tamoxifen resistance which could be abrogated by inhibition of ErbB2 activity. 
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In TAMRBU, the SILAC experiment showed that EBP1 was over expressed but 
in TAMRBU ErbB2 signalling was also over expressed (Figure 4-11). EBP1s effect on 
Tamoxifen sensitivity is mediated by its ability to modulate ErbB2. Perhaps in TAMRBU 
cells this modulation is avoided/ altered. However, this was not one of the 5 proteins 
selected for validation by Western blotting and did not feature on the antibody arrays 
used in this Thesis. As illustrated by the results from Ribophorin 2 in this project (Figure 
5-12) it is possible to get peaks from peptides which do not agree with results from 
Western blotting. The variation may be due to the mass spectrometer detecting peptides 
in a different region of the protein to that that is targeted by the antibody. 
   
Ribophorin 2: Fold change = 4.35  
Ribophorin 2 is a member of a ribosome receptor family of proteins that are associated 
with binding of ribosomes to the rough endoplasmic reticulum and as such is directly 
linked to the translation of proteins. There is not a large amount of literature regarding 
Ribophorin 2 in cancer. However, one report implicates Ribophorin 2 in docetaxel 
resistant breast cancer. The siRNA treatment of Ribophorin 2 decreased protein levels 
and caused a decrease in glycosylation of P-glycoprotein, conferring sensitivity to the 
MCF7 –ADR (Docetaxel resistant cells) in the presence of the drug (Honma et al., 2008). 
Interestingly in our study Ribophorin 2 was found to be over expressed in the TAMRBU 
cells via SILAC but in Western blot validation it was down regulated. As the two 
techniques are identifying different regions of the protein this could be accounted for by 
detection of degradation products or simply illustrates the need for cross validation of the 
SILAC results. 
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Figure 5-14 Peptide sequence of Ribophorin 2. The region of the protein highlighted in 
red is targeted by the antibody. Peptides in blue were found via SILAC. 
 
Staphylococcal nuclease domain-containing protein 1: Fold change = 3.44 
Ho et al., 2009 investigated novel breast cancer metastasis associated proteins found 
through the use of an iTRAQ labelled ESI MS approach on a panel of cells which was 
then validated using tissue microarrays; SND1 protein was more highly expressed in 
metastatic breast cancers. Higher expression of SND1 mRNA has also been reported in 
colon cancer (Tsuchiya et al., 2007) correlating with increasing grade and aggressiveness 
of the cancer. Its higher expression in TAMRBU cells would therefore be in keeping with 
the literature and this more aggressive phenotype. 
 
Talin-1: Fold change = 3.22 
Talin-1 is a focal adhesion complex protein that regulates interactions between intergrins 
and the extracellular matrix (ECM). This interaction has been implicated in many 
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functions such as regulation of cell signalling and cell adhesion regulated by cytoskeleton 
dynamic organisation. Some intergrins have been implicated in tumour invasion and also 
in resistance to cisplatin therapy in oral carcinomas as were intergrin effectors proteins 
such as p130cas, src and talin (Sansing et al., 2011). Knock down of the effector proteins 
in this study showed that they were required for invasion through Matrigel. Furthermore, 
decreasing talin expression increased cisplatin resistance, inhibited spread on collagen 
and laminin, and reduced cell proliferation (Sansing et al., 2011). Talin-1 over expression 
has also been reported in prostate cancer where it enhanced migration and invasion, the 
ability to avoid anoikis (attachment mediated programmed cell death) and increased cell 
adhesion (Sakamoto et al., 2010). 
Talin-1 has also been reported to interact with Akt signalling through 
phosphorylation by focal adhesion complex proteins such as focal adhesion kinase (FAK) 
and src. FAK has been shown as over expressed and have increased activation in many 
cancers, correlating with invasion and metastasis (Gabarra-Niecko, 2003) and has been 
implicated in Tamoxifen resistance (Hiscox et al., 2011).  
5.3.2 Proteins down regulated in resistance 
Actinin 4: Fold change = - 1.6 
Actinin 4 is a protein that is ubiquitously expressed and maintains cellular morphology 
and structure by cross linking actin filaments. It is also able to interact with nuclear 
receptors which is mediated by the LXXLL (nuclear receptor binding motif) functional 
motif, which allows it to interact with ER and the over expression of Actinin 4 
potentiates ER mediated transcription thought to be in part through an association with 
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HDAC7 promoting the proliferation of MCF7 cells (Khurana et al., 2011). Knock down 
of Actinin 4 has been shown to down regulate ER target gene expression which may 
infer a role in Tamoxifen resistance, as in TAMRBU this protein was shown to be 
decreased (Khurana et al., 2011). This down regulation of ER target gene expression 
may have an effect on the cells ability to bypass the oestrogen proliferative stimulus by 
using alternative signalling pathways to increasingly proliferate and grow.  However, 
location could be a key factor in the regulation of this protein as Honda et al., 1998 
showed that Actinin 4 when localised in the cytoplasm is associated with an infiltrative 
histological phenotype correlating to significant poor prognosis of breast cancer patients 
(Honda et al., 1998). This paper suggests a role for cytoplasmic Actinin 4 in the 
regulation and organisation of the actin cytoskeleton and cell motility.  
 
ATPase family gene 3, yeast like protein 2: Fold change = - 4.16 
The gene encoding ATPase family gene 3, yeast like protein 2 (AFG3L2) was first 
identified by Banfi et al., 1999 and was thought to be a novel paraplegin-related gene and 
was reported to have a similar expression pattern to paraplegin. The protein is also known 
as paraplegin like protein. It is a multi-pass membrane metalloprotease and it contains 
one AAA (ATPase associated with diverse cellular activities) domain. There is minimal 
literature on this protein but it is thought to be involved in signal transduction and 
potentially chaperone like activities and has been shown to form a complex with 
paraplegin in the mitochondria, potentially regulating the quality of protein by degrading 
the misfolded proteins and regulating ribosome assembly. This appears to be the first 
report to associate AFG3L2 protein with cancer. However, it has been previously shown 
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to be involved in ataxia; a misssense mutation in the proteolytic domain accounts for 
approximately 1.5% of European ataxias (Cagnoli et al., 2010). 
 
ALG-2-interacting protein X: Fold change = - 1.5 
ALG-2-interacting protein X (ALIX) or Programmed Cell Death 6 Interacting Protein 
(PCD6IP) is a protein that has been implicated to have many roles in the cell. It has been 
shown to regulate intergrin mediated cell adhesions and extra cellular matrix assembly 
(Pan et al., 2008). In Hela cells increased expression of ALIX promoted flattening and 
alignment of cells, and a decrease in expression produced the opposite effect (Cabezas et 
al., 2005). A decrease in ALIX expression is seen in the TAMRBU cells and this may be 
related to the more disorganised growth patterns seen in the Tamoxifen resistant cells 
(Figure 3-2). This protein is hypothesised to act as a switch between cell death, and cell 
proliferation (Krebs and Klemenz, 2000) found that phosphorylation of ALIX allowed 
binding of ALG-2 (a calcium ion binding protein involved in apoptosis) and subsequent 
recruitment of SETA (SH3 domain-containing adapter molecule) formed a complex 
which promoted cell survival by avoiding the inhibition of PI3K and activating Akt. It 
has been inferred that ALIX cooperates with ALG-2 to promote apoptosis, and that an 
increase in ALIX expression increases cell death (Blum et al., 2004 and Hemming et al., 
2004) possibly by an ALIX regulated caspase activation and apoptosis (Mahul-Mellier et 
al., 2006). The decreased expression of ALIX seen in TAMRBU cells may be part of the 
process by which the resistant cells avoid apoptosis in resistance. As phosphorylation and 
binding of ALG-2 also stops an apoptotic signal providing a way of avoiding cell death 
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further investigation of the phosphorylation status of this protein could add extra 
functional information and would be interesting to investigate further in the future. 
 Another role for ALIX is in the negative regulation of growth factor receptor 
endocytosis. Endocytosis is the first step to long term down regulation of activated EGFR 
and precedes the delivery of the receptor to the lysosomes via the multi vesicular body 
(MVB). The C terminus of the receptor undergoes ubiquitination, which triggers the 
endocytic process. As EGFR expression and activation has a role in Tamoxifen resistance 
ALIXs involvement in the turnover of the EGFR could be very important. Schmitt et al., 
2004 showed that over expression of ALIX produced a drop in EGFR internalisation and 
siRNA transient knock down of ALIX enhanced the endocytosis of EGFR. This may 
seem counter intuitive as it implies that the decrease in ALIX seen in TAMRBU cells 
would increase of endocytosis of EGFR; however, this could infer that there is a greater 
turnover of the receptor.  
 
Calponin-2:  Fold change = -2.32 
Calponin -2 has been shown to have a role in the regulation of cell proliferation, 
migration, and vascular construction in cancer cells (Wu and Jin, 2008). Some studies 
have implicated this protein in the growth and prognosis of cancer for example Dang et 
al., 2006 showed that an increase in CNN2 (the gene encoding the calponin-2 protein) 
was associated with skin cancer. However, this is the opposite of what we saw in our 
SILAC experiment where there was a decrease in calponin-2 expression. 
 This protein is thought to play a role in cell adhesion and actin remodelling (it 
can bind actin, calmodulin, troponin and tropomysin). Calponin-2 shows a broader tissue 
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expression than that of calponin 1 and 3. This protein has been shown to bind ERK1 and 
2 through a calponin homology (CH) domain. ERK1 and 2 have increased expression and 
activation in Tamoxifen resistance (Figure 3-6) and the binding of calponin-2 to the 
MAPKs suggest that it may have a role in ERK signalling (Rozenblum et al., 2008).  
 
Cathepsin D: Fold change = -1.6 
Cathepsin D is a ubiquitously expressed lysosomal proteinase implicated in proteolytic 
degradation, cell invasion and apoptosis (Steinfeld et al., 2006). Evidence in the literature 
seems to be contradictory, predicting good clinical outcome or associated with poor 
prognosis. Increased expression of Cathepsin D has been associated with an increased 
invasive and metastatic phenotype in breast cancer (Ohri et al., 2007 and Berchem et al., 
2002). Its role in Tamoxifen resistance has also been investigated (Long and Van den 
Berg, 1996) showing a decrease in expression and secretion of cathepsin D was 
associated with acquisition of Tamoxifen resistance and/or oestrogen independent growth 
(in both the pro-cathepsin form and the mature form) This is in agreement with what is 
reported in this Thesis as the TAMRBU showed a decrease in expression of cathepsin D. 
An increase in expression has also been shown clinically in breast cancer to correlate 
with node negative, progesterone receptor positive tumours which show a favourable 
response to Tamoxifen (Ferno et al., 1994) which correlates with the decrease in 
cathepsin D in Tamoxifen resistant cells seen in the SILAC experiment although a 
causative role was not established for deregulated Cathepsin D in this Thesis.  
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Centaurin Fold change = -1.56 
This protein is also called ARAP3 and is a multi-modular signalling protein that is a 
substrate of src family kinases. It was recently shown (Gambardella et al., 2011) that with 
a transient but complete knockdown of ARAP3 in murine neutrophils the cells are 
activated and exhibit increased 2 Intergrin affinity and avidity, these cells also showed a 
hyper response to adhesion response stimulus which was also demonstrated under flow 
conditions. If the same was seen in epithelial Tamoxifen resistant cells, this could 
implicate the decrease in ARAP3 in the metastatic potential of the cells. A decreased 
expression of ARAP3 has also been recently reported in gastric carcinoma (Yagi et al., 
2011) which implicates its involvement in cancer. Many phospho-tyrosine activated 
proteins and receptors and src substrates (such as cortactin - see section 5.3.1) are up-
regulated in cancer often more so in later/more aggressive stages of the disease (Yeatman 
et al., 2004) the opposite is true for ARAP3 in gastric cancer, it shows medium/high 
expression in normal gastric mucosa and the expression is decreased in poorly 
differentiated carcinomas which is similar to the result seen in here in Tamoxifen 
resistance which has a more aggressive phenotype.  
Expression of ARAP3 inhibits cell-extracellular matrix attachment and invasion 
in vitro (Yagi et al., 2011). ARAP3 is also thought to suppress PI3K effector proteins 
(Figure 5-15) which link ARAP3s expression to the regulation of actin cytoskeleton, the 
formation of actin stress fibres, cell spreading and the formation of lamellapodia 
(Krugmann et al., 2001 and Krugmann et al., 2006). PI3K mediates a wide range of 
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activities in the cell including cell proliferation; motility and survival (see Figure 5-15) its 
expression has also been associated with angiogenesis (Raajimakers et al., 2007). 
ARAP3 also undergoes tyrosine phosphorylation in response to EGF and PDGF 
stimulus; this is most likely to involve src-kinases (Frame, 2002) and could have 
implications for Tamoxifen resistance however, the phosphorylation of ARAP3 was not 
investigated in this Thesis, though this may provide interesting information if looked at in 
the future.  
 
 
Figure 5-15 Shows a model of the phosphoinositide 3-kinase (PI3K) dependent 
signalling. The synthesis of PI(3,4,5)P3 from PI(4,5)P2 through the phosphorylation of 
the inositol ring at the 3
rd
 position by PI3K. PTEN catalyses the conversion of 
PI(3,4,5)P3 back to PI(4,5)P2. Other proteins such as SHIP (member of the 5-
phosphatases family) convert PI(3,4,5)P3 to PI(3,4)P2 which both share downstream 
ARAP3 
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signalling effects increasing growth, proliferation, survival and motility. ARAP3 is an 
effector molecule of PI(3,4,5)P3. Adapted from Leslie et al., (2008). 
 
 
Cytochrome c1: Fold change = - 1.5  
Cytochrome c1 is a molecule found in the mitochondrial respiratory chain (RC) (see 
Figure 5-16). The RC can be affected when cancer cells become hypoxic and switch from 
oxidative phosphorylation to glycolysis which is often seen in both early and later stages 
of tumour growth and is the result of the cancer needing to acquire more energy in order 
to grow (Gatenby and Gilles, 2004). 
 
Figure 5-16 Figure shows the mitochondrial respiratory chain (RC) and the complexes 
provide energy through ATP production. Cytochrome c1 is circled in red and is has a 
lower expression in TAMRBU cells. Adapted from Lamarie and Grimm (2011). 
RESPIRATORY CHAIN
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 This shift is mediated by an up regulation of hypoxia inducible factor 1  (HIF1 ) which 
the work presented in this Thesis has shown to be statistically increased in Tamoxifen 
resistant cells (see section 4.4.5). There may also be a role for cytochrome c1 in 
activating apoptosis as its downstream binding partner is apoptotic protease activating 
factor (APAF-1). APAF-1 is known to interact with caspases and Bcl like 1 protein (see 
Figure 1-13). When cytochrome c1 is bound to APAF-1 it forms an apotosome which is a 
catalytic multi-protein platform that activates caspase-9 most likely through autocatalysis 
(Martin et al, 2005). There is less cytochrome c1 seen in the Tamoxifen resistant cells this 
may be related to the way in which the cells avoid apoptosis. 
 
Ezrin-radixin-moesin binding phosphoprotein: Fold change = 5.55 
 Ezrin-radixin-moesin binding phosphoprotein (EBP-50) showed one of the largest 
decreases in expression seen in the Tamoxifen resistant cells. It is also known as Na2/H2 
exchanger regulatory factor 1 (NHERF1). It is a scaffold protein that recruits membrane 
receptors and transporters and cytoplasmic signalling proteins forming functional 
complexes and interestingly has been shown to interact with many proteins involved in 
cancer progression including phosphatase and tensin homolog deleted on chromosome 10 
(PTEN) (Takahashi et al., 2006), EGFR (Lazar et al., 2004) and  – catenin (Kreimann et 
al., 2007).  Research suggests that EBP50 may have a tumour suppression role in breast 
cancer (Song et al., 2007), and in cell lines its up regulation correlated with a lower, less 
invasive tumour grade (Schindelmann et al., 2002). Over expression of EBP50 has been 
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shown to increase apoptosis, inhibit cellular growth and reduce the level of ERK1 and 2 
activation in MDA—MB- 231cells (an aggressive ER negative cell line) (Belizzi et al., 
2010). The role of EBP50 as a regulator of cell growth is however controversial as it has 
also been shown that an increase in EBP50 expression correlated with poor patient 
prognosis and high tumour staging (Belizzi et al., 2010) yet Pan et al., 2006, transiently 
knocked down the expression of EBP50 in MCF7 cells and found that it enhanced cell 
growth. A large decrease in EBP50 has been shown here in TAMRBU compared with the 
parental MCF7, for the first time. It could be postulated that there is a role for EBP50 in 
Tamoxifen resistance potentially acting through the ERK/ MAPK pathway and the 
avoidance of apoptosis, further investigation would have to be done to corroborate this.  
 
FAM49B: Fold change = - 6.66 
There is little information available on this protein and its role in cancer. The human 
protein atlas (Colwill et al., 2011 through Sigma-Aldrich UK website) shows weak 
immunohistochemistry (IHC) staining in normal glandular breast tissue whilst there was 
moderate staining in breast cancer tissue. Its expression was also looked at in MCF7 
cells, where weak staining was established. There is no literature suggesting any role for 
this protein in breast cancer or Tamoxifen resistance which makes this an interesting 
protein to have identified, especially since it was one of the more decreased expressions 
seen in the TAMRBU cells. FAM49B  is known to be able to interact with inhibitor of 
Kappa light polypeptide gene enhancer in B cells kinase epsilon (IKBKE) which is an 
oncogene amplified in 30% of breast cancers (Hutti et al., 2009). 
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Lamin B1: Fold change = - 2.32 
The lamin family of proteins are thought to provide a platform for the binding of proteins 
and chromatin (Dechat et al., 2009). They have been implicated in various roles within 
the cell in particular roles such as DNA repair and genome organisation and stabilisation. 
Lamin B1 specifically is a protein kinase C (PKC) binding protein (Tabellini et al., 2002) 
which makes this an interesting finding as if it could be involved in PKC signalling 
(increased activation of which is seen in Tamoxifen resistance, see Figure 3-9). Lamin B1 
is essential for cell survival and is expressed in most cells and expression of lamins is 
usually found to be decreased in carcinomas for example Moss et al., 1999 showed that 
there was a decrease in nuclear lamin in neoplasm’s of the gastro-intestinal tract, but has 
been shown to be increased in some such as prostate cancer (Coradeghini et al., 2006).  
 Lamin B1 has been implicated in numerous cellular processes including 
apoptosis, most likely mediated through the Bcl-2 pathway as Bcl-2 prevents apoptosis in 
part by stopping lamin B1 degradation (Mandal et al., 1996). An avoidance of apoptosis 
seems to have a role to play in Tamoxifen resistance (see section 4.4) and this protein 
found in SILAC, is an interesting finding and would require further investigation. 
 
Nuclear migration protein nudC: Fold change = - 4.3 
Nuclear migration protein nudC (NudC) has chaperone activity with no catalytic activity; 
there is some evidence in the literature that it may have a poorly defined role to play in 
cellular division and proliferation. Zhou et al., 2003 showed that NudC was essential for 
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cytokinesis, which is the last stage of mitosis where cells pull apart. The Human Protein 
Reference Database (HPRD--http://www.hprd.org Kesheva Prashad et al., 2009) has 
established that NudC is a cell cycle control protein, which is involved in communication 
and signalling within the cell. It has also been suggested that NudC has a role in the 
microtubule movement of the nucleus by association with dynein (a microtubule motor 
protein) potentially interacting with components of the dynein/dynactin complex. 
Microtubules play a central role in the coordination of a multitude of cell functions and 
can be targeted for therapy. NudC is seen in prostate cancer cells and it’s over expression 
led to a block on cell division (Lin et al., 2004). A decrease of NudC expression is 
observed in the TAMRBU cells and this could potentially correlate to this finding as the 
population of resistant cells have increased cell proliferation (see section 3.2.4). 
 
SET: Fold change = - 2.08 
SET is an onco-protein, also known as PHAPII, which has a role in multiple cellular 
functions including metastasis, migration, apoptosis, and nucleosome formation. The 
majority of the literature available indicates that increased expression of SET protein is 
associated with cancer progression and more proliferative cells, for instance in ovarian 
cancer (Ouellet et al., 2006). The SET protein affects multiple cellular processes, in 
particular inhibiting the tumour suppressor protein phosphatase 2A (PP2A) (Switzer et 
al., 2011). However, the protein is decreased in the TAMRBU cells. This result would 
correlate with the observation by Fukukwa et al., 2005 that SET negatively regulates the 
MEK/ERK pathway. They showed that siRNA depletion of SET resulted in enhanced 
cellular proliferation via the enhanced activation of ERK. When SET expression was 
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decreased using siRNA the cell cycle was altered. The cells in G1 phase of the cell cycle 
(where the cells increase in size) was decreased but there was an increase in S phase 
(where DNA replication takes place) indicating that SET also negatively regulates G1/S 
transition (see Figure 1-12 for basic cell cycle). 
 
Vigilin: Fold change = - 2.27 
In human cells vigilin functions as part of a complex of proteins involved in RNA 
binding and translation factors and has been implicated in translocation of the complex to 
the cytosol from the nucleus (Kruse et al., 2003). It has also been suggested that vigilin is 
induced by oestrogen (Dodson and Shapiro, 1997) where it binds to the 3’ untranslated 
region (3’UTR) of oestrogen stabilised vitellogenin mRNA, where vigilin may have a 
role in the hormonal control of mRNA metabolism. It was recently found that a decreased 
expression of vigilin conferred an increase in the expression of c-fms (macrophage 
colony-stimulating factor receptor) at the protein and mRNA level (Woo et al., 2011). 
This is relevant as the Tamoxifen resistant cells have a decreased expression of vigilin 
observed here and the increased phosphorylation of macrophage colony-stimulating 
factor receptor (see section 4.3.10).  
Woo et al., 2011 also propose that vigilin and ELAV-like protein 1 (HuR) 
compete to bind to the same 69 nucleotide sequence in the 3’UTR of the c-fms mRNA. 
This dynamic relationship between the ratio of vigilin and HuR affects the ability of these 
proteins to effectively associate with the mRNA, which in turn regulates the expression 
of c-fms which is then phosphorylated. The study also showed a correlation between HuR 
and vigilin expression when motility and invasion in breast cancer cell lines were 
~ 193 ~ 
 
investigated; the protein vigilin is shown to suppress cell motility and invasion this may 
link to a tumour suppressive role of vigilin and one could hypothesise that the decreased 
level of vigilin seen in the TAMRBU cells be linked concurrently to the increased 
activity seen in the M-CSF receptor (Figure 4-20).  
The importance of validating results from SILAC is widely reported in the 
literature, our validation blots are shown in Figure 5-9, Figure 5-10, Figure 5-11, Figure 
5-12and Figure 5-13. The need to validate can be seen in this thesis as the SILAC data 
shows that the expression of ribophorin 2 is increased, when this was validated used 
Western blots to be decreased (Figure 5-12). This could be due to the antibody 
corresponding to another epitope of the peptide to what was found in the SILAC sample 
as shown in Figure 5-14. 
SILAC provides a straight forward method, depending on cellular metabolism to 
incorporate the isotopes into the proteins. It can be used to generate large amounts of data 
which can subsequently lead to a more hypothesis driven investigation. 
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6 Functional assessment of IQGAP1 and Cortactin 
Functional assays are very useful, in combination with siRNA knockdowns, to analyse 
the role of proteins found to be differentially expressed by proteomic methods. The 
siRNA used in this study were silencer select validated siRNA from Ambion. They have 
been verified by Ambion experimentally to reduce the target gene expression by at least 
80% 48hours after transfection. Where negative control siRNA was used it was silencer 
select negative control #1 siRNA from Ambion or where this was not available the 
NeoFX transfection agent was used as a control. In this study they have been used to 
determine the functionality of IQGAP1 and Cortactin, two proteins identified by SILAC 
in the mechanisms of Tamoxifen resistance. These proteins were chosen for further 
investigation as they both have potentially interesting roles in progression of cancer but 
neither has previously been reported in the literature as having a role in Tamoxifen 
resistance. The proteins had been successfully validated by Western blot in section 5.2. 
Therefore assays to investigate their role in adhesion, proliferation, and invasion were 
utilised in this chapter to assess if a role in resistance to Tamoxifen is apparent.  
The role of adhesion in cancer is a contentious one; up regulation and down 
regulation both being associated with an increase in cancer progression. In order to 
progress there must be changes in the adhesive properties, as the cells must have the 
ability to detach from the primary tumour site in order to metastasise to a secondary site. 
However, the cell must then be able to attach to the site of the secondary cancer. A 
change in the adhesive properties has been established in Tamoxifen resistance (Hiscox et 
al., 2007). Increased invasion is generally accepted as a mark of more aggressive/ 
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metastatic phenotypes as cells have to be able to invade through the basement membrane 
in order to metastasise. Increases in proliferation are seen in more aggressive cancers. 
These phenotypic behaviours are all described as “hallmarks of cancer” (Hanahan and 
Weinberg, 2000). 
6.1 Functionality of IQGAP1 in Tamoxifen resistance 
6.1.1 siRNA & Western blot 
siRNA was used to transiently knock down the expression of IQGAP1 using the method 
described in section 2.5.4. Figure 6-1 shows the knock down of IQGAP1 in both MCF7 
and TAMRBU cells. The effect of Tamoxifen presence was also shown as it further 
decreases the expression of IQGAP1.  Beta actin was used as a loading control.  
 
 
Figure 6-1 Composite of the Western blot performed to determine extent of decreased 
expression when the siRNA IQGAP1 had been used (48 hours).  
Western blot analysis was carried out on whole cell extracts taken from siRNA treated 
MCF7 and TAMRBU breast cancer cells. The cells were grown to 80% confluence in 
media with Tamoxifen present or Tamoxifen absent. The 1D SDS PAGE gels were 4-
12% Bis-Tris gradient gels, and the blotted membranes were probed with primary 
antibodies for IQGAP1 and  Actin.  
 
MCF7 BU
siRNA IQGAP1                               +                                    +               +
TAM                                                                                       + 
Actin
IQGAP1
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6.1.2  AlamarBlue proliferation assay 
The AlamarBlue proliferation assay was performed in conjunction with siRNA to assess 
the functionality of IQGAP1 in acquired Tamoxifen resistance. The siRNA protocol was 
carried out as shown in section 2.5.4 and used with the AlamarBlue assay that was used 
to assess the cells in section 3.2.4. In Figure 6-2 we show that the vehicle had no effect on 
the cell growth. However, when the Tamoxifen treatment was applied to the MCF7 
siRNA negative and siRNA IQGAP1 treated cells, both showed a decrease in cell growth 
when compared to cells receiving no treatment.  
When the TAMRBU siRNA negative cells were treated with Tamoxifen there 
continued to be a significant increase in cell growth (as shown in and not statistically 
significantly different from the observations in section 3.2.4). However, in the presence 
of siRNA IQGAP, Tamoxifen caused the cells growth to be significantly decreased (-
38% compared to siRNA negative) p=0.002. Treatment with siRNA to IQGAP1 also 
significantly decreased (-18%, p=0.008) oestrodiol stimulated TAMRBU cell 
proliferation. When Tamoxifen and oestrogen treatments were added simultaneously to 
the MCF7 cells treated either with negative control siRNA or IQGAP1 siRNA there was 
no difference in cell proliferation. However, a statistically significant difference (-24%, 
p=0.012) was seen when TAMRBU cells grown in the presence of siRNA negative 
control or siRNA to IQGAP1, were treated with oestrodiol plus Tamoxifen. Again the 
siRNA to IQGAP1shows a significant decrease in the oestrodiol plus Tamoxifen 
stimulated growth.  
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Figure 6-2   Alamar blue proliferation assay showing the response of the cells to different 
treatments in the presence or absence of siRNA IQGAP1. 
The * denotes statistical significance (p≤0.05). 
Treatments: ETOH vehicle, TAM= Tamoxifen 10
-7
M, E2= Oestrodiol 10
-9
M, and 
TAM&E2= Both Tamoxifen 10
-7
 M and Oestrodiol 10
-9
 M. 
Results derived from 5 independent experiments normalised to cells with no treatment ± 
SEM. 
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In summary, there was no significant difference seen between the siRNA negative and 
the siRNA to IQGAP1 in MCF7 treated cells when treated with vehicle, Tamoxifen, 
oestrogen, or a combination of Tamoxifen and oestrogen. However, statistically 
significant differences were seen between TAMRBU cells treated with siRNA negative 
control or to siRNA IQGAP1, when the cells were subsequently treated with Tamoxifen, 
oestrogen or the combination of Tamoxifen and oestrogen treatments. 
6.1.3 Adherence assay 
An adherence assay was used to determine the effect of a siRNA to IQGAP1 on the cells’ 
ability to attach to a surface coated with attachment factor (0.1% Gelatin) after 45mins 
(see section 2.5.1 for methodology). Figure 6-3 shows that there was no significant 
difference between the adherences in TAMRBU and MCF7 cells treated with vehicle. 
Interestingly , siRNA knockdown of IQGAP1 in MCF7 cells reduced their ability to 
adhere to the surface. However, TAMRBU cells were still able to adhere to the surface to 
the same extent as in control cells, despite treatment with siRNA to IQGAP1, perhaps 
due to increases in other adherence mechanisms or as a result of the higher “normal” 
expression of IQGAP1 in TAMRBU. 
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Figure 6-3 Adherence assay results showing no difference in adhesion when IQGAP1 is 
knocked down in TAMRBU but a small (not statistically significant difference) in 
MCF7cells. Experiment carried out on 4 independent occasions. 
 
6.1.4 Invasion assay 
A Matrigel invasion assay was used to determine the effect of siRNA to IQGAP1 on the 
cells ability to invade an extracellular matrix (see section 2.5.3) the method is adapted 
from Al-Nasiry et al, 2007. The assay indicated that the TAMRBU cells showed a more 
invasive phenotype (p=0.017) (Figure 6-4) which is an observation that has previously 
been reported in the literature (Hutcheson et al, 2007). Here, we have shown that 
knocking down IQGAP1 using siRNA lessened the invasive potential of the TAMRBU 
cells. The TAMRBU cells ability to invade the Matrigel was significantly decreased by 
52.1% when compared to the negative control (p=0.004). The % invasion was worked out 
using % AlamarBlue reduction of invaded cells ÷ % AlamarBlue reduction of cells 
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without filters x 100. 100% would be the equivalent of all the cells within the inserts 
migrating through into the feeder wells. This allows for any differences between in 
proliferation seen between the cell lines. 
 
Figure 6-4    Alamar blue Invasion assay showing the ability of the cells to invade when 
treated with siRNA to IQGAP1. Results above are derived from 3 independent 
experiments normalised to cells with no treatment ± SEM. The * denotes statistical 
significance p≤0.05.  
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6.2 Functionality of Cortactin in Tamoxifen resistance 
6.2.1 siRNA & Western blot 
siRNA was used to transiently knock down the expression of cortactin using the method 
described in section 2.5.4. The figure below (Figure 6-5) shows the knock down of 
cortactin in both MCF7 and TAMRBU cells.  Beta actin was used as a loading control. 
The siRNA to cortactin decreased its expression in both MCF7 and TAMRBU cells, 
although to a lesser extent if Tamoxifen was present in the media. 
 
 
 
 
Figure 6-5 Western blot showing the decreased cortactin (CTTN) expression when the 
siRNA to CTTN had been used (48 hours). 
Western blot analysis was carried out on whole cell extracts taken from siRNA treated 
MCF7 and TAMRBU breast cancer cells. The cells were grown to 80% confluence in 
media with Tamoxifen present and Tamoxifen absent. The 1D SDS PAGE gels were 4-
12% Bis-Tris gradient gels, and the blotted membranes were probed with primary 
antibodies for CTTN and  Actin.  
 
 
MCF7 BU
siRNA CTTN                                              +                               +      +
TAM + 
CTTN
Actin
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6.2.2 AlamarBlue proliferation assay. 
The proliferation assay was the same as the one performed to examine the cells after they 
had been developed in Chapter 3 (Section 3.2.4). The results of this assay, when used in 
conjunction with the siRNA knockdown of cortactin, did not show any distinct 
differences in response to treatments between the siRNA negative treated cells (Figure 
6-6) and the non-siRNA treated cells shown in Figure 3-13. 
 
Figure 6-6 Alamar blue proliferation assay showing the response of the cells to different 
treatments when siRNA cortactin was used.  Alamar Blue proliferation assay was carried 
out on MCF7 and TAMRBU cells treated with siRNA (negative control and CTTN). 
Treatments: ETOH vehicle, TAM= Tamoxifen 10
-7
M, E2= Oestrodiol 10
-9
M, and 
TAM&E2= Both Tamoxifen 10
-7
 M and Oestrodiol 10
-9
 M. 
Results above are derived from 5 independent experiments normalised to cells with no 
treatment ± SEM. The * denotes statistical significance p≤0.05. 
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Interestingly, and in marked contrast to our results with siRNA IQGAP1 knockdown 
(Figure 6-2) the only statistically significant difference seen between a negative control 
and a cortactin knockdown siRNA was seen in MCF7 cells treated with Tamoxifen. Here 
we show a small (7.9%) statistically significant (p=0.03) increase in growth where the 
cortactin has been knocked down 
6.2.3 Adherence assay 
The adherence assay was used to determine the effect of siRNA knockdown of cortactin 
on the cells ability to attach to a surface coated with attachment factor (0.1% Gelatin) 
after 45mins (see section 2.5.1 for methodology). There was no significant difference 
seen between the MCF7 cells treated with vehicle and MCF7 with siRNA to cortactin 
(Figure 6-8). There were also no significant differences seen between TAMRBU cells in 
vehicle those treated with siRNA to cortactin. 
Interestingly, when the siRNA to CTTN and IQGAP1were used simultaneously a 
much more marked decrease in adherence was observed in the TAMRBU cells than was 
seen when either cortactin or IQGAP1 were knocked down alone (Figure 6-8), perhaps 
suggesting that these molecules can compensate for the loss of the other one, but the cells 
cannot adapt to this if both are lost. 
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Figure 6-7 Adherence assay results showing no statistical significant difference in 
adhesion when cortactin is knocked down in TAMRBU or MCF7 cells. Experiment 
carried out on 4 independent occasions.  
  
Figure 6-8 Adherence assay normalised to cells treated with neoFX transfection 
agent. The independent action of siRNA to cortactin or IQGAP1 appears to have no 
statistical affect upon the adherence of MCF7 or TAMRBU to 0.1% gelatin. However, a 
statistically significant (* p≤0.05) reduction in adherence is seen with a combination of 
siRNA IQGAP1 and cortactin (p=0.012). Experiment N=4. 
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6.3 Discussion 
IQGAP1 and cortactin were investigated further in this section after being 
successfully validated by Western blot analysis (Figure 5-9) and (Figure 5-10).  
These proteins were specifically chosen as they have been associated with breast cancer 
progression; increases in motility, proliferation and invasion. These cancer characteristics 
are well known in the acquisition and progression of cancer to a more aggressive 
phenotype and drug resistance (Hanahan and Weinberg, 2000). In this study proliferation, 
invasion and crude adherence, in combination with siRNA knockdowns were investigated 
to further assess the functionality of IQGAP1 and cortactin.  
Figure 6-2 shows that the transient knock down of IQGAP1 by siRNA treatment 
attenuated the increased cell proliferation seen in cells when treated with Tamoxifen, 
oestrogen or a combination of Tamoxifen and oestrogen suggesting a role of IQGAP1 in 
increased growth of these cells. Increased expression of IQGAP1 has been associated 
with breast cancer progression (Jadeski et al., 2008) and Trasuzumab resistance (White et 
al., 2011) but this is the first time it has been reported for Tamoxifen resistance. IQGAP1 
is a protein that has many roles in the normal function of a cell, including acting as a 
scaffold protein (Sacks, 2006). Its role is executed through interactions with a range of 
specific target proteins through conserved domains (White et al., 2009) as discussed in 
section 5.3.1. The IQGAP1 protein has been shown to bind proteins such as calmodulin, 
cadherin, actin and  cateninin and also has been shown to regulate the function of many 
of the proteins that it binds to (Kuroda et al., 1998). The diversity of the functions 
IQGAP1 is associated with is revealed by the large number of proteins that it binds to. 
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IQGAP1 has been documented to be a scaffold protein for proteins in the MAPK 
pathway; members of which are known to be involved in acquired Tamoxifen resistance 
(see section 4.5.1). IQGAP1 can bind directly to B-Raf, MEK1/2, ERK1/2 (Ren et al., 
2007, Roy et al., 2004 and Roy et al., 2005) and has also been shown to modulate MAPK 
activity when activated with EGF, CD44 and also N-cadherin (Roy et al., 2004, 
Bourguignon et al., 2005, and Schrick et al., 2007). Ren et al., 2007 showed that 
decreasing IQGAP1 expression attenuated the ability of the cells to activate MAPK 
following stimulation with VEGF, EGF, or PDGF. The mechanism by which IQGAP1 
connects MAPK and these growth factors has not been fully elucidated. Recently, 
McNulty et al., 2011 have demonstrated that EGF activation of EGFR catalyses the 
phosphorylation IQGAP1 on Ser
1443
, this phosphorylation enhances the EGF stimulated 
EGFR tyrosine phosphorylation potentially through a positive feedback mechanism able 
to modulate EGFR activation. This could have implications on the increased expression 
of IQGAP1 and its subsequent knock down having a role in cell growth, as activated 
EGFR triggers downstream signalling induction of the MAPK cascade. EGFR signalling 
is known to be involved in Tamoxifen resistance (Knowlden et al., 2003), the signal 
cascade is multifaceted and perhaps relies upon proteins such as IQGAP1, a scaffold 
protein, to form protein signalling complexes. The TAMRBU cells are known to express 
more EGFR (Figure 3-5), have increased activation of the MAPK pathway (section 4.5.1) 
which would fit with the increased IQGAP1 expression (Figure 5-9). This indicates that 
IQGAP1 may have a role in Tamoxifen resistance through modulation of 
EGFR/oestrogen signalling cross talk. The increase in EGFR expression, activation and 
downstream functions have long been associated with increased in proliferation in cancer 
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and Tamoxifen resistance, however, a direct involvement of IQGAP1 would have to be 
further investigated, perhaps by using the MAPK and RTK profilers used in section 4 
following siRNA knockdown of IQGAP1. Also, Wang et al., 2008 reported that 
phosphorylation of IQGAP1 appears to have an important role in its function; further 
proteomic investigation using instrumentation capable of phosphoproteomics to help 
elucidate its function in EGFR signalling/proliferation within Tamoxifen resistance. 
IQGAP1 may have a role in oestrogen signalling crosstalk between ER and EGFR as in 
Figure 6-2 there was a decrease in cell growth when siRNA IQGAP1 treated TAMRBU 
cells were stimulated with oestrogen, compared to siRNA negative cells (Figure 6-2). 
Cross talk has already been reported in Tamoxifen resistance (Britton et al., 2006) 
however, IQGAP1s involvement in this has not been previously described. 
The adherence assay investigated the ability of the cells to adhere to their 
surroundings. It showed that there was very little difference seen in the cells attachment 
to the 0.1% gelatin coated wells, with cells treated with neoFX transfection agent as the 
negative control in this experiment. There was no statistical difference in adhesion seen 
between the MCF7 and TAMRBU cells in the negative control. It has been previously 
demonstrated that proteins such as Src, known modulators of cell-matrix adhesion, are 
elevated in Tamoxifen resistance (Hiscox et al., 2007) who showed that the Tamoxifen 
resistant cells had the ability to adhere more rapidly, and showed a higher affinity to bind 
to matrix which was decreased with inhibitors of Src. In that report, a range of matrix 
substrates were used which may explain the differences seen here, as 0.1% gelatin 
provides a non specific binding platform.  There was also no significant difference in 
adherence seen between the MCF7 and the TAMRBU when the expression of IQGAP1 
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was decreased with siRNA (Figure 6-3) inferring that there is no role for IQGAP1 in the 
attachment of the cells to the 0.1% gelatin.  
Our results (Figure 6-4), clearly show that the ability of TAMRBU cells to invade 
Matrigel (mimicking the cells’ ability to invade the basement membrane) is severely 
diminished (p=0.004) when IQGAP1 expression is decreased to a level which is 
comparable to the capability of the MCF7 cell line. Over expression of IQGAP1 has been 
associated with invasive potential in many cancers including ovarian (Dong et al., 2008), 
colorectal (Hayashi et al., 2010), gliomas (Hu et al., 2009), thyroid (Lui et al., 2009) and 
breast (Jadeski et al., 2008). Jadeski et al., 2008 reported that when MCF7 cells that over 
expressed IQGAP1 formed invasive tumours when injected in to immune compromised 
mice, whereas, when IQGAP1 was stably knocked down there was still tumour formation 
yet the tumours were smaller and less invasive. This indicates that IQGAP1 has a role in 
the proliferation and the invasive potential of breast cancer in line with the results 
reported in this thesis. IQGAP1’s role in invasion has been linked with HGF stimulation 
(Hu et al., 2008) in glioma cells. They also reported that siRNA knockdown of IQGAP1 
significantly inhibits the ADP-ribosylation factor 6 (ARF6) (a member of the Ras super 
family of small GTPases), induced Rac1 activation and cell migration. Decreasing ARF6 
protein expression through siRNA led to decreased recruitment of IQGAP1 and 
attenuated protrusion and production of invasive structures.  
The implication that IQGAP1 having a role in Tamoxifen resistance is interesting 
as it has been implicated in the progression of a number of cancers and in epithelial 
mesenchymal transition in NPC (Lui et al., 2009); Tamoxifen resistant cells appear to 
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have acquired a phenotype that show increased progression and an EMT like phenotype 
(Hiscox et al., 2006). 
Increased expression and altered phosphorylation of cortactin has been associated 
with cancer progression and modulation of cell invasion (Cai et al., 2010). Cortactin is a 
protein known to bind to F-actin, complexing with cortical actin involved in lamelopodia 
formation and membrane ruffling (Kelley et al., 2010). It is also known to be a substrate 
of src suggesting a role in cell motility (Wu and Parsons, 1993) and is also discussed in 
section 5.3.1. Proliferation of MCF7 or TAMRBU cells was not statistically altered in 
cells that had cortactin transiently knocked down with siRNA (Figure 6-6), however, 
when the cells were treated with Tamoxifen the MCF7 cells with decreased expression of 
cortactin showed a slight (7.9%) statistically significant increase in cell growth. No 
previous reports in the literature have shown this induction of proliferation; in fact, there 
have been no reports that cortactin has been associated with breast cancer proliferation. 
Van Rossum et al., 2005 showed that in HBL-100 breast cancer cell lines there was a 
decrease in invasion and migration with siRNA cortactin treated cells. They also reported 
that the decreased expression had no role in proliferation which would fit with the 
findings in this Thesis. In head and neck cancer it has been reported that over expression 
has an oncogenic role attenuating the ligand induced down regulation of EGFR in turn 
leading to sustained EGFR signalling through the MAPK family specifically ERK 
(Timpson et al., 2007). This finding indicates that there may be an oncogenic 
proliferative role for cortactin in breast cancer, as increased EGFR and ERK signalling 
seen in Tamoxifen resistance (section 4.2.2 and 4.3.2) however, decreasing the protein 
expression of cortactin using siRNA did not alter the proliferation of the TAMRBU cells 
~ 210 ~ 
 
in this study. This may imply cortactin’s role is not significant or more likely, the 
decrease in cortactin expression achieved in the experiments was insufficient to produce a 
significant decrease in proliferation. This opens up the whole debate about how much 
expression is required to have an effect in the cell. 
The adherence assay showed that there was very little difference in the cells 
attachment to the 0.1% gelatin coated wells. NeoFX transfection agent was used as the 
negative control in this experiment. There were no differences seen between MCF7 cells 
and TAMRBU negative control treated cells. There was also no difference observed 
when expression of cortactin was decreased with siRNA.  As discussed above, it has been 
previously demonstrated that Tamoxifen resistant cells show altered adherence properties 
(Hiscox et al., 2007). The lack of change shown in our experiments may be due to the 
0.1% gelatin providing non specific binding platforms for the cells. Interestingly 
however, there was a small but significant loss in adhesion when IQGAP1 and cortactin 
were knocked down simultaneously (p=0.012). This reduced adhesion was only seen in 
the TAMRBU cells, this could be as a result of the TAMRBU cells over expressing both 
of these proteins. Knocking the proteins down may have additional effects on the 
resistant phenotype as it is possible that the cells have become more reliant on the 
proteins (or the pathways that the proteins are implicated in). It would be interesting to 
repeat these knock downs and perform more specific adhesion assay methods for some of 
the interesting proteins found to be differentially expressed in section 5.1, such as Talin-
1, cortactin and IQGAP1which have been shown in the literature to have roles in cell 
adhesion, actin re-modelling, cell motility and invasion. 
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7 Discussion & Future work 
7.1 General discussion 
Modern biological research and the rise of “omic” technology have provided useful and 
powerful tools for biological research. The generation of phenomenal amounts of data 
can confuse the actual reason for the research although it could be argued that biology is 
far too complex for hypothesis driven research. A combination of both “omics” and 
hypothesis driven approaches could deliver a more complete understanding of the 
biology, with “omics” providing leads which can then be used for important hypothesis 
driven experiments providing functional data. The combination of proteomics and 
functional biology was used in this research and has provided many interesting leads, of 
which 2 we have investigated further to investigate potential functional roles for these 
proteins in resistance (section 6). Several more proteins have been identified and could be 
investigated further after Western blot validation (Appendix (CD)). 
In the antibody array section of this work a total of 32 proteins, statistically 
different in expression or phosphorylation between the MCF7 and the resistant lines were 
identified. Of these proteins, 11 have been previously described in Tamoxifen resistance 
(see Table 4-7) and 21 proteins that have not been previously reported. This shows that 
using antibody array technology for signalling pathway and protein family analysis has 
led to a greater knowledge into the changes that occur in the Tamoxifen resistance 
cellular proteome.  
Using mass spectrometry analysis, a total of 262 proteins were found (each with at least 
one quantifiable peptide pair) 5 proteins were further investigated by Western blotting 
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and in 4 cases this confirmed the SILAC observations. In one case the result was not 
confirmed, perhaps indicating detection error in the MS analysis, or more likely due to 
differences in the specific peptides found within the protein detection using the two 
methods. For IQGAP1 and cortactin validation and further investigation into their 
function and role within Tamoxifen resistance proved interesting and more of the proteins 
found to be differentially expressed by SILAC could prove to be important in the 
acquisition of Tamoxifen resistance. 
Of the 262 proteins, 59% were over-expressed in resistance and 62% were 
decreased. The majority of them were cytoplasmic (67%). There is a slight bias of up 
regulated proteins but this is expected as biologically it is expected that the cell would 
turn on pathways and increase protein expression to overcome the presence of the drug. 
There were no receptors found in the MS SILAC data. The ontological profile of the 
proteins remained similar between the up and down regulated proteins however there 
were some differences; more transporters and peptidases were decreased in resistance. 
Bioactive peptides on the cell surface can be associated with a cancer phenotype 
(Nanus et al., 2003). Degradation of peptides is the job of the peptidases, which could be 
seen as a step in controlling growth and differentiation of normal cells by degrading the 
peptide before it induces tumour initiation and progression. In Tamoxifen resistance there 
was a decrease of peptidases seen; one could imagine that the loss or decreased 
expression of peptidases could result in a normal cells ability to inactivate a bioactive 
peptide leading to the stimulation of migration, invasion, cell growth or promotion of cell 
survival (Nanus et al., 2003). Conversely, 3% of peptidases increased in resistance. This 
could conceivably contribute to a gain in function through the increased expression of 
~ 213 ~ 
 
certain peptidases normally expressed at low levels, potentially converting a pro-peptide 
to a bio-active form to produce greater catalytic activity enabling the cell to become more 
proliferative (Nanus et al., 2003). 
Enzymes also showed a difference between proteins identified to be up and down 
regulated in resistance 25% were up, 18% down. Many classes of enzymes have been 
associated with increased metabolism and are often seen to be increased in more 
proliferative cancerous cells (Sabbisetti et al., 2009). They are thought to do this to fuel 
their increased growth. The increased expression of enzymes seen in resistance could 
conceivably be the cells needing more energy as they proliferate more rapidly. The 
resistant cells are also shown in this Thesis to be more invasive, specific enzymes such as 
MMPs are required to degrade the basement membrane in order to invade. However, 
there are also decreases in enzymes seen in the SILAC data which could be another class 
of enzyme, for example the cytochrome P450 2DS and sulfotransferases, which are used 
to convert Tamoxifen (pro-drug) to the active metabolite (Figure 1-11). These may well 
be decreased in Tamoxifen resistance as Wegman et al., 2005 showed that increasing 
these enzymes therapeutically could benefit the patients taking Tamoxifen. 
When the data gathered with SILAC and the data from the antibody arrays are 
studied collectively; a clearer picture starts to emerge. The global SILAC approach did 
not find any proteins that had been found with the antibody arrays (however, it did find 
proteins that had been reported in the literature to have a role in Tamoxifen resistance 
such as Cathepsin D), so the two approaches have an additive effect.  To analyse these 
sets of data collectively KEGG pathway analysis was used (Kanehisa, 2002). The results 
of this analysis can be seen in Figure 7-1, Figure 7-2 below.  
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Figure 7-1 The actin cytoskeleton is regulated by many proteins and complex networks as 
is displayed in the below figures. Below are the proteins identified in the pathways by the 
KEGG ontology pathway analysis program (http://www.genome.jp/kegg/pathway.html) 
(Red indicates an increase in expression, Blue a decrease) 
 
 Figure 7-1 Regulation of actin cytoskeleton - Homo sapiens (human) (10 proteins) 
 
ACTN1; actinin, alpha 1 
ACTN4; actinin, alpha 4 
EGFR; epidermal growth factor receptor  
EZR; ezrin 
FGFR2; fibroblast growth factor receptor 2  
IQGAP1; IQ motif containing GTPase activating protein 1 
MAPK1; mitogen-activated protein kinase 1  
MAPK3; mitogen-activated protein kinase 3  
MYH14; myosin, heavy chain 14, non-muscle  
PPP1CC; protein phosphatase 1, catalytic subunit, gamma isozyme  
 
Figure 7-2 Cancer is known to be regulated by many pathways. The pathways and 
proteins known to be associated with cancer are displayed below. Red indicates an 
increase in expression, Blue a decrease. Below are the proteins identified in the pathways 
by the KEGG ontology pathway analysis program 
(http://www.genome.jp/kegg/pathway.html) 
 
Figure 7-2 Pathways in cancer - Homo sapiens (human) (18 proteins) 
 
AKT1; v-akt murine thymoma viral oncogene homolog 1  
BAD; BCL2-associated agonist of cell death 
BAX; BCL2-associated X protein 
BCL2; B-cell CLL/lymphoma 2 
BCL2L1; BCL2-like 1 
BIRC2; baculoviral IAP repeat containing 2 
BIRC3; baculoviral IAP repeat containing 3 
BIRC5; baculoviral IAP repeat containing 5 
CSF1R; colony stimulating factor 1 receptor  
CTNNA1; catenin (cadherin-associated protein), alpha 1, 102kDa 
EGFR; epidermal growth factor receptor  
ERBB2; v-erb-b2 erythroblastic leukaemia viral oncogene homolog 2 
FGFR2; fibroblast growth factor receptor 2  
HIF1A; hypoxia inducible factor 1, alpha subunit  
HSP90AA1; heat shock protein 90kDa alpha (cytosolic), class A member 1 
MAPK1; mitogen-activated protein kinase 1  
MAPK3; mitogen-activated protein kinase 3  
XIAP; X-linked inhibitor of apoptosis 
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Figure 7-1 
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Figure 7-2
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Proteins found in this study have been implicated as key players in pathways in cancer 
(Figure 7-2) and also some have been shown to be over-expressed in Tamoxifen 
resistance such as EGFR, survivin and HIF  and these can be seen in this Figure 7-2 
coloured in red whilst those proteins that have lower expression in resistance can be seen 
coloured in blue, such as Bad. This could imply that the acquisition of Tamoxifen 
resistance may alter some of the most important pathways in cancer. This is already 
known in some respects as the ErbB2 and MAPK signalling pathway increases are well 
described for Tamoxifen resistance. Similarly for the evasion of apoptosis with the 
increase in survivin (which has been discussed in the literature Vanderlaag et al., 2010) 
however, the change in IAP expression has not been previously described. 
It is unlikely that there is one simple mechanism that underlies Tamoxifen 
resistance such as the loss of ER  signalling, or increased EGFR signalling. Many 
mechanisms have previously been implicated in Tamoxifen resistance (detailed in section 
1.6) in this study we have found evidence for many more. There were ten proteins with 
changes seen in Tamoxifen resistance associated with actin remodelling in cells, as can 
be seen in Figure 7-1. Actin and associated proteins such as RhoA-C, Rac1, Cdc42 (all in 
the Rho family of GTP-binding proteins), also IQGAP1 and cortactin are important in 
functions such as regulation of polymerisation of actin in the production of lamellapodia, 
stress fibres, membrane ruffles and invadapodia usually in response to extracellular 
signals, or proliferation or apoptosis. It has been reported in the literature that silencing of 
Rho Guandine dissociation inhibitors (Rho GDI) affect the metastatic phenotype and the 
responsiveness of breast cancer cells to Tamoxifen as investigated with xenograft models 
of resistance (Barone et al., 2011) Whilst these changes are observed in our TAMRBU 
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cells, whether they have a causal role in Tamoxifen resistance, or merely a consequence 
or requirement of the resistant phenotype has not been investigated in this Thesis.  
 There have been several studies that show an association between Tamoxifen 
resistance and the pathways and signalling networks that regulate the cytoskeleton. 
Tamoxifen therapy has also been implicated in the aberrant localisation of actin and 
fibronectin and actin remodelling in endometrial cancer cells (Albright et al., 1997). Over 
expression of Ras-GDP exchange factor AND34/BCAR3, known to associate with focal 
adhesion proteins and reported to modulate the actin cytoskeleton, gives the cells the 
ability to grow in the presence of Tamoxifen (Cai et al., 2003).  
The remodelling of actin and the motile and invasive (Figure 6-4) phenotype seen 
in Tamoxifen resistance are important steps in the development of a metastatic 
phenotype. The two proteins identified in this study and chosen for more in-depth 
investigation, IQGAP1 and Cortactin, are both known to have roles in development and 
progression of a more metastatic, invasive phenotype and are known modulators of the 
actin cytoskeleton. In this study we showed that IQGAP1over expression has a potential 
role in Tamoxifen resistance. How this over expression may fit with this role is discussed 
further below. 
IQGAP1 is a ubiquitously expressed 189KDa scaffold protein (White et al., 
2011), it has many interaction domains including; calmodulin binding (IQ domains), 
polyproline binding (WW domain), calponin domain and Ras GAP related region (White 
et al., 2009). There are many proteins that can bind through these domains; including 
Rac1/cdc42, actin, calmodulin, MAPK pathway components such as ERK1 and 2, 
adenomatous polyposis coli, VEGFR2, EGFR,  catenin, E-Cadherin (Johnston et al,. 
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2009). Through the binding and association with these proteins IQGAP1 is functional in 
many cell activities as was described in section 5.3.1. Through its involvement in these 
processes and its association with these proteins there is increasing evidence that 
IQGAP1 plays a major role in tumourigenesis (Johnson et al., 2009 and White et al., 
2009) many of the proteins that IQGAP1 binds to have roles in tumour progression 
or/and the initiation of cancer. Over expression of IQGAP1 has been described in several 
cancers as discussed above in section 5.3.1 and this together with the functions of its 
binding proteins infer that IQGAP1 has an oncogenic role in cancer. It has been shown in 
the literature that modulation of IQGAP1 expression in breast cancer cell lines (MCF7 
and MDA-MB 231) significantly alters their tumorigenicity and siRNA knockdown 
decreases this effect (Jadeski et al., 2008). It has recently been shown that IQGAP1 has a 
role in Trasuzumab (Herceptin) resistance (White et al., 2011) where it was shown that 
IQGAP1 binds directly to ErbB2 eliciting several effects in the cell including the 
stabilisation of ErbB2 expression (demonstrated in SkBR3 breast cancer cells) however, 
the mechanism by which this occurs remains elusive.  White et al., 2011 also suggest that 
IQGAP1 is necessary for the phosphorylation of ErbB2; we have shown that ErbB2 
phosphorylation is statistically up regulated in TAMR and TAMRBU cells (section 4.3.2) 
and this may contribute to the activation of the PI3K/Akt and MAPK signalling seen in 
Tamoxifen resistance (see section 4.2) as some studies have indicated these signalling 
pathways are inhibited when the phosphorylation of ErbB2 is reduced (Shattuck et al., 
2008 and Nahta et al., 2004). It has also been reported in the literature that IQGAP1 has a 
role in these pathways (PI3K/Akt and MAPK) (Roy et al., 2004, Roy et al., 2005 and Ren 
et al., 2007). Yamaoka-Toja et al., 2004, showed that the knockdown of IQGAP1 impairs 
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Akt activation by VEGF and White et al., 2011 show that knock down of IQGAP1 
increases p27 (a CDK inhibitor that causes cell cycle arrest and apoptosis  through the 
reduction of CDK2 activity) and subsequently reduces Akt phosphorylation and its ability 
to induce cell proliferation.  
IQGAP1 has also been associated with invasion in cancer which may result from 
the increased motile potential, the actin remodelling involved in invasive structures and 
also targeting of matrix metallo proteinase 1 (MMP1) to the invadapodia. The latter is 
imperative for the invading tumour cells to degrade the ECM to undergo metastasis as 
Bao et al., 2010 expression of MMP1 can also be ErbB2 mediated show in gastric cancer. 
IQGAP1 has been reported to bind to Sec3 and 8 (components of the exocyst complex) in 
order to target the MMP1 to the invadapodia (Sakurai-Yageta et al., 2008) this was 
regulated by Cdc42 and RhoA GTPase. This may be carried out through IQGAP1s 
function in the actin cytoskeleton modelling allowing the exocyst vesicles to be delivered 
to the invadapodia or through stimulation of actin to form the protrusions and exocytic 
complexes. 
The ability of IQGAP1 to interact with CD44, a hyaluron receptor, could also be 
important in the invasive potential of the cells. CD44 has been associated with many 
cancers and is regularly reported to be related to metastasis. It has also been shown to be 
elevated in the TAMR cell line (Baruah et al., 2009) where it was found that the over 
expression of CD44 sensitises cells to EGF and Hyaluron (HA). IQGAP1 over expression 
shown here and the CD44 over expression by Baruah et al., 2009 may act synergistically 
increasing the malignant phenotype of the Tamoxifen resistant cells.  
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The modulation of IQGAP1 expression (over expression and silencing) results in 
changes in the cytoskeleton associated with exhibition of both lamellopodia and 
membrane ruffles (Figure 7-3). At these structures, IQGAP1 acts as a scaffold protein to 
join actin and microtubule related proteins to proteins such as APC,  catenin and 
cadherin (Johnson et al., 2009). 
 
Figure 7-3 The potential role of IQGAP1 in malignant cell invasion. A basic figure 
showing that increased expression of IQGAP1 in cancer cells is localised in the invasive 
structures (B); membrane ruffles and invadapodia. Low expression of IQGAP1 is 
associated with low invasion and cell-cell contact (A). 
 
Here, in this study (sections 5.3.1 and 5.2.1) we showed that IQGAP1 is over 
expressed in our Tamoxifen resistant cell line TAMRBU by means of SILAC and 
validated this by Western blot. We also showed that it has a functional role in Tamoxifen 
resistance effecting cellular proliferation, adherence and invasion, by using functional 
assays in conjunction with transient knock down of the protein expression (Figure 6-1, 
Figure 6-2, Figure 6-3, and Figure 6-4). This would seem to fit in with the literature, 
In
c
re
a
s
in
g
 I
Q
G
A
P
1
 e
x
p
re
s
s
io
n
Central Tumour region
In
v
a
s
io
n
 p
o
te
n
ti
a
l?
B 
A 
~ 222 ~ 
 
discussed above. The expression of IQGAP1 protein has not previously been associated 
with Tamoxifen resistance in breast cancer. 
7.2 Future work 
The discovery of a role for IQGAP1 in acquired Tamoxifen resistance could just be 
a starting block for further work into exactly how this protein acts in order to have an 
effect on the phenotype of the resistant cells and through the binding of which proteins. 
There are several ways in which this could be studied; siRNA knockdowns of IQGAP1 in 
the MCF7, TAMR and TAMRBU cells could be investigated using the MAPK and the 
RTK antibody arrays. This would enable us to see whether the over expression of 
IQGAP1 in resistant cells has an effect on the MAPK and RTK family of proteins as the 
literature suggests that it can work with EGFR and ERK. This approach would also allow 
us to see whether any of the other family members are involved. It would be interesting to 
see whether EGFR and ErbB2 are involved, as they are the proteins that IQGAP1 has 
been associated with in the development of Traszumab resistance (White et al., 2011).  
Performing an immunoprecipitation of IQGAP1 in combination with SDS PAGE 
and MS could indicate the binding proteins of the IQGAP1 in the Tamoxifen resistant 
cells. This could be performed in a series of increasingly stringent washes (by varying the 
amount of NaCl) allowing us to see the proteins that are more bound than others.   
Stable suppression of IQGAP1 in MCF7 cells using a lentivirus would enable us to 
investigate whether the cells could still develop Tamoxifen resistance in culture using the 
chemical selection method which was used to develop the TAMRBU cell lines. In 
TAMRBU the decreased expression of IQGAP1 could be used to investigate whether the 
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resistant cells can continue to grow with Tamoxifen present in the media long term and if 
that is the case, whether they would develop a mechanism to overcome this decrease. 
Also, knocking out the IQGAP1 with lentivirus in MCF7 and TAMRBU would give us 
the ability to use assays which take a longer period of time to perform such as colony 
forming assays to investigate non-anchorage dependent growth – often used as a 
characteristic to show increased tumourgenicity. In order to determine whether IQGAP1 
over expression is relevant in failure of Tamoxifen therapy, the expression of IQGAP1 in 
clinical samples from patients who have responded to Tamoxifen or failed to respond to 
therapy after two years should be analysed. 
In this Thesis there was no discernible role seen for cortactin in the proliferation or 
adhesion of Tamoxifen resistant cells, the literature has suggested there may be a role for 
cortactin in invasion and motility; however, it seems that the function of cortactin may be 
reliant upon its phosphorylation status rather than its increased expression. Cortactin has 
been reported to be a master switch activating the maturation of invadapodia in breast 
cancer cells which is reliant upon the phosphorylation of cortactin (Mader et al., 2011). It 
is not known which kinases are responsible for this phosphorylation in the invadapodia, 
although an EGF induced phosphorylation (mediated by Src and Arg) has been shown to 
activate ECM degradation actin polymerisation in invadapodia and invasion (Mader et 
al., 2011). Oser et al., 2010 also reported that the phosphorylation of cortactin at 
particular residues was imperative for the maturation of the invadapodia but not 
associated with the EGFR- Src – Arg – Cortactin pathway described above. Further 
studies into the role of expression, and particularly phosphorylation, of cortactin in the 
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increased invasive potential seen in the Tamoxifen resistant TAMRBU cells would be 
interesting.  
It would be appealing to further develop the adhesion assay into a more robust 
assay using various matrices such as fibronectin and collagen, to investigate whether 
IQGAP1 and cortactin and the suppression of their expression does have an effect on 
these cells. As a change in adhesion has been reported in Tamoxifen resistant cells, this is 
an important phenotypic change to analyse the functional role of the proteins found in 
this study.  
In total there were 262 quantifiable proteins identified in this study (see section 
5.1). Of these 29% were over expressed in resistance and 25% were down regulated. This 
gives lots of further target proteins which, after validation by Western blotting, could be 
investigated further using functional assays in combination with siRNA technology. 
These proteins are detailed in the Appendix (CD) in the back of this Thesis. The potential 
of discovering biomarkers using SELDI or MALDI of secretomes is another potential 
area for further investigation.  
The opportunity to investigate some of the proteins found in this study in clinical 
samples, perhaps through tissue microarrays, would be the ultimate aim for any future 
work. Validating changes seen in the Tamoxifen resistant model in a clinical setting 
would be interesting – especially for the IQGAP1 where further work in Section 6 has 
shown it to have a role in Tamoxifen resistance/the progression of cancer. It would give 
us the opportunity to validate not only the proteins found in the study with patient 
samples but also have the potential to show that the changes seen in the cell culture 
model correlate in a clinical setting. 
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In conclusion, using proteomic technologies we have discovered several novel 
proteins that may be involved in the acquisition of Tamoxifen resistance. With further 
work this could help unfold the complicated network of proteins and signalling pathways 
that seem to play a role in Tamoxifen resistance and cancer progression. Figure 7-4 below 
is representative of the hallmarks of cancer (Hanahan and Weinburg, 2011) it has been 
adapted to show that in this study of Tamoxifen resistance there seems to be more 
emphasis on the hallmarks outlined in red; increased growth signalling, the ability to 
evade apoptosis/cell death, activation of invasion and metastasis and potentially limitless 
proliferation when TAMRBU are compared to the cancer cell line MCF7.  
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Figure 7-4 An adapted figure of the Hallmarks of cancer, this body of work suggests that 
Tamoxifen resistant phenotype relies upon increasing hallmarks shown here outlined in 
red. Adapted from Hanahan and Weinberg, 2011. 
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Appendices: From CD 
A. Quantifiable peptides found up regulated in TAMRBU 
B. Quantifiable peptides found  down regulated in TAMRBU 
C. Data from SILAC experiment  (with ratios)  
      Score 
Accessi
on   
QUANTIFIABLE PEPTIDES 
FOUND  MH+ Charge XC 
Delta 
Cn Sp RSp 
UPregulated in TAMRBU 
TALIN-1 -.TLAESALQLLYTAK.- 1522.77 2 3.78 0.51 1188.4 1 
-.TLAESALQLLYTAK#.- 1528.77 2 2.65 0.33 750.7 1 
 BCL2-ASSOCIATED 
ATHANOGENE         
-.MKILEEIDTLILPENFK.- 2053.44 3 2.61 0.12 473.2 1 
-.MKILEEIDTLILPENFK#.- 2059.44 3 2.66 0.09 543.3 1 
 RAS GTPASE-ACTIVATING-LIKE 
PROTEIN IQGAP1         
-.ATFYGEQVDYYK.- 1484.59 2 2.58 0.36 1123.0 1 
-.ATFYGEQVDYYK#.- 1490.59 2 3.03 0.45 1051.4 1 
-.TLQALQIPAAK.- 1154.39 2 3.06 0.45 1492.3 1 
-.TLQALQIPAAK#.- 1160.39 2 3.15 0.39 1363.8 1 
-.LPYDVTPEQALAHEEVK.- 1940.14 3 4.53 0.49 1318.5 1 
-.LPYDVTPEQALAHEEVK#.- 1946.14 3 4.25 0.41 1715.9 1 
-.LPYDVTPEQALAHEEVK.- 1940.14 2 4.34 0.55 802.4 1 
-.LPYDVTPEQALAHEEVK#.- 1946.14 2 2.65 0.46 376.6 1 
-.VDQIQEIVTGNPTVIK.- 1755.01 2 3.51 0.44 1454.3 1 
-.VDQIQEIVTGNPTVIK#.- 1761.01 2 2.13 0.16 829.6 1 
-
.SPDVGLYGVIPEC*GETYHSDLAEA
K.- 2708.91 3 5.20 0.52 986.3 1 
-
.SPDVGLYGVIPEC*GETYHSDLAEA
K#.- 2714.91 3 4.21 0.37 554.0 1 
-.LGLAPQIQDLYGK.- 1416.65 2 3.44 0.48 659.8 1 
-.LGLAPQIQDLYGK#.- 1422.65 2 3.01 0.36 434.5 1 
-.RLAAVALINAAIQK#.- 1458.77 2 2.60 0.20 542.5 1 
-.RLAAVALINAAIQK.- 1452.77 2 2.32 0.23 609.8 2 
-.EKLEAYQHLFYLLQTNPTYLAK.- 2685.07 3 5.20 0.39 1300.1 1 
-.EK#LEAYQHLFYLLQTNPTYLAK#.- 2697.07 3 3.85 0.31 836.2 2 
-.ILAIGLINEALDEGDAQK.- 1884.12 2 6.93 0.56 1627.6 1 
-.ILAIGLINEALDEGDAQK#.- 1890.12 2 6.63 0.58 2717.2 1 
-.FALGIFAINEAVESGDVGK#.- 1944.17 2 3.72 0.53 1251.5 1 
-.FALGIFAINEAVESGDVGK.- 1938.17 2 4.74 0.56 2082.1 1 
 ISOFORM 2 OF 
PHOSPHATIDYLINOSITOL 3,4,5-
TRISPHOSPHATE-DEPENDENT 
RAC EXCHANGER 1 PROTEIN.         
PREX -.IAC*YQEFAAQLK#.- 1448.64 2 2.63 0.31 694.8 1 
-.IAC*YQEFAAQLK.- 1442.64 2 3.03 0.36 1474.5 1 
 STAPHYLOCOCCAL NUCLEASE 
DOMAIN-CONTAINING PROTEIN 1 
SND1 -.KVNVTVDYIRPASPATETVPAFSER.- 2749.07 3 4.06 0.49 592.4 1 
-
.K#VNVTVDYIRPASPATETVPAFSER.
- 2755.07 3 2.28 0.41 407.2 1 
CALPAIN-1 CATALYTIC SUBUNIT         130.23 
27.05 - 27.55 -.YLGQDYEQLR.- 1285.39 2 3.74 0.43 766.7 1 
56.53 - 56.79 -.LPPGEYVVVPSTFEPNK.- 1874.13 2 2.97 0.40 694.5 1 
56.73 - 57.05 -.LEIC*NLTPDALK#.- 1393.60 2 2.61 0.35 478.6 2 
57.15 - 57.42 -.RPTELLSNPQFIVDGATR.- 2015.26 3 3.03 0.36 860.0 1 
57.32 - 57.65 -.RPTELLSNPQFIVDGATR.- 2015.26 2 3.51 0.41 559.2 1 
57.89 - 58.36 -.NYLSIFR.- 913.06 1 1.78 0.25 75.7 4 
61.59 - 61.95 -.K#APSDLYQIILK#.- 1401.67 2 3.56 0.48 1372.2 1 
61.61 - 62.08 -.KAPSDLYQIILK.- 1389.67 2 4.54 0.41 1208.6 1 
71.73 - 71.95 -.NYPATFWVNPQFK.- 1612.81 2 3.62 0.51 936.7 1 
72.67 - 72.92 -.APSDLYQIILK.- 1261.49 2 3.21 0.41 1655.0 1 
78.01 - 78.26 -.LPPGEYVVVPSTFEPNKEGDFVLR.- 2691.03 3 3.89 0.51 644.5 1 
78.17 - 78.45 
-
.LPPGEYVVVPSTFEPNK#EGDFVLR.- 2697.03 3 4.21 0.43 556.3 1 
108.18 - 108.43 -.LGLVEFNILWNR.- 1474.73 2 3.37 0.42 1415.5 1 
 SRC SUBSTRATE CORTACTIN         50.19 
945 - 958 -.NASTFEDVTQVSSAYQK.- 1875.97 2 3.83 0.51 1266.5 1 
963 - 978 -.NASTFEDVTQVSSAYQK#.- 1881.97 2 3.36 0.48 1322.1 1 
1197 - 1214 -.LPSSPVYEDAASFK.- 1511.66 2 3.27 0.50 708.3 1 
1200 - 1215 -.LPSSPVYEDAASFK#.- 1517.66 2 2.15 0.37 1198.9 1 
3047 - 3082 -.YGLFPANYVELR.- 1442.64 2 3.08 0.43 558.7 1 
 RIBOPHORIN II         80.26 
2296 - 2312 -.LQVTNVLSQPLTQATVK#.- 1847.14 2 3.81 0.37 1726.3 1 
2298 - 2315 -.LQVTNVLSQPLTQATVK.- 1841.14 2 5.27 0.60 1194.0 1 
3531 - 3542 -.KNFESLSEAFSVASAAAVLSHNR.- 2436.67 3 5.13 0.48 2017.4 1 
3539 - 3545 -.K#NFESLSEAFSVASAAAVLSHNR.- 2442.67 3 3.53 0.36 1261.0 1 
Proliferation-associated protein 
2G4       40.19 
1420 - 1431 -.ITSGPFEPDLYK.- 1367.53 2 2.61 0.37 710.5 1 
2278 - 2315 -.SLVEASSSGVSVLSLC*EK.- 1853.06 2 3.32 0.45 528.6 1 
2908 - 2928 -.HELLQPFNVLYEK.- 1630.87 2 3.81 0.29 1073.8 1 
2913 - 2925 -.HELLQPFNVLYEK#.- 1636.87 2 2.37 0.05 611.8 1 
 HEPATOMA-DERIVED GROWTH 
FACTOR   IPI00020956     30.23 
2692 - 2728 -.GFSEGLWEIENNPTVK.- 1820.98 2 4.03 0.36 668.6 1 
2720 - 2735 -.GFSEGLWEIENNPTVK#.- 1826.98 2 2.04 0.13 406.8 1 
3645 - 3656 -.YQVFFFGTHETAFLGPK.- 1990.25 3 2.76 0.48 274.5 1 
 PROHIBITIN-2 IPI00027252       70.23 
302 -.IVQAEGEAEAAK.- 1216.32 2 2.15 0.24 1404.6 1 
642 - 652 -.LGLDYEER.- 995.07 2 2.28 0.40 880.6 1 
1332 - 1364 -.FNASQLITQR.- 1178.32 2 3.05 0.33 720.0 1 
1373 - 1379 -.AQVSLLIR.- 900.10 2 2.23 0.23 643.3 4 
2129 - 2159 -.LLLGAGAVAYGVR.- 1260.51 2 4.01 0.42 1385.9 1 
2933 - 2951 -.IGGVQQDTILAEGLHFR.- 1855.09 2 4.60 0.49 1454.7 1 
4863 - 4898 -.IPWFQYPIIYDIR.- 1725.03 2 4.36 0.49 1665.4 1 
 TUMOR-ASSOCIATED 
CALCIUM SIGNAL 
TRANSDUCER 1 IPI00296215       30.24 3 (3 0 0 0 0) 
2068 - 2094 
-
.AKPEGALQNNDGLYDPDC*D
ESGLFK.- 2754.89 3 4.73 0.42 674.3 1 28/96 
3766 - 3777 -.TQNDVDIADVAYYFEK.- 1892.01 2 4.63 0.57 1639.3 1 22/30 
3782 - 3832 -.TQNDVDIADVAYYFEK#.- 1898.01 2 3.38 0.42 1104.1 1 20/30 
 PROHIBITIN IPI00017334       40.22 4 (4 0 0 0 0) 
1091 - 1101 -.IFTSIGEDYDER.- 1445.51 2 2.16 0.28 749.2 1 17/22 
1468 - 1492 -.FDAGELITQR.- 1150.27 2 4.20 0.50 1485.0 1 16/18 
1698 - 1714 -.ILFRPVASQLPR.- 1397.69 3 2.94 0.36 366.4 1 20/44 
2123 - 2164 -.K#LEAAEDIAYQLSR.-  1607.79 2 4.32 0.49 2091.2 1 20/26 
-. KLEAAEDIAYQLSR.-  1613.79 2 4.39 0.48 2091.2 1 20/26 
 CHLORIDE INTRACELLULAR 
CHANNEL PROTEIN 1 IPI00010896       60.27 6 (6 0 0 0 0) 
2483 - 2498 
-
.VLDNYLTSPLPEEVDETSAEDE
GVSQR.- 2994.13 2 4.39 0.50 480.5 1 21/52 
2753 - 2754 
-
.EEFASTC*PDDEEIELAYEQVA
K.- 2574.68 2 2.05 0.35 304.9 1 15/42 
2895 - 2954 -.LAALNPESNTAGLDIFAK.- 1846.07 2 4.44 0.61 921.6 1 22/34 
2955 - 2978 -.LAALNPESNTAGLDIFAK#.- 1852.07 2 4.50 0.48 999.0 1 23/34 
2960 - 2972 -.LAALNPESNTAGLDIFAK.- 1846.07 2 5.30 0.58 1025.3 1 22/34 
3240 - 3251 -.FLDGNELTLADC*NLLPK.- 1934.17 2 3.42 0.19 689.5 1 14/32 
 HIGH MOBILITY GROUP 
PROTEIN B1       20.28 2 (2 0 0 0 0) 
2999 - 3008 -.RPPSAFFLFC*SEYRPK.- 2003.29 3 5.64 0.50 1724.3 1 29/60 
3011 - 3027 -.RPPSAFFLFC*SEYRPK#.- 2009.29 3 5.09 0.41 1478.2 1 27/60 
QUANTIFIABLE PEPTIDES FOUND  
Down regulated in TAMRBU 
 ISOFORM 1 OF NF-X1-TYPE 
ZINC FINGER PROTEIN NFXL1.         
28.2
7 
3 (2 1 
0 0 0) 
35.04 - 35.21 -.FLDPNTLER.- 1105.23 2 3.27 0.26 656.7 14/16 
69.28 - 69.89 -.LAAKLSATLEQAAATAR.- 1686.94 2 4.34 0.50 1374.3 19/32 
82.83 - 83.30 -.QVVSAVTTLVEAAER.- 1573.77 2 5.37 0.50 1787.7 22/28 
 VIGILIN.         
90.3
2 
9 (9 0 
0 0 0) 
1589 - 1619 
-
.IREESNTKIDLPAENSNSETI
IITGK.- 2874.15 3 2.89 0.30 201.1 20/100 
1589 - 1619 -.IDLPAENSNSETIIITGK.- 1916.12 2 4.26 0.43 624.4 19/34 
1599 - 1620 
-
.IREESNTKIDLPAENSNSETI
IITGK#.- 2880.15 3 2.86 0.24 234.0 20/100 
1599 - 1620 -.IDLPAENSNSETIIITGK#.- 1922.12 2 3.59 0.34 580.7 19/34 
1668 - 1678 -.GNSLQEILER.- 1159.28 2 3.14 0.32 1262.0 15/18 
2121 - 2140 -.ANSFTVSSVAAPSWLHR.- 1831.02 2 3.21 0.55 678.3 16/32 
2740 - 2763 -.ASVITQVFHVPLEER.- 1725.97 2 2.79 0.36 551.4 13/28 
2747 - 2756 -.ASVITQVFHVPLEER.- 1725.97 3 3.31 0.53 535.0 23/56 
2795 - 2808 -.DKFPEVIINFPDPAQK.- 1859.12 2 2.77 0.39 660.5 16/30 
  ALPHA-ACTININ-4.         
198.
29 20 (19 1 0 0 0) 
615 - 630 
-
.ASFNHFDKDHGGALGPEEF
K.- 2204.34 3 3.75 0.30 2494.5 31/76 
1139 - 1163 -.LSGSNPYTTVTPQIINSK.- 1921.14 2 3.40 0.17 770.1 19/34 
1186 - 1204 -.LSGSNPYTTVTPQIINSK#.- 1927.14 2 3.45 0.39 988.8 19/34 
1304 - 1320 -.LVSIGAEEIVDGNAK.- 1515.69 2 4.60 0.54 1307.7 19/28 
1312 - 1334 -.LVSIGAEEIVDGNAK#.- 1521.69 2 3.15 0.42 969.2 17/28 
1342 - 1352 -.VLAGDKNFITAEELR.- 1676.90 3 3.33 0.22 654.1 22/56 
1360 - 1392 -.VLAGDKNFITAEELR.- 1676.90 2 2.75 0.39 417.9 16/28 
1536 - 1557 -.KAGTQIENIDEDFRDGLK.- 2050.22 3 5.49 0.54 2026.3 33/68 
1775 - 1800 -.KDDPVTNLNNAFEVAEK.- 1905.06 2 5.66 0.60 1809.1 26/32 
1901 - 1910 -.QLEAIDQLHLEYAK.- 1671.88 2 3.40 0.38 879.7 16/26 
1950 - 1958 -.NVNVQNFHISWK.- 1486.66 2 3.68 0.48 1758.5 18/22 
1965 - 1976 -.DGLAFNALIHR.- 1227.40 2 3.27 0.38 979.7 15/20 
1980 - 1985 -.DGLAFNALIHR.- 1227.40 3 2.53 0.38 447.6 20/40 
1983 - 1996 -.QFASQANVVGPWIQTK.- 1775.00 2 4.92 0.52 771.2 20/30 
1984 - 2025 -.ETTDTDTADQVIASFK.- 1742.82 2 5.71 0.58 1757.4 21/30 
2004 - 2014 -.ETTDTDTADQVIASFK#.- 1748.82 2 3.57 0.50 1405.2 19/30 
2092 - 2104 -.AC*LISLGYDVENDR.- 1625.76 2 2.99 0.28 1082.9 19/26 
2103 - 2121 -.IC*DQWDALGSLTHSR.- 1759.90 3 3.89 0.51 1470.3 32/56 
2112 - 2124 -.IC*DQWDALGSLTHSR.- 1759.90 2 2.93 0.31 1119.0 17/28 
2247 - 2294 -.DDPVTNLNNAFEVAEK.- 1776.88 2 4.54 0.57 1593.8 24/30 
 PDCD6IP PROTEIN         40.21 4 (4 0 0 0 0) 
47.15 - 47.58 -.HYQFASGAFLHIK.- 1519.73 3 3.48 0.39 2052.3 28/48 
68.14 - 68.65 -.SVIEQGGIQTVDQLIK.- 1728.97 2 4.30 0.52 1829.5 20/30 
68.20 - 68.44 -.SVIEQGGIQTVDQLIK#.- 1734.97 2 2.74 0.34 1572.7 21/30 
85.48 - 85.72 -.FYNELTEILVR.- 1397.60 2 3.18 0.45 1091.2 17/20 
 AFG3-LIKE PROTEIN 2         78.39 8 (7 1 0 0 0) 
608 - 620 
-
.QGDMVLEKPYSEATAR.- 1796.00 2 2.02 0.19 397.5 15/30 
1438 - 1449 -.GLGYAQYLPK.- 1110.29 2 2.47 0.33 1184.6 15/18 
1832 - 1844 -.VGQISFDLPR.- 1132.29 2 3.11 0.30 777.0 15/18 
2301 - 2310 -.VALLLLEK.- 899.15 2 2.17 0.12 806.6 13/14 
2302 - 2304 -.VALLLLEK.- 899.15 1 1.72 0.17 416.1 11/14 
2442 - 2450 -.NLETLQQELGIEGENR.- 1843.97 2 4.39 0.49 1364.7 19/30 
2609 
-
.TVAYHEAGHAVAGWYL
EHADPLLK.- 2649.94 3 2.55 0.22 430.0 27/92 
4056 -.NAPC*ILFIDEIDAVGR.- 1804.03 2 2.48 0.44 556.7 16/30 
 PDCD6IP PROTEIN         70.31 7 (7 0 0 0 0) 
1209 - 1220 -.LALASLGYEK.- 1065.25 2 2.02 0.16 822.4 14/18 
1671 - 1684 -.HYQFASGAFLHIK.- 1519.73 3 4.59 0.45 2307.1 31/48 
1674 - 1698 -.HYQFASGAFLHIK#.- 1525.73 3 2.91 0.40 1299.0 23/48 
2157 - 2170 -.LANQAADYFGDAFK.- 1531.65 2 2.11 0.09 980.2 17/26 
2633 - 2669 -.SVIEQGGIQTVDQLIK#.- 1734.97 2 4.80 0.52 1634.9 21/30 
2636 - 2666 -.SVIEQGGIQTVDQLIK.- 1728.97 2 6.18 0.47 2649.2 25/30 
3408 - 3426 -.FYNELTEILVR.- 1397.60 2 3.56 0.33 771.7 13/20 
 CENTAURIN-DELTA-3         20.38 
2224 - 2258 
-
.PDWAAVNLGVVIC*K#Q
CAGQHR.- 2329.66 3 2.69 0.08 231.0 2 (2 0 0 0 0) 
2331 - 2368 
-
.PDWAAVNLGVVICK#QC
*AGQHR.- 2329.66 3 2.52 0.13 162.9 17/80 
18/80 
 LAMIN-B1.         40.29 4 (4 0 0 0 0) 
1113 - 1133 -.SLETENSALQLQVTER.- 1818.96 2 5.76 0.40 2249.7 22/30 
1323 - 1385 -.IESLSSQLSNLQK.- 1447.62 2 2.99 0.36 1114.3 17/24 
1331 - 1389 -.IESLSSQLSNLQK#.- 1453.62 2 2.46 0.36 642.3 13/24 
2111 - 2158 -.IQELEDLLAK.- 1172.35 2 2.35 0.12 607.7 14/18 
 PLASTIN-1         20.15 2 (2 0 0 0 0) 
597 - 604 
-
.EGITAIGGTSTISSEGTQHSY
SEEEK#.- 2705.78 3 3.00 0.30 289.2 1 25/100 
2162 - 2178 -.AYFHLLNQIAPK.- 1415.66 2 2.14 0.37 853.6 1 14/22 
 Ezrin-radixin-moesin-
binding 
phosphoprotein 50       30.28 3 (3 0 0 0 0) 
515 - 537 
-
.AQEAPGQAEPPAAAEVQGA
GNENEPR.- 2589.67 2 5.60 0.57 812.8 1 25/50 
1062 - 1072 -.LLVVDPETDEQLQK.- 1627.82 2 3.30 0.45 725.0 1 18/26 
1064 - 1077 -.LLVVDPETDEQLQK#.- 1633.82 2 3.51 0.42 1070.1 1 21/26 
Cytochrome b-c1 
complex subunit 2 
mitochondrial       84.23 9 (8 0 0 1 0) 
851 - 861 -.ATAAPAGAPPQPQDLEFTK.- 1911.11 2 3.81 0.44 495.8 1 22/36 
867 - 888 
-
.ATAAPAGAPPQPQDLEFTK#.
- 1917.11 2 3.27 0.46 480.8 1 19/36 
1336 - 1350 -.NALANPLYC*PDYR.- 1567.72 2 2.37 0.31 431.9 1 13/24 
1557 - 1571 
-
.AVAFQNPQTHVIENLHAAAY
R.- 2351.61 3 3.32 0.46 973.5 1 26/80 
1882 - 1893 -.YEDFSNLGTTHLLR.- 1666.82 3 3.31 0.24 702.5 1 27/52 
1895 - 1930 -.YEDFSNLGTTHLLR.- 1666.82 2 2.08 0.37 410.2 11 15/26 
1943 - 1959 -.VTSEELHYFVQNHFTSAR.- 2166.34 3 3.68 0.50 1008.4 1 27/68 
3488 - 3508 -.LPNGLVIASLENYSPVSR.- 1930.19 2 2.85 0.41 708.4 1 14/34 
3639 - 3674 -.LPNGLVIASLENYSPVSR.- 1930.19 2 4.50 0.51 1728.2 1 22/34 
 NUCLEAR 
MIGRATION PROTEIN 
NUDC       30.62 3 (3 0 0 0 0) 
743 - 800 -.LKPNLGNGADLPNYR.- 1642.84 3 3.77 0.33 1167.8 1 29/56 
802 - 814 -.LK#PNLGNGADLPNYR.- 1648.84 3 2.64 0.04 357.3 2 23/56 
1899 - 1925 -.GQPAIIDGELYNEVK.- 1646.82 2 4.30 0.45 1471.1 1 22/28 
 ISOFORM 1 OF 
PROTEIN SET       20.22 2 (2 0 0 0 0) 
2968 - 2987 -.IDFYFDENPYFENK.- 1841.95 2 4.48 0.44 2003.2 1 21/26 
2969 - 2986 -.IDFYFDENPYFENK#.- 1847.95 2 3.58 0.27 1652.7 1 19/26 
 CATHEPSIN D       40.24 4 (4 0 0 0 0) 
498 - 509 -.VGFAEAAR.- 820.92 2 2.41 0.24 1009.7 1 13/14 
1750 - 1820 -.VSTLPAITLK.- 1043.28 2 2.13 0.35 267.9 7 11/18 
1805 - 1814 -.VSTLPAITLK#.- 1049.28 2 2.11 0.19 317.2 2 12/18 
4134 - 4161 -.LVDQNIFSFYLSR.- 1602.82 2 4.82 0.46 1337.5 1 20/24 
 VOLTAGE-
DEPENDENT ANION-
SELECTIVE CHANNEL 
PROTEIN 2       100.24 10 (10 0 0 0 0) 
506 - 513 
-
.SC*SGVEFSTSGSSNTDTGK.- 1908.91 2 3.42 0.43 679.3 1 17/36 
508 
-
.SC*SGVEFSTSGSSNTDTGK#
.- 1914.91 2 3.05 0.54 575.5 1 17/36 
1260 - 1264 -.LTFDTTFSPNTGKK.- 1557.73 2 2.53 0.33 590.7 1 14/26 
1634 - 1646 -.LTFDTTFSPNTGK.- 1429.56 2 3.98 0.51 912.2 1 15/24 
1700 - 1740 
-
.VNNSSLIGVGYTQTLRPGVK.- 2104.40 3 3.73 0.34 621.1 1 23/76 
1709 - 1719 
-
.VNNSSLIGVGYTQTLRPGVK#.
- 2110.40 3 2.90 0.37 681.9 1 26/76 
1863 - 1883 
-
.TGDFQLHTNVNDGTEFGGSIY
QK.- 2529.66 3 4.84 0.43 1096.2 1 30/88 
1864 - 1887 
-
.TGDFQLHTNVNDGTEFGGSIY
QK#.- 2535.66 3 3.21 0.21 894.4 1 27/88 
2276 - 2301 -.LTLSALVDGK.- 1017.20 2 3.18 0.46 815.7 1 15/18 
2280 - 2289 -.LTLSALVDGK#.- 1023.20 2 2.54 0.40 1229.1 1 16/18 
 CALPONIN-2       20.50 2 (2 0 0 0 0) 
4134 - 4178 -.TWIEGLTGLSIGPDFQK.- 1863.10 2 4.68 0.64 1406.0 1 21/32 
4179 - 4206 -.TWIEGLTGLSIGPDFQK#.- 1869.10 2 4.04 0.59 900.5 1 17/32 
FAM49B        20.16 2 (2 0 0 0 0) 
4565 - 4600 -.NVFDEAILAALEPPEPK.- 1854.09 2 3.11 0.37 378.3 1 15/32 
4598 -.NVFDEAILAALEPPEPK#.- 1860.09 2 2.13 0.28 577.6 1 19/32 
RATIO 
LIGHT HEAVY 
TAMRBU MCF7 
 TUMOR-ASSOCIATED CALCIUM SIGNAL 
TRANSDUCER 1 3 (3 0 0 0 0) 1 :0.11 
P16422 
9.09090 1 
 BCL2-ASSOCIATED ATHANOGENE (BAG-1) 2 (2 0 0 0 0) 1 : 0.14 Q99933 7.14285 1 
Alpha-enolase 6 (6 0 0 0 0) 1 : 0.20 P06733 5 1 
 RIBOPHORIN II 4 (4 0 0 0 0) 1 : 0.23 P04844 4.34782 1 
 ISOCITRATE DEHYDROGENASE [NADP] 
CYTOPLASMIC 4 (4 0 0 0 0) 1 : 0.25 
O75874 
4 1 
 CHLORIDE INTRACELLULAR CHANNEL 
PROTEIN 1 11 (9 2 0 0 0) 1 : 0.26 
O00299 
3.84154 1 
 HIGH MOBILITY GROUP PROTEIN B1 2 (2 0 0 0 0) 1 : 0.28 P09429 3.57142 1 
 ISOFORM 2 OF PHOSPHATIDYLINOSITOL 
3,4,5-TRISPHOSPHATE-DEPENDENT RAC 
EXCHANGER 1 PROTEIN. 10 (10 0 0 0 0) 1 : 0.28 
Q8TCU6 
3.57142 1 
 CALPAIN-1 CATALYTIC SUBUNIT 6 (6 0 0 0 0) 1 : 0.29 P07384 3.44827 1 
 STAPHYLOCOCCAL NUCLEASE DOMAIN-
CONTAINING PROTEIN 1 (snd1) 4 (4 0 0 0 0) 1 : 0.29 
Q7KZF4 
3.44827 1 
Proliferation-associated protein 2G4 4 (4 0 0 0 0) 1 : 0.30 Q9UQ80 3.33333 1 
 TALIN-1. 6 (6 0 0 0 0) 1 : 0.31 Q9Y490 3.22580 1 
 ISOFORM 1 OF CYTOSKELETON-
ASSOCIATED PROTEIN 4. 6 (6 0 0 0 0) 1 : 0.32 
Q8IYA6 
3.125 1 
 ISOFORM 4 OF HETEROGENEOUS 
NUCLEAR RIBONUCLEOPROTEIN A/B 4 (4 0 0 0 0) 1 : 0.34 
Q99729 
2.94117 1 
 ISOFORM A1-B OF HETEROGENEOUS 
NUCLEAR RIBONUCLEOPROTEIN A1 2 (2 0 0 0 0) 1 : 0.37 
P09651 
2.70270 1 
 RAS GTPASE-ACTIVATING-LIKE PROTEIN 
IQGAP1 36 (36 0 0 0 0) 1 : 0.38 
P46940 
2.63157 1 
 Purine nucleoside phosphorylase 6 (6 0 0 0 0) 1 : 0.40 P00491 2.5 1 
 ISOFORM 1 OF EXPORTIN-2. 7 (7 0 0 0 0) 1 : 0.41 P55060 2.43902 1 
 SRC SUBSTRATE CORTACTIN 5 (5 0 0 0 0) 1 : 0.42 Q14247 2.38095 1 
 D-3-PHOSPHOGLYCERATE 
DEHYDROGENASE 7 (7 0 0 0 0) 1 : 0.43 
O43175 
2.32558 1 
 HEPATOMA-DERIVED GROWTH FACTOR 3 (3 0 0 0 0) 1 : 0.46 P51858 2.17391 1 
 VOLTAGE-DEPENDENT ANION-SELECTIVE 
CHANNEL PROTEIN 2 10 (10 0 0 0 0) 1 : 0.47 
P45880 
2.12766 1 
 CYTOCHROME B-C1 COMPLEX SUBUNIT 2, 
MITOCHONDRIAL 10 (10 0 0 0 0) 1 : 0.50 
P22695 
2 1 
 PROHIBITIN 7 (7 0 0 0 0) 1 : 0.50 P35232 2 1 
Thioredoxin domain-containing protein 5 3 (3 0 0 0 0) 1 : 0.52 Q8NBS9 1.92307 1 
 ISOFORM 1 OF CATENIN ALPHA-1 3 (3 0 0 0 0) 1 : 0.53 P35221 1.88679 1 
 PUTATIVE ANNEXIN A2-LIKE PROTEIN 11 (11 0 0 0 0) 1 : 0.45 A6NMY6 1.85185 1 
 ISOFORM GAMMA-1 OF 
SERINE/THREONINE-PROTEIN 
PHOSPHATASE PP1-GAMMA CATALYTIC 
SUBUNIT 4 (4 0 0 0 0) 1 : 0.55 
P36873 
1.81818 1 
 PYRROLINE-5-CARBOXYLATE 
REDUCTASE 1 ISOFORM 2 4 (4 0 0 0 0) 1 : 0.56 
A6NFM2 
1.78571 1 
 14-3-3 PROTEIN EPSILON 8 (8 0 0 0 0) 1 : 0.57 P62258 1.75438 1 
 PLASTIN 3. 2 (2 0 0 0 0) 1 : 0.58 P13797 1.72413 1 
 HEAT SHOCK 70 KDA PROTEIN 4 8 (8 0 0 0 0) 1 : 0.58 P34932 1.72413 1 
Rab GDP dissociation inhibitor beta 3 (3 0 0 0 0) 1 : 0.6 P50395 1.66666 1 
 THIOREDOXIN DOMAIN-CONTAINING 
PROTEIN 4. 5 (5 0 0 0 0) 1 : 0.60 
Q9BS26 
1.66666 1 
 HEAT SHOCK 70 KDA PROTEIN 1 16 (16 0 0 0 0) 1 : 0.61 P34931 1.63934 1 
 14-3-3 PROTEIN ZETA/DELTA 6 (6 0 0 0 0) 1 : 0.61 P63104 1.63934 1 
 INTERLEUKIN ENHANCER-BINDING 
FACTOR 2 5 (5 0 0 0 0) 1 : 0.61 
Q12905 
1.63934 1 
 ELONGATION FACTOR 1-BETA 4 (2 2 0 0 0) 1 : 0.62 P24534 1.61290 1 
 ISOFORM 2 OF PHOSPHATIDYLINOSITOL-
BINDING CLATHRIN ASSEMBLY PROTEIN 2 (2 0 0 0 0) 1 : 0.62 
Q13492 
1.61290 1 
 ISOFORM 1 OF EXTENDED-
SYNAPTOTAGMIN-1. 11 (11 0 0 0 0) 1 : 0.62 
Q9BSJ8 
1.61290 1 
Elongation factor 1-alpha 2 15 (15 0 0 0 0) 1 : 0.63 Q05639 1.58730 1 
HSP HEAT SHOCK PROTEIN 90KDA ALPHA 
(CYTOSOLIC), CLASS A MEMBER 1 
ISOFORM 1 12 (12 0 0 0 0) 1:0.63 
P07900 
1.5625 1 
 ISOFORM 1 OF PLECTIN-1 69 (68 1 0 0 0) 1 : 0.64 Q15149 1.5625 1 
 GLUCOSE-6-PHOSPHATE ISOMERASE 9 (9 0 0 0 0) 1 : 0.65 P06744 1.53846 1 
 ISOFORM LONG OF SPECTRIN BETA 
CHAIN, BRAIN 1 8 (8 0 0 0 0) 1 : 0.65 
Q01082 
1.53846 1 
 GUANINE NUCLEOTIDE-BINDING PROTEIN 
SUBUNIT BETA 2-LIKE 1 6 (6 0 0 0 0) 1 : 0.66 
P63244 
1.51515 1 
 ISOFORM 1 OF CLATHRIN HEAVY CHAIN 1. 18 (17 1 0 0 0) 1 : 0.66 Q00610 1.51515 1 
 TRANSLATIONAL ACTIVATOR GCN1 8 (8 0 0 0 0) 1 : 0.66 Q92616 1.51515 1 
 ISOFORM 2 OF WD REPEAT-CONTAINING 
PROTEIN 1 2 (2 0 0 0 0) 1 : 0.67 
O43379 
1.49253 1 
 GLUTAREDOXIN-3 2 (2 0 0 0 0) 1 : 0.67 O76003 1.49253 1 
 ISOFORM 1 OF EXPORTIN-5 5 (5 0 0 0 0) 1 : 0.68 Q9HAV4 1.47058 1 
 ALPHA-ACTININ-1 13 (13 0 0 0 0) 1 : 0.70 P12814 1.42857 1 
 ISOFORM 1 OF FILAMIN-B 28 (26 2 0 0 0) 1 : 0.71 O75369 1.40845 1 
 EARLY ENDOSOME ANTIGEN 1. 5 (5 0 0 0 0) 1 : 0.72 Q15075 1.38888 1 
 ISOFORM 1 OF IMPORTIN-4 6 (6 0 0 0 0) 1 : 0.72 Q8TEX9 1.38888 1 
cDNA FLJ13940 fis, clone Y79AA1000833, 
moderately similar to TUBULIN ALPHA-1 
CHAIN 3 (3 0 0 0 0) 1 : 0.72 
Q9H853 
1.38888 1 
 EUKARYOTIC INITIATION FACTOR 4A-I 5 (5 0 0 0 0) 1 : 0.73 P60842 1.36986 1 
Dynactin subunit 2 3 (3 0 0 0 0) 1 : 0.73 Q13561 1.36986 1 
 HSPA5 PROTEIN 3 (3 0 0 0 0) 1 : 0.73 Q2KHP4 1.36986 1 
 ISOFORM M1 OF PYRUVATE KINASE 
ISOZYMES M1/M2 20 (20 0 0 0 0) 1 : 0.74 
P14618 
1.35135 1 
 EZRIN. 3 (3 0 0 0 0) 1 : 0.75 P15311 1.33333 1 
Rab GDP dissociation inhibitor alpha 2 (2 0 0 0 0) 1 : 0.75 P31150 1.33333 1 
 IMPORTIN SUBUNIT BETA-1 3 (3 0 0 0 0) 1 : 0.75 Q14974 1.33333 1 
Calcium-binding mitochondrial carrier protein 
SCaMC-1 2 (2 0 0 0 0) 1 : 0.76 
Q6NUK1 
1.31578 1 
 ISOFORM 1 OF SQUAMOUS CELL 
CARCINOMA ANTIGEN RECOGNIZED BY T-
CELLS 3 2 (2 0 0 0 0) 1 : 0.77 
Q15020 
1.29870 1 
 PUTATIVE NASCENT POLYPEPTIDE-
ASSOCIATED COMPLEX SUBUNIT ALPHA-
LIKE PROTEIN 3 (2 0 0 1 0) 1 : 0.78 
Q9BZK3 
1.29870 1 
Gamma-enolase 5 (2 3 0 0 0) 1 : 0.80 P09104 1.25 1 
 ACYL-COA DEHYDROGENASE FAMILY 
MEMBER 9, MITOCHONDRIAL 2 (2 0 0 0 0) 1 : 0.81 
Q9H845 
1.23456 1 
 STRESS-INDUCED-PHOSPHOPROTEIN 1 3 (2 1 0 0 0) 1 : 0.82 P31948 1.21951 1 
 PUROMYCIN-SENSITIVE 
AMINOPEPTIDASE 10 (10 0 0 0 0) 1 : 0.82 
P55786 
1.21951 1 
Protein disulfide-isomerase A6 8 (8 0 0 0 0) 1 : 0.82 Q6ZSH5 1.21951 1 
 ISOFORM 1 OF KINECTIN 7 (7 0 0 0 0) 1 : 0.82 Q86UP2 1.21951 1 
 PHOSPHOENOLPYRUVATE 
CARBOXYKINASE [GTP], MITOCHONDRIAL 4 (4 0 0 0 0) 1 : 0.83 
P35558 
1.20481 1 
 ATP synthase subunit beta, mitochondrial 5 (5 0 0 0 0) 1 : 0.84 P06576 1.19047 1 
 PROTEIN DISULFIDE-ISOMERASE 13 (13 0 0 0 0) 1 : 0.84 P07237 1.19047 1 
 60 KDA HEAT SHOCK PROTEIN, 
MITOCHONDRIAL 14 (14 0 0 0 0) 1 : 0.84 
P10809 
1.19047 1 
 UBIQUITIN-LIKE MODIFIER-ACTIVATING 
ENZYME 1 5 (5 0 0 0 0) 1 : 0.84 
P22314 
1.19047 1 
Tubulin beta-8 chain 2 (2 0 0 0 0) 1 : 0.84 Q3ZCM 1.19047 1 
Elongation factor 1-gamma 5 (5 0 0 0 0) 1 : 0.85 P26641 1.17647 1 
 Hsc70-interacting protein 3 (3 0 0 0 0) 1 : 0.85 P50502 1.17647 1 
 ELONGATION FACTOR 2 9 (9 0 0 0 0) 1 : 0.87 P13639 1.14942 1 
 ISOFORM 2 OF AP-2 COMPLEX SUBUNIT 
BETA-1 2 (2 0 0 0 0) 1 : 0.87 
P63010 
1.14942 1 
 ENDOPLASMIN 7 (7 0 0 0 0) 1 : 0.88 P14625 1.13636 1 
Hsp90 co-chaperone Cdc37 2 (2 0 0 0 0) 1 : 0.88 Q16543 1.13636 1 
 ISOFORM 1 OF DNA-DEPENDENT 
PROTEIN KINASE CATALYTIC SUBUNIT 27 (27 0 0 0 0) 1 : 0.89 
P78527 
1.12359 1 
 CYTOPLASMIC DYNEIN 1 HEAVY CHAIN 1 58 (57 1 0 0 0) 1 : 0.89 Q14204 1.12359 1 
 SIMILAR TO HEAT SHOCK PROTEIN HSP 
90-BETA 2 (2 0 0 0 0) 1:0.91 
P08238 
1.09890 1 
  CALRETICULIN   3 (3 0 0 0 0) 1 : 0.91 P27797 1.09890 1 
 ELONGATION FACTOR 1-DELTA 6 (5 1 0 0 0) 1 : 0.91 P29692 1.09890 1 
 ISOFORM R-TYPE OF PYRUVATE KINASE 
ISOZYMES R/L 2 (2 0 0 0 0) 1 : 0.91 
P30613 
1.09890 1 
 HETEROGENEOUS NUCLEAR 
RIBONUCLEOPROTEIN H 2 (2 0 0 0 0) 1 : 0.91 
P31943 
1.09890 1 
 NASCENT POLYPEPTIDE-ASSOCIATED 
COMPLEX SUBUNIT ALPHA 5 (4 1 0 0 0) 1 : 0.91 
Q13765 
1.09890 1 
 EXPORTIN-1. 5 (5 0 0 0 0) 1 : 0.92 O14980 1.08695 1 
 ISOFORM 1 OF U5 SMALL NUCLEAR 
RIBONUCLEOPROTEIN 200 KDA HELICASE 10 (10 0 0 0 0) 1 : 0.92 
O75643 
1.08695 1 
 ARGININOSUCCINATE SYNTHASE 5 (5 0 0 0 0) 1 : 0.92 P00966 1.08695 1 
 ADP/ATP TRANSLOCASE 2 9 (9 0 0 0 0) 1 : 0.92 P05141 1.08695 1 
 BIFUNCTIONAL AMINOACYL-TRNA 
SYNTHETASE 12 (12 0 0 0 0) 1 : 0.92 
P07814 
1.08695 1 
 ISOFORM 1 OF POLYADENYLATE-BINDING 
PROTEIN 1. 12 (12 0 0 0 0) 1 : 0.92 
P11940 
1.08695 1 
 ADP/ATP TRANSLOCASE 3 3 (3 0 0 0 0) 1 : 0.22 P12236 1.08695 1 
 TRANSITIONAL ENDOPLASMIC 
RETICULUM ATPASE 8 (8 0 0 0 0) 1 : 0.92 
P55072 
1.08695 1 
 GLUCOSAMINE--FRUCTOSE-6-
PHOSPHATE AMINOTRANSFERASE 
[ISOMERIZING] 2 2 (2 0 0 0 0) 1 : 0.92 
Q06210 
1.08695 1 
 UBIQUITIN CARBOXYL-TERMINAL 
HYDROLASE 7 4 (4 0 0 0 0) 1 : 0.92 
Q93009 
1.08695 1 
 LEUCYL-TRNA SYNTHETASE, 
CYTOPLASMIC 6 (6 0 0 0 0) 1 : 0.92 
Q9P2J5 
1.08695 1 
 CDNA FLJ54957, HIGHLY SIMILAR TO 
TRANSKETOLASE 4 (4 0 0 0 0) 1 : 0.93 
B4DE31 
1.07526 1 
 ISOFORM 1 OF MYOSIN-9 43 (43 0 0 0 0) 1 : 0.93 P35579 1.07526 1 
 EUKARYOTIC INITIATION FACTOR 4A-III 3 (3 0 0 0 0) 1 : 0.98 P38919 1.07526 1 
 MALATE DEHYDROGENASE, 
CYTOPLASMIC. 6 (6 0 0 0 0) 1 : 0.93 
P40925 
1.07526 1 
 ISOFORM 1 OF CLATHRIN HEAVY CHAIN 2 10 (10 0 0 0 0) 1 : 0.93 P53675 1.07526 1 
 COMPLEMENT COMPONENT 1 Q 
SUBCOMPONENT-BINDING PROTEIN, 
MITOCHONDRIAL 3 (3 0 0 0 0) 1 : 0.93 
Q07021 
1.07526 1 
 MULTISYNTHETASE COMPLEX AUXILIARY 
COMPONENT P38 3 (3 0 0 0 0) 1 : 0.93 
Q13155 
1.07526 1 
 ISOFORM 1 OF DIPEPTIDYL-PEPTIDASE 3 12 (12 0 0 0 0) 1 : 0.93 Q9NY33 1.07526 1 
 ATP SYNTHASE SUBUNIT ALPHA, 
MITOCHONDRIAL 9 (8 1 0 0 0)  1 : 0.94 
O43175 
1.06383 1 
 EUKARYOTIC TRANSLATION INITIATION 
FACTOR 3 SUBUNIT A 5 (4 0 1 0 0) 1 : 0.94 
O75821 
1.06383 1 
 PHOSPHOGLYCERATE KINASE 1 10 (10 0 0 0 0) 1 : 0.94 P00558 1.06383 1 
 TROPOMYOSIN 3 4 (4 0 0 0 0) 1 : 0.94 P06753 1.06383 1 
 L-LACTATE DEHYDROGENASE B CHAIN 5 (5 0 0 0 0) 1 : 0.94 P07195 1.06383 1 
 DNA TOPOISOMERASE 1. 2 (2 0 0 0 0) 1 : 0.94 P11387 1.06383 1 
 ISOFORM 1 OF MYOSIN-10 9 (7 1 0 1 0) 1 : 0.94 P35580 1.06383 1 
 TUBULIN ALPHA-4A CHAIN 16 (16 0 0 0 0) 1 : 0.94 P68366 1.06383 1 
 ISOFORM 2 OF SIGNAL RECOGNITION 
PARTICLE 68 KDA PROTEIN. 4 (4 0 0 0 0) 1 : 0.94 
Q9UHB9 
1.06383 1 
 ISOFORM 2 OF N-ACETYLSEROTONIN O-
METHYLTRANSFERASE-LIKE PROTEIN. 2 (2 0 0 0 0) 1 : 0.95 
O95671 
1.05263 1 
 ISOFORM 1 OF HEAT SHOCK COGNATE 71 
KDA PROTEIN. 13 (13 0 0 0 0) 1 : 0.95 
P11142 
1.05263 1 
 ATP SYNTHASE SUBUNIT BETA, 
MITOCHONDRIAL 10 (10 0 0 0 0) 1 : 0.95 
P24539 
1.05263 1 
 SWI/SNF-RELATED MATRIX-ASSOCIATED 
ACTIN-DEPENDENT REGULATOR OF 
CHROMATIN A4 ISOFORM D. SMARCA4 5 (5 0 0 0 0) 1 : 0.95 
Q12824 
1.05263 1 
 2,4-DIENOYL-COA REDUCTASE, 
MITOCHONDRIAL 7 (7 0 0 0 0) 1 : 0.95 
Q16698 
1.05263 1 
 LEUCINE-RICH REPEAT-CONTAINING 
PROTEIN 59 11 (11 0 0 0 0) 1 : 0.95 
Q96AG4 
1.05263 1 
 ISOFORM 2 OF U5 SMALL NUCLEAR 
RIBONUCLEOPROTEIN 200 KDA HELICASE 3 (3 0 0 0 0) 1 : 0.96 
O75643 
1.04166 1 
 EUKARYOTIC TRANSLATION INITIATION 
FACTOR 3 SUBUNIT C 4 (4 0 0 0 0) 1 : 0.96 
Q99613 
1.04166 1 
 ISOFORM 3 OF OBG-LIKE ATPASE 1 3 (3 0 0 0 0) 1 : 0.96 Q9NTK5 1.04166 1 
 ATP-DEPENDENT RNA HELICASE DDX3X 6 (6 0 0 0 0) 0.97 : 1 O00571 1.03092 1 
 C-1-TETRAHYDROFOLATE SYNTHASE, 
CYTOPLASMIC 7 (7 0 0 0 0) 1 : 0.97 
P11586 
1.03092 1 
 ATP-DEPENDENT DNA HELICASE 2 
SUBUNIT 1 5 (5 0 0 0 0) 1 : 0.97 
P46063 
1.03092 1 
 FATTY ACID SYNTHASE 62 (62 0 0 0 0) 1 : 0.97 P49327 1.03092 1 
Tubulin beta-2A chain 2 (2 0 0 0 0) 1 : 0.97 Q13885 1.03092 1 
 SIMILAR TO BETA-ACTIN 2 (2 0 0 0 0) 1 : 0.97 Q9BYX7 1.03092 1 
  PCTP-LIKE PROTEIN  3 (3 0 0 0 0) 1 : 0.97 Q9Y365 1.03092 1 
 ISOFORM 1 OF HETEROGENEOUS 
NUCLEAR RIBONUCLEOPROTEIN Q 6 (6 0 0 0 0) 1 : 0.98 
O60506 
1.02040 1 
 HETEROGENEOUS NUCLEAR 
RIBONUCLEOPROTEIN C-LIKE 1 5 (5 0 0 0 0) 1 : 0.98 
O60812 
1.02040 1 
 KERATIN, TYPE II CYTOSKELETAL 1 3 (2 1 0 0 0) 1 : 0.98 P04264 1.02040 1 
 PROTEIN DISULFIDE-ISOMERASE A4 7 (7 0 0 0 0) 1 : 0.98 P13667 1.02040 1 
 ELECTRON TRANSFER FLAVOPROTEIN 
SUBUNIT ALPHA, MITOCHONDRIAL 8 (8 0 0 0 0) 1 : 0.98 
P13804 
1.02040 1 
 PROTEASOME SUBUNIT ALPHA TYPE-4 4 (4 0 0 0 0) 1 : 0.98 P25789 1.02040 1 
 ISOFORM LONG OF DELTA-1-PYRROLINE-
5-CARBOXYLATE SYNTHETASE 9 (8 1 0 0 0) 1:0.98 
P54886 
1.02040 1 
 ISOFORM 1 OF EUKARYOTIC 
TRANSLATION INITIATION FACTOR 3 
SUBUNIT B 2 (2 0 0 0 0) 1 : 0.98 
P55884 
1.02040 1 
Epiplakin 42 (40 2 0 0 0) 1 : 0.98 P58107 1.02040 1 
 PUTATIVE HEAT SHOCK PROTEIN HSP 90-
ALPHA A2 4 (4 0 0 0 0) 1:0.98 
Q14568 
1.02040 1 
 116 KDA U5 SMALL NUCLEAR 
RIBONUCLEOPROTEIN COMPONENT 9 (9 0 0 0 0) 1 : 0.98 
Q15029 
1.02040 1 
 BETA-ACTIN-LIKE PROTEIN 2 4 (2 2 0 0 0) 1 : 0.98 Q562R1 1.02040 1 
 ISOFORM 1 OF CULLIN-ASSOCIATED 
NEDD8-DISSOCIATED PROTEIN 1 18 (18 0 0 0 0) 1 : 0.97 
Q86VP6 
1.02040 1 
 ISOFORM 2 OF SWI/SNF COMPLEX 
SUBUNIT SMARCC2 4 (4 0 0 0 0) 1 : 0.98 
Q8TAQ2 
1.02040 1 
 MYOSIN-IA. 3 (3 0 0 0 0) 1 : 0.98 Q9UBC5 1.02040 1 
 ISOFORM 2 OF FILAMIN-A 60 (60 0 0 0 0) 1 : 0.99 P21333 1.01010 1 
 PROTEIN DISULFIDE-ISOMERASE A3 12 (12 0 0 0 0) 1 : 0.99 P30101 1.01010 1 
 PHOSPHOENOLPYRUVATE 
CARBOXYKINASE, CYTOSOLIC [GTP]. 2 (2 0 0 0 0) 1 : 0.99 
P35558 
1.01010 1 
 ISOFORM 1 OF TRANSCRIPTION 
INTERMEDIARY FACTOR 1-BETA 3 (3 0 0 0 0) 1 : 0.99 
Q13263 
1.01010 1 
 TUBULIN BETA-3 CHAIN. 3 (3 0 0 0 0) 1 : 0.99 Q13509 1.01010 1 
 ISOFORM 2 OF NEUTRAL ALPHA-
GLUCOSIDASE AB 10 (10 0 0 0 0) 1 : 0.99 
Q14697 
1.01010 1 
 ISOFORM 4 OF ABHYDROLASE DOMAIN-
CONTAINING PROTEIN 11 5 (5 0 0 0 0) 1 : 0.99 
Q8NFV4 
1.01010 1 
 ISOCHORISMATASE DOMAIN-CONTAINING 
PROTEIN 1 4 (4 0 0 0 0) 1 : 0.99 
Q96CN7 
1.01010 1 
 VACUOLAR PROTEIN SORTING-
ASSOCIATED PROTEIN 35 10 (10 0 0 0 0) 1 : 0.99 
Q96QK1 
1.01010 1 
 PUTATIVE TUBULIN-LIKE PROTEIN ALPHA-
4B 2 (2 0 0 0 0) 1 : 0.99 
Q9H853 
1.01010 1 
 ISOFORM 3 OF RIBOSOME-BINDING 
PROTEIN 1 11 (11 0 0 0 0) 1 : 0.99 
Q9P2E9 
1.01010 1 
 CDNA FLJ55574, HIGHLY SIMILAR TO 
CALNEXIN. 9 (9 0 0 0 0) 1:1.00 
B4DGP8 
1 1 
 GLYCERALDEHYDE-3-PHOSPHATE 
DEHYDROGENASE 26 (26 0 0 0 0) 1 : 1.00 
P04406 
1 1 
 TUBULIN BETA CHAIN 2 (2 0 0 0 0) 1 : 1.00 P07437 1 1 
 6-PHOSPHOFRUCTOKINASE, LIVER TYPE 
(EC 2.7.1.11) (PHOSPHOFRUCTOKINASE 1) 
(PHOSPHOHEXOKINASE) 
(PHOSPHOFRUCTO-1-KINASE ISOZYME B) 
(PFK-B). ISOFORM 2. 10 (10 0 0 0 0) 1 : 1.00 
P17858 
1 1 
 ISOFORM 1 OF VINCULIN 4 (4 0 0 0 0) 1 : 0.93 P18206 1.075269 1.07526 
 ALANYL-TRNA SYNTHETASE, 
CYTOPLASMIC. 7 (7 0 0 0 0) 1 : 1.00 
P49588 
1 1 
 ISOFORM 1 OF HOST CELL FACTOR 4 (3 1 0 0 0) 1 : 1.00 P51610 1 1 
 HETEROGENEOUS NUCLEAR 
RIBONUCLEOPROTEIN F 2 (2 0 0 0 0) 1 : 1 
P52597 
1 1 
Spliceosome RNA helicase BAT1 3 (3 0 0 0 0) 0.82 : 1 Q13838 1 1 
 ISOFORM 1 OF MYOSIN-IB. 6 (6 0 0 0 0) 0.99 : 1 O43795 1 1.01010 
 ACTIN, CYTOPLASMIC 1 5 (5 0 0 0 0) 0.99 : 1 P60709 1 1.01010 
 ISOFORM 1 OF L-LACTATE 
DEHYDROGENASE A CHAIN 6 (6 0 0 0 0) 0.98 : 1 
P00338 
1 1.02040 
 NCL PROTEIN 4 (4 0 0 0 0) 0.98 : 1 P19338 1 1.02040 
 KINESIN-1 HEAVY CHAIN. 6 (6 0 0 0 0) 0.98 : 1 P33176 1 1.02040 
 ISOFORM 1 OF NADH-CYTOCHROME B5 
REDUCTASE 3 4 (4 0 0 0 0) 0.97 : 1 
P00387 
1 1.03092 
 FRUCTOSE-BISPHOSPHATE ALDOLASE A. 2 (2 0 0 0 0) 0.97: 1 P04075 1 1.03092 
 COATOMER SUBUNIT BETA' 5 (5 0 0 0 0) 0.97: 1 P35606 1 1.03092 
 ISOFORM 1 OF UBX DOMAIN-CONTAINING 
PROTEIN 1 2 (2 0 0 0 0) 0.96 : 1 
Q04323 
1 1.04166 
 ISOFORM 2 OF RING FINGER PROTEIN 213 4 (3 0 1 0 0) 0.96: 1 Q63HN8 1 1.04166 
 ISOFORM 1 OF MYOFERLIN. 2 (2 0 0 0 0) 0.96 : 1 Q9NZM1 1 1.04166 
ISOFORM 1 OF GELSOLIN. 10 (10 0 0 0 0) 0.95:1 P06396 1 1.05263 
 ISOCITRATE DEHYDROGENASE [NADP], 
MITOCHONDRIAL 13 (12 1 0 0 0) 0.95 : 1 
P48735 
1 1.05263 
 DOLICHYL-
DIPHOSPHOOLIGOSACCHARIDE--PROTEIN 
GLYCOSYLTRANSFERASE 67 KDA 
SUBUNIT PRECURSOR 18 (18 0 0 0 0) 0.95 : 1 
P54652 
1 1.05263 
translation elongation factor 1 alpha 1 3 (2 1 0 0 0) 0.95 : 1 Q2F837 1 1.05263 
 ANNEXIN VI ISOFORM 2 13 (13 0 0 0 0) 0.93 : 1 P07355 1 1.07526 
 4F2 CELL-SURFACE ANTIGEN HEAVY 
CHAIN CD98 4 (4 0 0 0 0) 0.94:1 
P08195 
1 1.07526 
 STRESS-70 PROTEIN, MITOCHONDRIAL 11 (11 0 0 0 0) 0.93 : 1 P38646 1 1.07526 
 MYOSIN-IC 11 (11 0 0 0 0) 1 : 0.91 O00159 1 1.09890 
  ATP- CITRATE SYNTHASE 10 (10 0 0 0 0) 0.91 : 1 P53396 1 1.09890 
ACONITATE HYDRATASE, 
MITOCHONDRIAL 11 (11 0 0 0 0) 0.91 : 1 
Q99798 
1 1.09890 
Keratin, type I cytoskeletal 18 7 (7 0 0 0 0) 0.90 : 1 P05783 1 1.11111 
 MALATE DEHYDROGENASE, 
MITOCHONDRIAL 22 (22 0 0 0 0) 0.89 : 1 
P40926 
1 1.12359 
 ISOFORM 1 OF ACETYL-COA 
CARBOXYLASE 1 3 (3 0 0 0 0) 0.89 : 1 
Q13085 
1 1.12359 
 POLY(RC)-BINDING PROTEIN 1 3 (3 0 0 0 0) 0.89 : 1 Q15365 1 1.12359 
 ISOFORM 1 OF INORGANIC 
PYROPHOSPHATASE 2, MITOCHONDRIAL 5 (5 0 0 0 0) 0.89 : 1 
Q9H2U2 
1 1.12359 
 KERATIN, TYPE II CYTOSKELETAL 8 6 (6 0 0 0 0) 0.88 : 1 P05787 1 1.13636 
 ISOFORM 1 OF CARNITINE O-
PALMITOYLTRANSFERASE I, LIVER 
ISOFORM 2 (2 0 0 0 0) 0.87:1 
P50416 
1 1.14942 
 40S RIBOSOMAL PROTEIN S3 7 (7 0 0 0 0) 0.86 : 1 P23396 1 1.16279 
 ISOFORM 1 OF PROTEASOME ACTIVATOR 
COMPLEX SUBUNIT 3 3 (3 0 0 0 0) 0.86 : 1 
P61289 
1 1.16279 
 40S RIBOSOMAL PROTEIN S4, X ISOFORM 7 (7 0 0 0 0) 0.86 : 1 P62701 1 1.16279 
 MITOCHONDRIAL 2-
OXOGLUTARATE/MALATE CARRIER 
PROTEIN 5 (5 0 0 0 0) 0.86 : 1 
Q02978 
1 1.16279 
 DYNC1H1 PROTEIN 5 (4 1 0 0 0) 0.86 : 1 Q6P2H7 1 1.16279 
 CDNA FLJ56425, HIGHLY SIMILAR TO 
VERY-LONG-CHAIN SPECIFIC ACYL- 
COADEHYDROGENASE, MITOCHONDRIAL 7 (7 0 0 0 0) 0.85 : 1 
B4DEA8 
1 1.1764 
ATP DEPENDENT DNA HELICASE 2 
SUBUNIT 2 14 (13 1 0 0 0) 0.85 : 1 
P63010 
1 1.17647 
 HETEROGENEOUS NUCLEAR 
RIBONUCLEOPROTEIN U ISOFORM A 2 (2 0 0 0 0) 0.85 : 1 
Q00839 
1 1.17647 
 NAD(P)H DEHYDROGENASE [QUINONE] 1 5 (5 0 0 0 0) 0.84 : 1 P15559 1 1.19047 
 MATRIN-3. 5 (5 0 0 0 0) 0.84 : 1 P43243 1 1.19047 
 PDCD6IP PROTEIN 4 (4 0 0 0 0) 0.84 : 1 Q8WUM4 1 1.19047 
 ISOFORM 1 OF TROPOMYOSIN ALPHA-4 
CHAIN 2 (2 0 0 0 0) 0.82 : 1 
P67936 
1 1.21951 
 ISOFORM 1 OF MYOSIN-14 4 (4 0 0 0 0) 0.95 : 1 Q7Z406 1 1.21951 
 ANNEXIN A5 13 (13 0 0 0 0) 0.80 : 1 P08758 1 1.25 
 LANOSTEROL SYNTHASE 2 (2 0 0 0 0) 0.80 : 1 P48449 1 1.25 
 60S RIBOSOMAL PROTEIN L7A 4 (4 0 0 0 0) 0.79 : 1 P62424 1 1.26582 
 6-PHOSPHOFRUCTOKINASE TYPE C 5 (5 0 0 0 0) 0.79:1 Q01813 1 1.26582 
  ISOFORM 2 OF NUCLEAR MITOTIC 
APPARATUS PROTEIN 1 9 (8 1 0 0 0) 0.79 : 1 
Q14980 
1 1.26582 
 ISOFORM 7 OF TITIN 11 (11 0 0 0 0) 0.79 : 1 Q8WZ42 1 1.26582 
 TRANSALDOLASE 4 (3 0 1 0 0) 0.78 : 1 P37837 1 1.28205 
 TRIPARTITE MOTIF-CONTAINING PROTEIN 
25 2 (2 0 0 0 0) 0.77 : 1 
O75382 
1 1.29870 
 PROTEASOME ACTIVATOR COMPLEX 
SUBUNIT 1 13 (13 0 0 0 0) 0.77 : 1 
P61289 
1 1.29870 
 ZINC FINGER PROTEIN 347 2 (2 0 0 0 0) 0.77 : 1 Q96SE7 1 1.29870 
 HUMAN IMMUNODEFICIENCY VIRUS TYPE 
I ENHANCER BINDING PROTEIN 1 2 (2 0 0 0 0) 0.76 : 1 
P15822 
1 1.31578 
 40S RIBOSOMAL PROTEIN S2 7 (7 0 0 0 0) 0.76 : 1 P15880 1 1.31578 
 ISOFORM HEART OF ATP SYNTHASE 
SUBUNIT GAMMA, MITOCHONDRIAL 4 (4 0 0 0 0) 0.76 : 1 
P36542 
1 1.31578 
 TRIFUNCTIONAL ENZYME SUBUNIT 
ALPHA, MITOCHONDRIAL 3 (3 0 0 0 0) 0.76 : 1 
P40939 
1 1.31578 
 HEAT SHOCK PROTEIN 75 KDA, 
MITOCHONDRIAL 9 (9 0 0 0 0) 0.76 : 1 
Q12931 
1 1.31578 
 ISOFORM 1 OF AFLATOXIN B1 ALDEHYDE 
REDUCTASE MEMBER 4 2 (2 0 0 0 0) 0.76 : 1 
Q8NHP1 
1 1.31578 
 ALPHA-ACTININ-4. 20 (19 1 0 0 0) 0.74 : 1 O43707 1 1.35135 
 ELONGATION FACTOR 1-ALPHA 2 4 (4 0 0 0 0) 0.71 : 1 P68104 1 1.40845 
 ISOFORM 1 OF ACYLGLYCEROL KINASE, 
MITOCHONDRIAL 2 (2 0 0 0 0) 0.71 : 1 
Q53H12 
1 1.40845 
Obsolete 3 (3 0 0 0 0) 0.70 : 1 Q05524 1 1.42857 
 PUTATIVE UNCHARACTERIZED PROTEIN 
PSME2 4 (4 0 0 0 0) 0.70 : 1 
Q9UL46 
1 1.42857 
Elongation factor Tu, mitochondrial 3 (3 0 0 0 0) 0.69 : 1 P49411 1 1.44927 
 ALPHA-CENTRACTIN 2 (2 0 0 0 0) 0.69 : 1 P61163 1 1.44927 
 ISOFORM 1 OF ACIDIC LEUCINE-RICH 
NUCLEAR PHOSPHOPROTEIN 32 FAMILY 
MEMBER B. 4 (4 0 0 0 0) 0.69 : 1 
Q92688 
1 1.44927 
 T-COMPLEX PROTEIN 1 SUBUNIT DELTA 4 (4 0 0 0 0) 0.68 : 1 P50991 1 1.47058 
 T-COMPLEX PROTEIN 1 SUBUNIT BETA 6 (6 0 0 0 0) 0.68 : 1 P78371 1 1.47058 
 VOLTAGE-DEPENDENT ANION-SELECTIVE 
CHANNEL PROTEIN 1 9 (9 0 0 0 0) 0.67 : 1  
P21796 
1 1.49253 
 ISOFORM LONG OF UBIQUITIN 
CARBOXYL-TERMINAL HYDROLASE 5 5 (5 0 0 0 0) 0.66 : 1 
P45974 
1 1.51515 
 INORGANIC PYROPHOSPHATASE 6 (6 0 0 0 0) 0.66 : 1 Q15181 1 1.51515 
 CENTAURIN-DELTA-3 2 (2 0 0 0 0) 0.65 : 1 D3DQE3 1 1.53846 
 CYTOCHROME C1, HEME PROTEIN, 
MITOCHONDRIAL 5 (5 0 0 0 0) 0.61 : 1 
P08574 
1 1.5625 
 THREONYL-TRNA SYNTHETASE, 
CYTOPLASMIC 8 (7 1 0 0 0) 0.64 : 1 
P26639 
1 1.5625 
 T-COMPLEX PROTEIN 1 SUBUNIT EPSILON 4 (4 0 0 0 0) 0.64 : 1 P48643 1 1.5625 
 COATOMER SUBUNIT GAMMA. 6 (6 0 0 0 0) 0.64 : 1 Q9Y678 1 1.5625 
 CATHEPSIN D 4 (4 0 0 0 0) 0.62 : 1 P07339 1 1.61290 
 T-COMPLEX PROTEIN 1 SUBUNIT ZETA 2 (2 0 0 0 0) 0.61 : 1 P40227 1 1.63934 
Beta-enolase 2 (2 0 0 0 0)  0.60: 1 P13929 1 1.66666 
 ALPHA-ENOLASE - deleted from swiss prot 4 (4 0 0 0 0) 0.6 : 1 Q05524 1 1.66666 
 ISOFORM LONG OF GLUCOSE-6-
PHOSPHATE 1-DEHYDROGENASE 20 (20 0 0 0 0) 0.59 : 1 
P11413 
1 1.69491 
 TUBULIN BETA-2C CHAIN 12 (12 0 0 0 0) 0.59 : 1 P68371 1 1.69491 
 PLASTIN-1 2 (2 0 0 0 0) 0.56 : 1 Q14651 1 1.78571 
 UBIQUITIN AND RIBOSOMAL PROTEIN 
S27A PRECURSOR 2 (2 0 0 0 0) 0.55 : 1 
P62979 
1 1.81818 
 LARGE NEUTRAL AMINO ACIDS 
TRANSPORTER SMALL SUBUNIT 1 3 (3 0 0 0 0) 0.50 : 1 
Q01650 
1 2 
 ISOFORM 1 OF PROTEIN SET. 3 (3 0 0 0 0) 0.48 : 1 Q01105 1 2.08333 
Bullous pemphigoid antigen 1 2 (2 0 0 0 0) 0.48 : 1 Q03001 1 2.08333 
 KERATIN, TYPE I CYTOSKELETAL 19 4 (4 0 0 0 0) 0.47 : 1 P08727 1 2.12766 
 ISOFORM 1 OF REGULATOR OF 
NONSENSE TRANSCRIPTS 1 7 (7 0 0 0 0) 0.47 : 1 
Q92900 
1 2.12766 
 BIFUNCTIONAL PURINE BIOSYNTHESIS 
PROTEIN PURH 9 (9 0 0 0 0) 0.46 : 1 
P31939 
1 2.17391 
 HEAT REPEAT-CONTAINING PROTEIN 6 3 (3 0 0 0 0) 0.46 : 1 Q6AI08 1 2.17391 
 VIGILIN. 9 (9 0 0 0 0) 0.44 : 1 Q00341 1 2.27272 
 FRUCTOSE-1,6-BISPHOSPHATASE 1 2 (2 0 0 0 0) 0.43 : 1 P09467 1 2.32558 
 LAMIN-B1. 4 (4 0 0 0 0) 0.47 : 1 P20700 1 2.32558 
 CALPONIN-2 2 (2 0 0 0 0) 0.43 : 1 Q99439 1 2.32558 
 ISOFORM 1 OF ENOLASE-PHOSPHATASE 
E1 2 (2 0 0 0 0) 0.42 : 1 
Q9UHY7 
1 2.38095 
 ANNEXIN A4 6 (6 0 0 0 0) 0.41 : 1 P09525 1 2.43902 
 unnamed protein product (blast) 4 (4 0 0 0 0) 0.38 : 1 Unnamed 1 2.63157 
 ISOFORM 3 OF RUN DOMAIN-CONTAINING 
PROTEIN 3A 3 (2 0 1 0 0) 0.36 : 1 
Q59EK9 
1 2.77777 
elongation factor 1-alpha 2 2 (2 0 0 0 0) 0.28 : 1 Q8IYJ1 1 3.57142 
 Putative uncharacterized protein  3 (3 0 0 0 0) 0.28 : 1 Q9HBQ4 1 3.57142 
 NUCLEAR MIGRATION PROTEIN NUDC 3 (3 0 0 0 0) 0.28 : 1 Q9Y266 1 3.57142 
 AFG3-LIKE PROTEIN 2 8 (7 1 0 0 0) 0.24 : 1 Q9Y4W6 1 4.16666 
 ISOFORM 1 OF NF-X1-TYPE ZINC FINGER 
PROTEIN NFXL1. 3 (2 1 0 0 0) 0.23 : 1 
Q6ZNB6 
1 4.34782 
 60S ACIDIC RIBOSOMAL PROTEIN P0 6 (6 0 0 0 0) 0.19 : 1 P05388 1 5.26315 
 Ezrin-radixin-moesin-binding phosphoprotein 
50 3 (3 0 0 0 0) 0.18 : 1 
O14745 
1 5.55555 
 PROTEIN FAM49B 3 (3 0 0 0 0) 0.15 : 1 Q9NUQ9 1 6.66666 
    
357.577 347.156 
